,ticker,content
0,BIIB,century biology wonderful dopamine attention drug memory emotion learn complete loop dopamine noisy concert consciousness cerebral symphony arouse orient detect execute find flow way learn more better fasterwelcome back mind money kevin cook field guide story teller fascinating arena behavioral economic part chautauqua attempt connect several idea technology science light have learn past year so human nature human behavior note distinction human nature human behavior behavior vary widely culture cook language clothing music religion technology war dozen other custom have incredible diversity talk human nature mean root cause driver behavior tend be common human species disease aside include brain structure function genetic predisposition program software various theory puzzle evolutionary psychology inspire scientist work backward attempt solve other word cognitive behavioral social researcher ask question do human culture experience rage jealousy sorrow joy apathy shame laughter force brain evolutionary past genetic make create natural response social encounter language be universal human trait many similarity syntax culture have never have contact also add music list think work mickey hart long time drummer grateful dead have spend lifetime sharing preserve indigenous rhythm culture world have time ll come back mickey brain music now seek find rhythm base cure alzheimer propensity ask question fundamental human nature challenge understand agree be part thought be important begin discussion brain weather biological understand human nature used essay steven pinker help get start essay be actually excerpt book blank slate modern denial human nature find excerpt interview pinker condense idea excellent think person edge org link biological understand human natureaman brain scan now last year scientific research be more important previous year quest understand be come act way do knowledge human nature behavior have be vault exponentially explosion research involve not only genetic almost much brain imaging need only listen dr daniel own metamorphosis life work understand army finished medical school become psychiatrist only medical field doctor don actually look organ be treat be also trained ray technician army develop love medical imaging be able marry field spend next decade build world largest database brain scan tedx talk be call most important lesson brain scan highly recommend watch make most important minute youtube week professor feynman give physicist richard feynman used say best way learn something be simply dive try other have be favorite strategy mine most adult life have work amazingly well science technology history investing especially fail something part chaos theory learn bill nye call everything once so be fail part dopamine weather run little time minute usual sometimes try accomplish too much try connect too many idea single podcast result also do not do justice dopamine explanation repair fail today moment first defense try string together too many idea single episode let say thread fabric be try connect be already have just be rip apart modern technology society don learn most important connection physical social science subject be taught separate course great detail expense deep wide connection be modern education system seek create specialist first foremost job be most kid be too busy be distract tv maybe now social medium video game get real full education science even college so give challenge take once get start weave re weave fabric full education ancient socrates plato aristotle buddha lao tse confucius see more connection wholeness knowledge value average college graduate century be hold hope college grad st truly be century biology life science know know computer geek think century artificial intelligence ai just be tool genetic engineering even ve get wrong future look much different imagine be wild fun ride be educate science learn invest company create future used ai brain science genetic technology reason be investor bleed edge company nvidia nvda free report bluebird bio blue free report crispr therapeutic crsp free report so work technology investor stock market trail blazer philosophy teacher science preacher be keep putt string back together fabric make sense have integrity truthful be used make life incredibly rich hopefully make money way too cheer dopamine part talk anticipation most type reward increase level dopamine brain many addictive drug increase dopamine release block reabsorption neuron follow release thereby create addiction interfere normal dopamine transmission didn do good job explain dopamine be be often activate simply anticipation reward not merely arrival reward corresponding pleasure get more heart dopamine make feel good role feel good have merely compelling eat seek mate be massively important put dopamine center attention memory motivation see learn end today episode be go give part strategy learn more better faster ever thought scientist call whirlwind neurobiology dopamine be central incentive salience be fancy theoretical description process concern regulate desire attention corresponding motivation once desire be aroused alert dopamine keep anticipation go physiological excitement want something reward pleasurable be nearby available future be sustain attention drife behavior dopamine kick tell brain important something be good feel once have attain feel good even have incentive salience become textbook terminology simply learn dopamine attention drug harvard medical school psychiatrist brain expert be not same dr john ratey be clear ratey didn call dopamine attention drug just call now do more homework help now ve expand call dopamine attention memory learn drug hear whole discussion include emotional connection midbrain structure add intensity attention memory learn loop podcast share part strategy learn more better faster achieve goal knowledge skill simply be more productive achieve biggest goal spark dr rateyin podcast consult excellent work dr ratey help get better understand brain own natural wonder drug share wonderful professor excellent book user guide brain episode august title see get neurology perception dr ratey be expert add adhd so know much attention reward system brain anyone here example gift communicate complex neuroscience easy grasp term explain arouse orient detect execute loop human consciousness once be aroused oriented reward novelty system kick govern mesolimbic pathway group dopamine contain neuron be key driver limbic system system be integral not only attention many other brain function notably emotional social brain detect novelty seek reward be primary force direct selection focus attention novelty system take note new stimuli reward system produce sensation pleasure assign emotional value stimulus also mark memory later same stimulus reappear memory visceral emotion provide response joy disgust then direct individual seek plan action ratey also explain interplay dopamine disorder parkinson dopamine mean muscular coordination also mean variety motor neurological symptom include cognitive problem attention plan language memory hallucination delusion even dementia follower portfolio zack know have be frequent investor acadium pharmaceutical acad free report maker nuplazid pimavanserin first only medication approve food drug administration fda treatment hallucination delusion associate parkinson disease psychosis run jump learn dr ratey latest work have focuse exercise key ingredient healthy brain publish book spark revolutionary new science exercise brain give watch ted talk title run jump learn exercise transform school earlier mentioned creative teacher name mickey hart effort help brain suffering alzheimer appear ratey be teach exercise hart have be do music concert cerebral lobe be connect imaging equipment display massive screen overhead so fan see brain music have also be investor biogen biib free report maker different drug clinical trial treat alzheimer unfortunately sell position recently stock fall stock vault last week positive datum company amyloid plaque target drug throw be almost clinical trial dementia related be exact have fail past decade so even pfizer throw towel recently search new compound neuroscientist dementia expert have always question narrow focus biotech company amyloid protein cause cure battleground even now be lot excitement phase trial datum be statistically significant evidence ban antibody target beta amyloid protein slow progression deadly disease term cognition amyloid reduction most analyst be still predict final drug have only percent chance get approve phase trial aducanumab be biogen other alzheimer drug currently phase trial win see datum biogen have expand study size number patient trial drug sentiment turn so sour biib share so be review ban month be originally deem unsuccessful month time patient trial demonstrated statistically significant slow disease progression compare take placebo company better chance success drug alzheimer be probably investment be reconsider many sell stock manager model portfolio zack call healthcare innovator pose question subscriber last week have exposure alzheimer think answer be undoubtedly yes most common form dementia be believe expert alzheimer single handedly bankrupt medicare matter decade degeneration neural function be so rapid debilitating researcher not give fight heavy investment find cure even stabilize treatment cure be find make sure know exercise music part strategy learn more better faster prevention alzheimer ve nickname strategy amyl be also first letter amyloid protein plaque be believe drown neuron alzheimer be sure check podcast hear amyl stand disclosure own share nvda zack tazr trader share blue crsp zack healthcare innovator kevin cook be senior stock strategist zack investment research run healthcare innovator tazr trader service click follow author receive latest stock research macro analysis
1,BIIB,abbvie abbv free report announce combination regimen blockbuster cancer drug imbruvica ibrutinib fail phase iii study dbl evaluate first line treatment diffuse large cell lymphoma dlbcl drug fail improve event free survival ef compare current standard care dlbcl be aggressive form hodgkin lymphoma nhl type blood cancer new therapy have be approve decade treatment naive patient chop combination rituximab doxorubicin vincristine prednisone chemotherapy be standard care patient share abbvie slide jul follow news company share have decrease year date compare industry decline phase iii study be conduct collaboration johnson johnson jnj free report evaluate imbruvica combination chop versus chop placebo together primary endpoint study be superiority ef combination regimen be investigate treatment dlbcl patient have germinal center cell gcb activate cell abc subtype patient subtype commonly have poorer treatment outcome greater unmet medical need however datum study demonstrated improvement certain patient sub population be clinically meaningful be analyze further company present detailed analysis study future scientific conference publish peer review medical journal separate press release abbvie partner roche rhhby free report announce submission supplemental new drug application snda label expansion leukemia drug venclexta venetoclax snda be seek approval venclexta combination hypomethylating agent hma low dose cytarabine ldac treat newly diagnosed patient acute myeloid leukemia aml be ineligible intensive chemotherapy snda be file base datum separate early stage study evaluate venclexta combination mha ldac venclexta label be expand last month monotherapy combination roche biogen biib free report rituxan treatment relapse refractory chronic lymphocytic leukemia small lymphocytic lymphoma second later line setting abbvie inc price abbvie inc price abbvie inc quoteabbvie currently carry zack rank buy see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2,BIIB,positive datum release bigwig biogen inc biib free report mid stage study treatment alzheimer disease create stir biotech sector last week other news celgene corporation celg free report report positive datum key pipeline candidate late stage study axovant axon free report gain yet licensing deal recap important story biogen soar positive alzheimer study result share biogen soar company report encourage top line result mid stage study pipeline candidate ban treatment early alzheimer disease ad ban amyloid beta protofibril antibody be be evaluate phase ii study ad biogen be develop ban humanize beta amyloid antibody collaboration japan eisai co ltd candidate be be investigate see slow progression memory problem associate amyloid top line result final analysis phase ii study demonstrated statistically significant slow disease progression key clinical endpoint adcom month treatment patient receive highest treatment dose mg kg biweekly ban compare placebo meanwhile treatment high dose month also lead reduction amyloid beta accumulate brain read more biogen alzheimer disease candidate succeed phase ii positive result give investor much reason cheer ad have always be challenge market give spate study failure recent time so abovemention result be deem important breakthrough biogen eisai ad market raise hope possible cure biogen currently carry zack rank hold see complete list today zack rank strong buy stock here celgene report positive datum thalassemia drug late stage study celgene corporation partner acceleron pharma inc xlrn free report report positive result second randomize double blind multus center clinical phase iii study believe pipeline candidate result show achieve highly statistically significant improvement primary endpoint erythroid response be defined least reduction baseline red blood cell rbc transfusion burden reduction least unit protocol defined period consecutive week week week compare placebo moreover also meet key secondary endpoint demonstrate statistically significant improvement rbc transfusion burden baseline least reduction period week week notably be second positive phase iii study candidate last month company announce positive result phase iii study medalist meet primary key secondary endpoint compare placebo patient ipss very low low intermediate risk myelodysplastic syndrome mds chronic anaemia third study be also ongoing evaluate transfusion dependent beta thalassemia read more celgene acceleron report positive datum thalassemia drug meanwhile celgene also announce positive result phase iii study impassion experimental combination roche immuno oncology drug tecentriq abraxane former compare abraxane monotherapy significantly reduce risk disease worsening death pfs patient metastatic unresectable locally advanced triple negative breast cancer axovant gain yet gene therapy deal axovant science share gain announce licensing agreement benitec biopharma agreement axovant license exclusive global right experimental silence replace gene therapy program benitec biopharma treatment oculopharyngeal muscular dystrophy opmd axovant obtain right axo aav opmd utilize proprietary silence replace technology axo aav opmd be adeno associate viral aav vector gene therapy deliver time intramuscular administration silence mutant pabpn gene replace functional copy be currently preclinical development stage axovant plan initiate placebo controlled clinical study candidate enjoy orphan drug status unite state europe treatment opmd company have also enter research collaboration development additional gene therapy product neurological disorder agreement benitec bolster axovant pipeline innovative gene therapy serious neurological disease read more axovant benitec gain licensing deal gene therapy idera announce termination merger agreement biocryst idera pharmaceutical inc idra free report announce merger agreement biocryst pharmaceutical have be terminate stockholder latter vote same special meeting consequently biocryst reimburse idera connection termination company have enter merger agreement january biocryst gain news share idera slump majority idera stockholder vote favor adoption merger agreement biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock biogen have gain past month celgene have lose vertex have gain see last biotech stock roundup here biotech stock roundup gild positive chmp nod regulatory update more next biotech stay tune regulatory update pipeline development news more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3,BIIB,biogen inc biib free report be star performer friday trading session stock rally much close little lower rise day trade massive gain biotech firm come encourage phase clinical study datum alzheimer treatment final analysis month patient phase clinical study ban early alzheimer disease demonstrated statistically significant slow cognitive decline reduction amyloid beta accumulate brain company press release amyloid beta protein fragment be find brain patient suffering disease believe cause alzheimer be most common form dementia affect person worldwide accord alzheimer association currently be treatment disease way stop progression however food drug administration have approve medication treat symptom related memory loss language other thought process see healthcare etfs here such result mark important milestone company quest tackle alzheimer disease fact analyst welcome news first trial study drug be disappointing result risk environment many investor pull capital high growth high beta sector other large cap biotech stock also gain gilead gild free report celgene celg free report amgen amgn free report suggest investor be pin hope fast grow company see trading come day etf trading stock world also send biotech etfs space green day particular ishare nasdaq biotechnology etf ibb free report steal show climb follow more gain first trust amex biotechnology index fbt free report invesco dynamic biotechnology genome etf pbe free report vaneck vector biotech etf bbh free report fund provide exposure firm tracking nasdaq biotechnology index biogen take top spot ibb be most popular fund be biotech space aum expense ratio come ibb have zack etf rank hold high risk outlook read small cap biotech etfs be soar fund follow nyse arca biotechnology index measure performance company biotechnology industry be primarily involved use biological process develop product provide service hold security basket biogen occupy fifth position share charge bps annual fee have accumulate asset base have zack etf rank buy high risk outlook read sector etfs crushed year bull run fund provide exposure firm tracking dynamic biotech genome intellidex index biogen take top spot asset etf have manage asset base charge expense ratio have zack etf rank high risk outlook read pharma biotech etfs soar trump drug plan fund offer exposure large biotechnology corporation tracking mvis list biotech index here biogen be fifth firm accounting share bbh have amassed asset base charge bps fee year have zack etf rank strong buy high risk outlook lie ahead uptrend sector be likely continue year tax reform rise positive regulatory backdrop read top rank sector etfs buy new tax legislation have entice large pharmaceutical company bring offshore cash back home reduce tax rate instead prior repatriate money lead increase merger acquisition activity share buyback dividend additionally slower growth mature drug have also compel prominent biotechs acquire smaller one even hefty premium promising pipeline further trump most await plan lower drug price have add strength be not enough sector cyclical nature be advantage current market be ruffle trade war fear china unite state well geopolitical tension want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
4,BIIB,wall street continue winning streak second straight session major stock index close positive territory friday investor ignore trade conflict unite state china strong job addition june indicated fundamental economy remain robust reduce concern unite state be late stage economic expansion offer little sweetness market participant healthcare stock gain most record breaking performance biogen lift entire sector dow jone industrial average dji close index inx increase close nasdaq composite index ixic close gain point total share be trade friday lower last session average share advancer outnumber decliner nyse ratio nasdaq advancer have edge decliner ratio cboe vix decrease close do benchmark perform dow rise stock index close green trade red trading blue chip index rally point close point higher gain lead rise health care select sector xlv increase technology select sector spdr xlk notably sector benchmark index end positive territory healthcare sector share price biogen inc biib free report increase biggest gain february follow announcement positive result phase trial alzheimer drug ban likewise tech heavy nasdaq composite gain point due strong show large tech stock such apple inc aapl free report microsoft corp msft free report facebook inc fb free report facebook carry zack rank buy see complete list today zack rank strong buy stock here robust labor market dataon jul department labor report economy add farm job june outpace consensus estimate moreover bureau labor statistic revise april job addition together month add more job initially state unemployment rate have increase june however rise unemployment rate be primarily due increase labor force participation rate june american re enter job market professional business service sector add highest number job follow manufacturing health care construction notably average wage rate rise marginally year year basis be lower consensus estimate however low wage hike indicate hyper inflationary expectation be overblown enable fed follow steady state rate hike policy economic datum commerce department report trade deficit unite state decline figure be lowest month trade deficit reduce revise april read be also lower consensus estimate export be record import rise marginally weekly roundupdespite trade induced volatility wall street end appositive note first week july major stock index close green reverse straight weekly loss dow nasdaq composite gain respectively market close slightly higher monday initial decline owing uncertainty revolve president trump trade policy be reversed rally tech stock see index end day positive territory survive choppy trading session market close lower tuesday selloff tech stock pare earlier gain make energy stock trade war fear continue haunt investor feel jittery lead huge selloff see major index end negative territory however thursday market close higher lead rally tech stock major index end green look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
5,BIIB,several major biotech stock rally friday biogen biib free report report positive result phase study ban therapy seek reduce toxic amyloid protein associate cognitive decline alzheimer disease share biogen be more afternoon trading hour thursday japan eisai co esaly free report partner ban development see gain nearly momentum be enough lift rest biotech space evidence ishare nasdaq biotechnology index fund ibb free report add biotech giant biogen celgene celg free report amgen amgn free report gilead gild free report have underperform broader nasdaq index past year industry likely need positive news spark optimistic trading speaking street real money column atlantic equity analyst steve chesney say investor finally be notice value effort company be believe innovation company biogen come report positive clinical result disease alzehimer imply probability success rest industry pipeline move little bit higher chesney tell street celgene share add touch intraday month high meanwhile amgen moved higher gilead gain more biogen latest test include patient early alzheimer disease company share positive result group period month nevertheless trial be still only phase challenge phase additional regulatory hurdle be still loom still biogen hope commercialize ban timely manner new product likely inspire positive analyst sentiment lift growth prospect come year past month zack consensus estimate biogen earning have drop share share mark year year growth early estimate have company earning peg share represent increase year project total biib be currently sporting zack rank hold medical biomedical genetic industry be sit bottom zack industry rank want more market analysis author make sure follow ryan_mcqueeney twitter make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
6,BIIB,sanofi sny free report announce committee medicinal product human use chmp european medicine agency ema have issue positive opinion recommend approval cablivi caplacizumab marketing authorization application maa be seek approval candidate treatment patient experience episode acquire thrombotic purpura attp rare blood clot disorder be first drug receive chmp recommendation treatment attp potential approval european medical agency expect come month help drug gain market share first mover advantage indication sanofi add candidate pipeline acquisition ablynx earlier january stock have lose so far year underperform industry decrease maa be backed positive datum phase ii titan study phase iii hercule study evaluate cablivi combination standard care datum show combination achieve significantly shorter time platelet count response significant reduction attp related death recurrence attp least major thromboembolic event follow study be evaluate cablivi patient have complete hercule study long term safety efficacy candidate biologic license application be expect be file cablivi unite state year note genentech subsidiary roche rhhby free report biogen inc biib free report be develop rituxan partnership be currently be evaluate phase ii study treatment attp sanofi be focuse strengthen leadership rare disease have make few acquisition year so far regard albynx acquisition have also add respiratory syncytial virus nanobody sanofi pipeline apart albynx sanofi acquire bioverativ add hemophilia candidate company also obtain global right fitusiran alnylam pharmaceutical inc alny free report be be develop treatment hemophilia sanofi price sanofi price sanofi quotesanofi currently carry zack rank sell see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
7,BIIB,biogen inc biib free report share be market trading thursday positive top line datum mid stage study evaluate pipeline candidate ban treatment early alzheimer disease ad biogen be develop ban humanize beta amyloid antibody collaboration japan eisai co ltd amyloid be protein form plaque brain person alzheimer candidate be be investigate see slow progression memory problem associate amyloid top line result final analysis phase ii study demonstrated statistically significant slow disease progression key clinical endpoint adcom month treatment patient receive highest treatment dose mg kg biweekly ban compare placebo meanwhile treatment high dose month also lead reduction amyloid beta accumulate brain study include dose regimen datum marked important breakthrough biogen eisai challenge ad market lead share price increase however so far year biogen share have decline almost inline industry decline same time frame late datum announce same study fail show early positive result raise investor concern candidate chance success independent datum monitoring committee say ban do not meet criterium success base bayesian analysis month primary endpoint study fail show early positive result company say blind study be be conduct patient mild cognitive impairment mci due ad mild alzheimer dementia collectively know early alzheimer disease continue comprehensive final analysis be conduct month detailed datum study be expect be present future conference alzheimer fatal illness cause progressive decline memory have always be highly challenge area not much progress be make spite significant investment fund resource several company have fail develop safe effective treatment option deadly brain disease last month lilly lly free report swiss partner astrazeneca azn free report discontinue late stage study alzheimer disease candidate lanabecestat recommendation idmc idmc say study be unlikely meet primary goal completion back november lilly say not seek approval investigational ad treatment solanezumab follow disappointing result late stage study year jnj free report halter development atabecestat investigational bace inhibitor be be develop preclinical stage ad due safety concern february year merck discontinue second late stage study evaluate bace inhibitor verubecestat treatment prodromal ad success be unlikely february last year merck discontinue late stage study evaluate verubecestat mild moderate ad due lack efficacy january pfizer say end effort alzheimer parkinson disease area long back pfizer have shelved late stage ad candidate bapineuzumab iv fail phase iii study setback several company continue invest heavily develop alzheimer disease treatment give high commercial potential market success area mean huge return consider more american be live alzheimer disease number expect triple datum alzheimer association be consider be biggest burden society be sixth lead cause death age unite state market have immense commercial potential company come new treatment rake billion dollar sale biogen currently carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
8,BIIB,sarepta therapeutic inc srpt free report be star performer tuesday trading session stock sky-rocket much new high close little lower rise read sector etfs crushed year bull run surge propel company market cap more make fifth most valuable drugmaker headquarter massachusett biogen biib free report vertex pharmaceutical vrtx free report alexion pharmaceutical alxn free report alnylam pharmaceutical alny free report massive gain mid cap biotech firm come encourage early trial result gene therapy duchenne muscular dystrophy dmd study be conduct patient reveal average reduction more creatine kinase enzyme find muscle cell leak bloodstream damage have occur muscle day indicate sarepta muscular dystrophy drug successfully treat produce robust level protein protect muscle cell dmd be rare genetic disease marked progressive muscle degeneration cause physical disability life threaten problem heart respiratory system disease mostly affect boy age typically kill patient age positive clinical trial also send share fellow dmd gene therapy developer solid bioscience sldb free report more yesterday see healthcare etfs here etf news lead surge biotech etfs especially virtus lifesci biotech product etf bbp free report ishare nasdaq biotechnology etf ibb free report andspdr biotech etf xbi free report trio have rise respectively fact bbp xbi touch new week high bbp etf follow lifesci biotechnology product index measure performance biotechnology company primary product offer product candidate have receive food drug administration approval hold stock sarepta therapeutic take fourth position basket share product have accumulate aum charge bps fee year have zack etf rank buy high risk outlook ibb fund provide exposure firm tracking nasdaq biotechnology index sarepta accounting asset ibb be most popular fund be biotech space aum expense ratio come ibb have zack etf rank hold high risk outlook read small cap biotech etfs be soar xbi aum xbi provide equal weight exposure stock tracking biotechnology select industry index sarepta be seventh firm fund portfolio make share xbi have expense ratio zack etf rank high risk outlook bottom linein fact etfs clearly outpaced other product biotech space last trading session alp medical breakthrough etf sbio free report virtus lifesci biotech clinical trial etf bbc free report add just day product have exposure sarepta therapeutic want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
9,BIIB,drug stock value trap opportunity tracey top stock pick health service industry episode roundup podcast zack comwelcome episode value investor podcastevery week tracey ryniec editor zack value investor portfolio service share top value investing tip stock pick recently investor stocktwit twitter have be ask drug stock look valuation see many be dirt cheap trading single digit es problem be street hate make perfect value investor retail energy stock be hate last several year too have stage big turnaround drug stock be next big turnaround success story definition value trapremember value trap be stock look cheap base basic value fundamental ratio doesn company trading earning sometimes reason cheapness investor have look value fundamental earning be rise fall rise earning low tell something right be go company earning decline be sign company have lose way value stock trap gilead science gild free report have forward just share be last year have gain time be earning expect do biogen biib free report be trading forward year date share be ve gain prior year estimate have be cut last day be earning growth celgene celg free report have take beating year share fall year date now trading forward just cheap be trap lannett lci free report be cheapest group have forward only take chance share be year date have fall prior year valeant vrx free report have have problem last few year share have rebound be compare return also cheap forward just be bottom earning decline be lot category healthcare sector include insurer hospital device manufacturer staffing other drug company have be hit especially hard just re cheap however doesn mean re good buy investor need do homework value stock trap find week podcast wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
10,BIIB,alzheimer fatal illness cause progressive decline memory have always be highly challenge area not much progress be make spite significant investment fund resource tuesday lilly lly free report swiss partner astrazeneca azn free report say be discontinue late stage study alzheimer disease candidate lanabecestat recommendation independent datum monitoring committee idmc idmc say study be unlikely meet primary goal completion prompt decision stall study oral beta secretase cleave enzyme bace inhibitor several company have fail develop safe effective treatment option deadly brain disease year jnj free report halter development atabecestat investigational bace inhibitor be be develop preclinical stage ad due safety concern february year merck mrk free report discontinue second late stage study evaluate bace inhibitor verubecestat treatment prodromal ad success be unlikely february last year merck discontinue late stage study evaluate verubecestat mild moderate ad due lack efficacy january pfizer pfe free report say end effort alzheimer parkinson disease area long back pfizer have shelved late stage ad candidate bapineuzumab iv fail phase iii study late biogen biib free report ad study ban fail show early positive result raise investor concern candidate chance success clinical stage company axovant science suffer major setback september investigational ad candidate fail meet co primary efficacy endpoint late stage study company decide discontinue development mg dose treatment ad lilly decide november not seek approval investigational ad treatment solanezumab follow disappointing result late stage study candidate be be evaluate see slow progression memory problem associate amyloid protein form plaque brain person alzheimer accord alzheimer association year drug be test alzheimer study register clinicaltrial gov only succeed go gain fda approval be somewhat underlie cause severe neurological ailment alzheimer not be clear disease cancer also alzheimer progress go unnoticed year time symptom ailment become evident significant function be already lose make develop drug treat disease difficult interest still alive setback several company continue invest heavily develop alzheimer disease treatment give high commercial potential market success area mean huge return consider more american be live alzheimer disease number expect triple datum alzheimer association be consider be biggest burden society be sixth lead cause death age unite state market have immense commercial potential company come new treatment rake billion dollar sale biogen novartis nvs free report eisai astrazeneca amgen be presently work alzheimer disease treatment biogen ad pipeline comprise mid well late stage candidate different mechanism action include tau candidate biib amyloid aducanumab candidate well bace inhibitor elenbecestat program candidate be be develop collaboration eisai meanwhile novartis amgen be collaborate bace inhibitor cnp have fast track status unite status roche be collaborate ac immune development alzheimer disease treatment lilly astrazeneca be also develop treatment alzheimer disease antibody target beta amyloid early stage study earlier year fda propose new guideline be aim lower clinical study goal alzheimer disease drug aim treat earlier stage patient have not yet display functional disability clinical abnormality strategy be part fda ongoing effort expand access safe effective treatment option many serious condition effort fda also reinvigorate research effort alzheimer drug repeat failure lilly merck carry zack rank buy see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
11,BIIB,roche holding rhhby free report announce fda have approve rituxan rituximab treatment adult moderate severe pemphigus vulgaris pv company rituxan be first biologic therapy approve fda pv remind investor fda have grant priority review breakthrough therapy designation orphan drug designation rituxan treatment pv be autoimmune blister disease affect skin mucous membrane pf affect person unite state result approval rituxan be now approve treat autoimmune disease rheumatoid arthritis ra granulomatosis polyangiitis gpa microscopic polyangiitis mpa pv approval be base datum ritux trial compare ritux regimen eu approve rituximab product short term corticosteroid cs cs alone first line treatment patient newly diagnosed moderate severe pemphigus result study show pv patient treat ritux regimen meet endpoint compare pv patient treat cs alone note roche subsidiary genentech biogen biib free report have collaboration agreement rituxan unite state roche market mabthera brand name rituxan outside unite state rest world japan rituxan be co market chugai zenyaku kogyo co ltd approval new drug potential label expansion exist drug bode well roche legacy drug herceptin mabthera be face competition biosimilar sale mabthera rituxan be first quarter sale europe be adversely impact market entry biosimilar roche stock have lose last month compare industry decline novartis nvs free report have already launch biosimilar version rituxan mabthera europe amgen amgn free report have also obtain fda approval biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer zack rankroche currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
12,BIIB,have be month last earning report biogen inc biib free report share have add time frame recent positive trend continue lead next earning release be biib due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important driver biogen top earning miss salesfirst quarter earning share be beat zack consensus estimate earning rise year year backed lower expect cost lower tax rate sale come year period however sale marginally miss zack consensus estimate revenue growth be principally drive spinraza growth international market biosimilar other revenue performance ms franchise spinraza unite state be soft quarter top line exclude hemophilia revenue grow year year quarter detailbiogen multiple sclerosis ms revenue be reporter quarter include approximately royalty sale roche ms drug ocrevus ms revenue decline year year sequentially expect competition ocrevus seasonality larger expect inventory drawdown unite state hurt performance biogen ms franchise first quarter however call company say demand ms product unite state improve quarter discontinuation remain relatively stable international market see strong progress emerge market tecfidera sale increase year year however tecfidera sale decline sequentially include sale year year ex sale unite state tecfidera sale be affected inventory drawdown compare drawdown approximately first quarter last year exclude impact tecfidera revenue have be flat year year tecfidera price increase offset impact ocrevus meanwhile patient growth major european market strong emerge market growth drive international tecfidera sale positive impact currency also benefit international growth tysabri sale decline year year be flat sequentially tysabri sale decline quarter hurt ocrevus launch seasonality inventory dynamic international revenue decline quarter due recognition previously defer revenue prior year period be absent first quarter combine interferon revenue avonex plegridy first quarter be year year sequentially avonex revenue decline year period plegridy contribute revenue decrease year year sequentially interferon revenue be experience decline trend due patient transition other oral high efficacy ms therapy well due higher discount allowance zinbryta launch collaboration abbvie contribute revenue first quarter compare fourth quarter spinraza register revenue first quarter almost line previous quarter strong international growth be offset moderate performance unite state expect spinraza sale quarter be mainly drive ex market spinraza sale be first quarter decrease sequentially due lower expect uptake adult segment however ex market spinraza record sale sequentially company say spinraza international revenue be mainly gross germany turkey japan however biogen highlighted call overall patient number grow quarter number patient spinraza grow approximately unite state outside unite state quarter biogen say sale first quarter be patient receive less intensive maintenance dose dose only once month versus previous quarter call management say growth spinraza sale be flat least next quarters give continue transition patient load phase less intensive maintenance phase management be optimistic patient start grow market capture penetrate adult segment ex expansion continue first quarter biogen record biosimilar revenue compare fourth quarter drive primarily benepali record revenue sequentially increase market share flixabi record revenue compare previous quarter revenue cd therapeutic program include biogen share rituxan gazyva operate profit climb year period primarily drive ocrevus royalty well strong performance rituxan spend increase year year decrease sequentially due higher pipeline related cost other hand sg spend be year year decrease sequentially have estimate be move then past month investor have witness downward trend fresh estimate have be revision higher current quarter compare lower biogen inc price consensus biogen inc price consensus biogen inc quotevgm scoresat time biib have nice growth score be lag lot momentum front however stock be allocate grade value side putt second quintile investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested zack style score indicate company stock be suitable value growth investor outlookestimate have be broadly trend downward stock magnitude revision indicate downward shift notably biib have zack rank hold expect line return stock next few month
13,BIIB,look broad exposure healthcare biotech segment equity market consider powershare dynamic biotechnology genome portfolio pbe free report passively manage exchange trade fund launch excellent vehicle long term investor passively manage etfs be popular choice institutional retail investor due low cost transparency flexibility tax efficiency sector etfs be also fund convenience offer many way gain low risk diversify exposure broad group company particular sector healthcare biotech be broad zack sector zack industry classification be currently rank place bottom index fund be sponsored invesco powershare have amassed asset make average size etfs attempt match performance healthcare biotech segment equity market pbe seek match performance dynamic biotechnology genome intellidex index fee expense be comprise stock biotechnology genome company be company be principally engage research development manufacture marketing distribution various product service process company benefit significantly scientific technological advance biotechnology genetic engineering research costsexpense ratio be important factor return etf long term cheaper fund significantly outperform more expensive counterpart other thing remain same annual operate expense etf be make par most peer product space have month trail dividend yield sector exposure top holdingsit be important delve etf holding investing many upside kind fund diversify exposure minimize single stock risk most etfs be very transparent product disclose holding daily basis etf have heaviest allocation healthcare sector portfolio look individual holding illumina inc ilmn free report account total asset follow qiagen nv qgen free report biogen inc biib free report top holding account total asset management performance riskso far year pbe have gain approximately last year past week period fund have trade etf have beta standard deviation trail year period make high risk choice space holding have more concentrated exposure peer dynamic biotechnology genome portfolio hold zack etf rank buy be base expect asset class return expense ratio momentum other factor pbe be outstanding option investor seek exposure health care etfs segment market be other additional etfs space investor consider well spdr biotech etf xbi free report track biotechnology select industry index ishare nasdaq biotechnology etf ibb free report track nasdaq biotechnology index spdr biotech etf have asset ishare nasdaq biotechnology etf have xbi have expense ratio ibb charge bottom lineto learn more product other etfs screen product match investment objective read article latest development etf investing universe please visit zack etf center
14,BIIB,biotech space remain key area investor focus several bigwig announce quarterly result alexion alxn free report report solid result gilead gild free report report dismal number other development week regeneron regn free report sanofi announce plan lower price praluent amgen amgn free report receive positive opinion prolium recap important story progress report company alexion gilead vertex vrtx free report other report first quarter result last trading session alexion vertex deliver solid result quarter gilead earning sale miss estimate wider expect decline hcv franchise follow result alexion raise guidance also report positive datum long act complement inhibitor alxn show patient pnh be effectively safely switch treatment soliris week treatment alxn week tentative approval bode well alexion read more alexion earning beat estimate guidance vertex first quarter result be drive stellar performance cf product read more vertex earning beat strong cf product sale gilead be zack rank buy stock see complete list today zack rank strong buy stock here amgen get positive opinion prolium amgen announce committee medicinal product human use chmp european medicine agency ema have adopt positive opinion marketing authorization prolium treatment bone loss associate long term systemic glucocorticoid therapy adult patient increase risk fracture chmp opinion now be review european commission meanwhile company supplemental biologic license application prolium expand indication be also review unite state prescription drug user fee act action date note drug be already approve unite state treatment postmenopausal woman osteoporosis high risk fracture addition chmp have adopt positive opinion recommend label variation kyproli carfilzomib include final overall survival datum phase iii trial aspire demonstrated addition kyproli lenalidomide dexamethasone krd reduce risk death versus lenalidomide dexamethasone alone rd extend os month patient relapse refractory multiple myeloma regeneron partner sanofi cut praluent price regeneron partner sanofi announce company lower net price pcsk inhibitor praluent alirocumab injection more affordable patient access express script consequently praluent become exclusive pcsk inhibitor therapy express script national formulary agreement effective jul provide praluent lower net price enable streamline patient access base physician attestation meanwhile fda have accept priority review company biologic license application cemiplimab treatment patient metastatic cutaneous squamous cell carcinoma cscc patient locally advanced cscc be not candidate surgery candidate be grant breakthrough therapy designation status fda september target action date be oct biogen negotiate agreement neurimmune biogen biib free report neurimmune announce former have exercise option further reduce previously negotiate royalty rate payable potential future sale alzheimer disease candidate aducanumab candidate be currently phase iii result biogen make time payment neurimmune exchange reduction original royalty rate potential commercial sale aducanumab company have earlier announce reduction royalty rate reduce royalty rate potential commercial sale aducanumab be high single digit low teen biogen license worldwide right aducanumab neurimmune biomedical genetic industry yr return medical biomedical genetic industry yr return nasdaq biotechnology index gain last trading session major biotech stock alexion gain last month regeneron lose vertex gain see last biotech stock roundup here biotech stock roundup prta amgn revise view biib miss sale next biotech stay tune more earning regulatory update look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
15,BIIB,cti biopharma corp ctic free report privately hold partner servier announce failure pivotal phase iii study evaluate cancer drug pixuvri combination roche rhhby free report biogen biib free report rituxan rituximab treatment cell hodgkin lymphoma nhl cti biopharma share fall almost jul follow disappointing news however share company have rally so far year industry gain pivotal pix study compare pixuvri rituxan combination regimen combination chemo drug gemcitabine rituxan treatment aggressive cell nhl form blood cancer patient disease relapse follow chop chemotherapy datum study show patient treat pixuvri regimen fail achieve improvement progression free survival compare patient treat gemcitabine regimen however company have plan conduct thorough review datum study cti biopharma expect submit datum pix study european medicine agency review end pixuvri have conditional approval europe monotherapy treatment multiply relapse refractory aggressive cell nhl however be yet receive approval unite state be approximately newly diagnosed nhl patient year unite state europe several company be develop drug treatment disease few be develop most advanced form cancer treatment car therapy treat nhl include celgene celg free report lisocabtagene disappointing datum pix study negatively impact pixuvri prospect already competitive market cti biopharma corp price cti biopharma corp price cti biopharma corp quotezack rankcti biopharma currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
16,BIIB,biotech sector witness series event past week quite few company report quarterly result week announce pipeline update past week amgen revise annual guidance biogen report quarterly number sale miss estimate recap important story prothena plunge discontinuation study share prothena corp prta free report plunge company decide discontinue development lead pipeline candidate neod candidate antibody be be evaluate treatment al amyloidosis phase iib study pronto do not meet primary secondary endpoint hence company ask independent datum monitoring committee dmc phase iii vital study review futility analysis ongoing vital study thereafter dmc recommend discontinuation vital study futility hence company decide discontinue study development neod include vital study well open label extension study decision come major blow investor company have very limit number candidate pipeline neod be lead candidate prothena carry zack rank buy see complete list today zack rank strong buy stock here incyte lilly drug get fda advisory committee nod incyte corp incy free report eli lilly company lly free report announce fda arthritis advisory committee have recommend approval mg dose baricitinib once daily oral medication treatment moderately severely active rheumatoid arthritis adult patient have have inadequate response intolerance methotrexate however advisory committee do not recommend approval mg dose baricitinib propose indication base adequacy safety benefit risk profile fda be generally not require follow advisory committee recommendation consider same review nda baricitinib fda have earlier issue complete response letter same drug be approve olumiant europe amgen revise annual guidance amgen inc amgn free report revise guidance concurrent first quarter result company beat sale earning first quarter drive strong performance newly recently launch drug company now expect revenue be compare earlier estimate earning share be now project come compare earlier estimate biogen miss sale biogen biib free report miss revenue estimate first quarter spinraza sale be drab company lead multiple sclerosis franchise also see sale decline biotech have be struggle nevertheless earning beat estimate share re-cover end positive note end session earlier company also extend collaboration ionis pharmaceutical ion free report new year agreement develop novel antisense drug candidate broad range neurological disease agreement biogen pay ionis cash include purchase share ionis common stock price share read more biogen earning beat sale miss share calithera kidney cancer candidate get fast track status share calithera bioscience inc cala free report gain company announce fda have grant fast track designation lead candidate cb candidate be be develop combination exelixis exel cabozantinib treatment metastatic kidney cancer calithera cb selective potent inhibitor glutaminase be be evaluate phase ii study cantata combination cabometyx clear cell renal cell carcinoma patient previously treat least vascular endothelial growth factor tyrosine kinase inhibitor combination opdivo yervoy read more calithera kidney cancer candidate get fast track status biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index lose last trading session major biotech stock alexion lose last month regeneron lose vertex gain see last biotech stock roundup here biotech stock roundup alk cldx alxn acquire wilson therapeutic next biotech world stay tune quite be schedule report result later week early next week investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
17,BIIB,novartis ag nvs free report announce encourage datum phase iii study expand oral once daily siponimod baf patient secondary progressive multiple sclerosis spms siponimod be investigational selective modulator specific subtype sphingosine phosphate receptor result be present american academy neurology annual meeting los angele be schedule be hold apr randomize double blind placebo controlled expand study be compare efficacy safety siponimod versus placebo spms patient datum study show siponimod reduce risk disability progression largely disassociate relapse patient spms new post analysis also demonstrated risk reduction siponimod be largely disassociate relapse datum study show siponimod result significant benefit cognitive process speed key cognitive function impact ms impact affected patient meanwhile novartis have initiate submission siponimod unite state approval spms filing eu approval be plan follow later potential approval strengthen novartis ms portfolio include gilenya fingolimod modulator approve relapse form ms be also development pediatric ms interferon beta subcutaneous injection be approve unite state treatment relapse form ms novartis also have ms candidate pipeline apart siponimod ofatumumab omb fully human monoclonal antibody be evaluate phase iii study relapse ms generic division sandoz market glatopa glatiramer acetate injection mg ml mg ml generic version teva teva free report copaxone give complexity market ms drug have long history serious side effect make risky therapeutic area autoimmune inflammatory disease centrol nervous system ms disrupt normal function brain optic nerve spinal cord inflammation tissue loss be type ms widely know affect adult relapse remit ms spms primary progressive ms however competition be stiff market biogen biib free report be dominant player ms market drug avonex tysabri tecfidera plegridy zinbryta fda recently issue refusal file letter celgene celg free report new drug application ozanimod be development treatment patient relapse form multiple sclerosis novartis stock have lose last month compare industry decline share have decline further follow first quarter result be report yesterday revenue earning beat estimate sale psoriasis drug cosentyx fall short expectation sandoz revenue decline due pricing pressure zack ranknovartis currently carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
18,BIIB,biogen inc biib free report well know name multiple sclerosis ms market report first quarter result apr market open last quarter company deliver negative earning surprise biogen share have decline year underperform industry decline same time frame biogen earning performance have be decent so far have deliver positive surprise last quarters average earning beat last quarters be biogen inc price ep surprise biogen inc price ep surprise biogen inc quotelet see thing be shape considerin fourth quarter biogen witness higher sale multiple sclerosis drug patient growth major european market strong emerge market growth drive international tecfidera sale inventory build quarter benefit sale however call biogen mentioned seasonality absence inventory build benefit fourth quarter result hurt performance ms franchise first quarter continue competitive pressure especially roche rhhby free report newly launch ms drug ocrevus hurt performance biogen ms franchise particularly sale tysabri zack consensus estimate sale tecfidera first quarter be peg tysabri global market sale be fourth quarter conference call biogen say ocrevus launch have witness decrease number patient start increase discontinuation tysabri unite state negative trend continue quarter combine number patient used avonex plegridy be expect decline patient transition other oral ms therapy well due higher discount allowance zinbryta be unlikely have make significant contribution revenue quarter march biogen partner abbvie announce decision withdraw zinbryta market less year approval due grow safety concern limit commercial adoption drug due restrictive label company decide discontinue marketing drug ground complex evolve benefit risk profile zinbryta update be expect first quarter conference call biogen newly launch drug spinraza approve spinal muscular atrophy be likely see strong demand trend particularly international market fourth quarter conference call biogen management have say significant portion spinraza revenue growth be expect come outside unite state biogen biosimilar product flixabi biosimilar reference remicade benepali biosimilar reference enbrel be also generate significant revenue trend continue quarter well fourth quarter call company have also say operate expense be expect be sequentially lower first quarter however earning growth be expect be higher second fourth quarters yearearning whispersour proven model do not conclusively show biogen be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be most accurate estimate stand zack consensus estimate be peg higher uncover best stock buy sell re report earning esp filter zack rank biogen zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considerbiotech stock have positive esp favorable zack rank include alexion pharmaceutical inc alxn free report schedule release result apr have earning esp zack rank see complete list today zack rank stock here amgen inc amgn free report have earning esp zack rank company be schedule release result apr wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
19,BIIB,earning season have start gather steam latest earning preview member accounting index have already release financial figure apr total earning member have report result already be same period last year higher revenue beating ep estimate beating revenue estimate proportion company beating ep revenue estimate be ongoing earning phase seem have also begin encouragingly drug biotech sector major large cap player johnson johnson jnj free report kick season strong note beating zack consensus estimate earning well sale large cap player report earning last week be novartis nvs free report also surpass earning revenue expectation quarter also biogen inc biib free report release result week surpass earning miss sale expectation higher demand be expect boost new product sale also innovation successful product line expansion positive clinical study result fda approval consistent performance key product grow demand drug especially rare treat disease agee population well increase healthcare expenditure be factor keep sector growth trajectory also accord earning preview broader medical sector inclusive drug biotech well medical device company be likely record year year growth revenue rise earning quarter review pharma biotech giant be schedule report earning result apr let see thing be shape company upcoming release abbvie inc abbv free report be slate releaseresult market open company deliver positive earning surprise last report quarter moreover company performance have be impressive recent past earning surpass expectation trail quarters average positive earning surprise proven model show abbvie be likely beat earning be report quarter have right combination key ingredient positive earning esp zack rank hold zack consensus estimate company earning quarter review be peg share company key drug humira be likely remain key growth driver first quarter backed strong demand trend drug abbvie expect humira sale reflect rise low teen band imminent earning release internationally growth rate be project mid single digit range operationally other drug namely duopa creon be also likely maintain encourage performance soon be report quarter read more be beat card abbvie earning abbvie inc price ep surprise abbvie inc price ep surprise abbvie inc quote alexion alxn free report be slate report result open bell company deliver positive earning surprise last report quarter company track record be excellent have consistently top estimate last quarters average positive earning surprise alexion be likely beat earning be report quarter have positive earning esp zack rank buy zack consensus estimate quarterly earning be peg share see complete list today zack rank strong buy stock here alexion blockbuster drug soliris continue perform well company be work expand soliris label additional indication alexion recently announce acquire sweden base wilson therapeutic transaction be expect close second quarter acquisition add late stage candidate wtx alexion pipeline candidate be currently phase iii treatment wilson disease rare genetic disorder alexion be look diversify portfolio reduce dependence blockbuster drug soliris deal strengthen alexion rare disease pipeline late stage candidate read more be beat store alexion earning season alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc quote bristol myer squibb bmy free report be slate report result open bell company deliver positive earning surprise last quarter company deliver positive earning surprise trail quarters average beat model show bristol myer be likely beat estimate quarter combination bristol myer zack rank positive earning esp make confident earning beat upcoming report consensus mark quarter be report be peg cent share bristol myer blockbuster immuno oncology drug opdivo be expect remain main sale driver first quarter follow several line extension soon be report quarter company announce encourage result phase iii study evaluate opdivo first line small cell lung cancer label expansion leukemia drug sprycel approve november bring more sale drug moreover continue strong performance yervoy orencia have favorable impact read more be beat store bristol myer earning bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quote vertex pharmaceutical incorporate vrtx free report be slate report result market close vertex track record have be impressive so far company deliver positive earning surprise last quarters average positive earning surprise last quarters be last report quarter vertex deliver positive earning surprise model show vertex be likely beat estimate quarter combination bristol myer zack rank positive earning esp make confident earning beat upcoming report consensus mark quarter be report be peg cent share uncover best stock buy sell re report earning esp filter vertex cystic fibrosis cf drug kalydeco orkambi perform well sale rise almost expect positive trend continue soon be report quarter also boost vertex cf franchise fda approve vertex third cf drug symdeko be combination tezacaftor ivacaftor february expect company provide update symdeko plan initial uptake company be also likely provide full year revenue guidance include symdeko sale call read more be beat store vertex earning season vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate quote investor alert breakthrough pending medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
20,BIIB,biogen inc biib free report report first quarter earning share beat zack consensus estimate moreover bottom line rise year year sale come year period however metric marginally miss zack consensus estimate top line exclude hemophilia revenue grow year year remind investor last year biogen spun hemophilia business new company call bioverativ earlier january sanofi sny free report announce have enter agreement bioverativ buy latter share biogen be more pre market trading stock have decline year so far underperform industry decrease quarter detailbiogen multiple sclerosis ms revenue be year year reporter quarter include approximately royalty sale roche rhhby free report ms drug ocrevus deal roche biogen be entitle receive royalty sale ocrevus oral ms drug tecfidera sale increase year year decrease sequentiallyto other ms drug tysabri sale decline year year be flat sequentially combine interferon revenue avonex plegridy first quarter be year year sequentially avonex revenue decline year period plegridy contribute revenue decrease year year sequentially interferon revenue be experience decline trend due patient transition other oral ms therapy well due higher discount allowance zinbryta launch collaboration abbvie abbv free report contribute revenue first quarter compare fourth quarter notably march biogen announce decision withdraw zinbryta market less year fda approval due grow safety concern limit commercial adoption drug restrictive label company decide discontinue drug marketing ground complex evolve benefit risk profile biogen newest drug spinraza spinal muscular atrophy logged revenue first quarter almost line previous spinraza sale be first quarter decrease sequentially however ex market spinraza record sale sequentially significantly number patient receive spinraza grow unite state outside unite state quarter review compare precede period company say spinraza international revenue be mainly gross germany turkey japan first quarter biogen record biosimilar revenue compare fourth quarter revenue cd therapeutic program include biogen share rituxan gazyva operate profit climb year period spend increase year year decrease sequentially other hand sg spend be year year decrease sequentially biogen inc price consensus ep surprise biogen inc price consensus ep surprise biogen inc quotezack rankbiogen carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
21,BIIB,share ptc therapeutic inc ptct free report gain jun follow presentation encourage preliminary datum part pivotal firefish study study be evaluate pipeline candidate risdiplam rg baby type spinal muscular atrophy sma early stage datum have show promising motor function improvement milestone achievement baby datum be present last weekend annual sma researcher meeting datum study show risdiplam achieve point increase baseline chop intend score more baby year day chop intend be test determine motor milestone development patient sma type firefish study be part program collaboration roche rhhby free report sma foundation part be dose escalation safety assessment study part ii evaluate select dose part baby type sma month enrollment part ii firefish study be underway follow presentation share rival company biogen inc biib free report fall more monday remind investor biogen spinraza be available treatment sma pediatric adult patient successful development risdiplam likely have unfavorable impact spinraza sale generate biogen total product sale first quarter note follow completion acquisition avexis novartis also add sma candidate pipeline create potential large cap competitor biogen ptc therapeutic so far year ptc therapeutic share have sky-rocket compare increase register industry ptc therapeutic be evaluate risdiplam several clinical study apart firefish candidate be be evaluate part pivotal study sunfish treatment patient type ii iii sma exploratory study be currently evaluate risdiplam patient have receive treatment therapy target smn splice clinical study sma be rare neuromuscular disorder cause muscle atrophy due loss motor neuron spinal cord lead impair movement patient press release new born baby have debilitating disease ptc therapeutic inc price ptc therapeutic inc price ptc therapeutic inc quotezack rank stock considerptc therapeutic currently carry zack rank hold aeglea biotherapeutic inc agle free report be better rank stock pharma sector carry zack rank buy see complete list today zack rank strong buy stock here aeglea loss estimate narrow last day company deliver positive earning surprise trail quarters average beat share price have increase so far year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
22,BIIB,roche rhhby free report announce encourage datum final analysis cll study evaluate gazyva base treatment previously untreated chronic lymphocytic leukaemia cll phase iii multicenter open label randomize arm study be conduct evaluate safety efficacy profile gazyva combination chlorambucil compare mabthera combination chlorambucil chlorambucil alone nearly patient previously untreated cll comorbidity final result follow almost year show clinically meaningful improvement gazyva chlorambucil multiple endpoint include progression free survival pfs overall survival os compare head head rituxan chlorambucil long term datum confirm gazyva efficacy extend life patient suffering cll compare mabthera rituxan gazyva base treatment reduce risk death compare mabthera rituxan base treatment gazyva be approve combination chlorambucil patient previously untreated cll roche be leader oncology market wide portfolio drug breast cancer cll other additionally roche announce new datum multiple sclerosis ms drug ocrevus be present congress european academy neurology ean jun lisbon portugal datum new exploratory analysis extend control period phase iii study oratorio primary progressive multiple sclerosis ppms patient show ocrevus significantly delay time need wheelchair year measure length time person reach expand disability status scale greater edss used week confirm disability progression cdp patient treat ocrevus show reduction risk progress wheelchair compare placebo treat group analysis also show placebo treat patient population study oratorio have similar disability progression rate untreated real world ppms population extrapolate median time wheelchair edss placebo treat person oratorio study be year longer term efficacy safety datum be consistent drug favourable benefit risk profile ppms relapse ms rm addition new global study floodlight open be now enrolling patient unite state study used proprietary floodlight mobile technology collect monitor anonymize patient datum help gain better understand ms disease progression study be observational open access study aim enroll person globally include person relapse progressive form ms year roche be initiate new phase iiib study ocrevus ms market hold immense potential competition be stiff like biogen inc biib free report approval new drug potential label expansion exist drug bode well roche legacy drug herceptin mabthera be face competition biosimilar roche stock have lose last month compare industry decline novartis nvs free report have already launch biosimilar version rituxan europe amgen amgn free report have also obtain fda approval biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer zack rankroche currently carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
23,BIIB,biotech sector be focus last week regular pipeline update collaboration licensing deal biotech bigwig amgen amgn free report drug win fda ec approval axovant axon free report soar licensing deal oxford biomedica meanwhile regeneron regn free report collaborate zoetis new veterinary treatment recap important story amgen get fda nod addition datum kyproli amgen announce fda have approve supplemental new drug application snda add positive overall survival os datum phase iii trial aspire myeloma drug kyproli datum add label show kyproli revlimid dexamethasone krd significantly reduce risk death extend overall survival month versus revlimid dexamethasone alone rd patient relapse refractory multiple myeloma addition european commission ec approve label expansion prolium denosumab treatment bone loss associate long term systemic glucocorticoid therapy adult patient increase risk fracture be third indication prolium have receive ec approval read more amgen get fda nod add aspire datum kyproli label amgen prolium get label expansion approval europe regeneron collaborate zoetis regeneron announce year collaboration agreement zoetis latter use monoclonal antibody therapeutic animal new veterinary treatment term regeneron have grant zoetis license proprietary velocimmune antibody technology latter use develop monoclonal antibody modify species specific use companion livestock animal exchange regeneron receive license fee approval sale milestone payment royalty potential veterinary treatment axovant science soar gene therapy deal share axovant science gain company announce have license exclusive worldwide right develop commercialize axo lentipd oxford parkinson disease axo lentipd formerly oxb be experimental gene therapy be develop parkinson disease deliver gene encode critical set enzyme require dopamine synthesis brain axovant plan initiate phase ii dose escalation study axo lentipd patient advanced parkinson disease end term agreement axovant make initial payment cash obtain right axo lenti pd well predecessor product prosavin be apply credit process development work clinical supply oxford biomedica provide axovant addition oxford biomedica also be entitle receive additional development regulatory commercial milestone payment potentially excess tiered royalty net sale axo lenti pd approve meanwhile axovant receive equity financing roivant science support clinical development axo lenti pd additional business development company also get new chief technology officer fraser read more axovant gain licensing deal oxford biomedica axovant currently sport zack rank strong buy see complete list today zack rank stock here biogen acquire asset thrombosis biogen biib free report enter exclusive option agreement tms co ltd acquire tms backup compound upfront payment agreement also include additional payment biogen exercise option potential development milestone well tiered royalty tms plasminogen activator enable restore blood flow follow acute stroke extend treatment window versus current standard care candidate be currently be evaluate double blind placebo controlled phase ii study japan safety efficacy single iv administration tms approximately patient ais hour stroke onset first patient be dose february acquisition be line biogen effort broaden neurology portfolio alexion team complement pharma alexion pharmaceutical inc alxn free report announce partnership complement pharma co develop preclinical complement inhibitor cp disorder cp be humanize monoclonal antibody preclinical stage bound circulation inhibit function body prevent mac formation periphery central nervous system alexion complement pharma collaborate development program cp complement pharma be responsible conduct preclinical phase study well manufacturing cp exchange alexion provide complement pharma milestone dependent payment phase ib development alexion be look develop pipeline reduce dependence key drug soliris pipeline development read more alexion complement pharma tie treat neuro disorder biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock vertex gain past month celgene have lose vertex have gain see last biotech stock roundup here biotech stock roundup regeneron celgene amgen impress asco next biotech stay tune regulatory update pipeline development news hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
24,BIIB,biogen inc biib free report announce have sign option agreement private biotech tms co ltd acquire latter phase ii acute stroke candidate tms backup compound biogen be expect pay upfront additional exercise option payable potential milestone payment tms design restore blood flow follow acute stroke be be evaluate phase ii study august candidate complete phase study acquisition biogen aim boost acute neurology portfolio strategic move company growth pursue innovative approach therapeutic area biogen already have phase iii ready pipeline candidate biib development prevention treatment edema large hemispheric infarction severe type stroke however february biogen multiple sclerosis ms drug tysabri natalizumab fail meet primary secondary endpoint phase iib program evaluate indication acute ischemic stroke ais investor believe natalizumab failure ais study be reason buyout tms biogen core business area be multiple sclerosis ms disable disease brain spinal cord key multiple sclerosis drug portfolio be tecfidera avonex tysabri however be look diversify business aim be leader neuroscience adjacent therapeutic space biogen add new clinical stage program neuroscience pipeline advance internal pipeline candidate well external deal year march biogen agree acquire phase iib ready candidate pf cognitive impairment associate schizophrenia cia pfizer pfe free report january biogen acquire right karyopharm phase ready investigational oral compound kpt certain neurological condition primarily focuse amyotrophic lateral sclerosis al biogen plan start phase trial end share biogen have lose year date outperform industry decline biogen currently carry zack rank hold better rank stock same sector include crispr therapeutic ag crsp free report genomic health inc ghdx free report sporting zack rank strong buy see complete list today zack rank stock here crispr therapeutic loss share estimate have narrow last day stock have sky-rocket year date genomic health earning estimate surge past day stock have soar so far year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
25,BIIB,pfizer inc pfe free report say plan invest pfizer venture venture capital arm funding be invest small biotechs other emerge growth company newly available fund be earmark company involved promising early stage neuroscience research pfizer venture first invest company focus neuro degeneration neuro inflammation neuro metabolic disorder pfizer venture already have investment neuroscience company include aquinnah autifony cortexyme mindimmune mission neuronetic pfizer become part dementia discovery fund ddf be form speed development new treatment neurological disease bring together major pharma company government alzheimer research uk fund be involved financing new early stage drug development project launch october ddf have raise more have be invest dementia drug discovery company project other investor ddf include biogen biib free report eli lilly lly free report glaxo gsk free report other other neuroscience venture capital arm area interest include oncology inflammation immunology rare disease internal medicine vaccine pfizer venture manage more company currently have new member pfizer have already invest venture capital arm latest funding total asset management add more year so far pfizer share have increase decrease industry ironically news come less month pfizer say drop plan develop treatment disorder alzheimer parkinson disease be highly challenge area not much progress be make significant investment fund well resource pfizer currently carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
26,BIIB,investor biotech sector be glue last week highly await annual meeting american society clinical oncology asco overshadowed usual regulatory other update space meeting hold chicago jun jun provide company platform showcase datum scientist physician investment community other focus be mainly asco datum company biogen biib free report vertex vrtx free report remain limelight pipeline update recap important story biogen eisai report encourage datum elenbecestat biogen partner eisai announce encourage result alzheimer candidate elenbecestat bace inhibitor phase ii study study study be multicenter randomize double blind placebo controlled parallel group month study patient mild cognitive impairment mci due alzheimer disease mild moderate dementia due alzheimer disease confirm amyloid pathology pet positron emission tomography screening patient be randomize treatment arm receive elenbecestat mg placebo daily more half patient elenbecestat mg mg arm be switch mg arm month more datum show elenbecestat be generally safe well tolerate result demonstrated statistically significant difference amyloid beta aβ level brain measure amyloid pet suggest delay clinical symptom decline exploratory endpoint eisai biogen be jointly develop elenbecestat march company be currently conduct global phase iii study mission ad early alzheimer disease biogen currently carry zack rank hold see complete list today zack rank strong buy stock here vertex crispr sickle cell disease candidate put hold vertex pharmaceutical incorporate crispr therapeutic announce fda have place clinical hold investigational new drug application ind ctx treatment sickle cell disease pending resolution certain question raise fda company have submit ind fda april support plan initiation phase ii trial unite state adult patient sickle cell disease ctx be experimental gene edit autologous hematopoietic stem cell therapy be also be evaluate patient suffering thalassemia sickle cell disease fda clinical hold company plan initiate phase ii trial ctx europe adult patient transfusion dependent thalassemia crispr vertex equally share research development cost profit worldwide ctx read more vertex crispr sickle disease candidate put hold fda sarepta get negative chmp opinion exondys sarepta therapeutic inc srpt free report announce committee medicinal product human use chmp european medicine agency ema have adopt negative opinion duchenne muscular dystrophy dmd candidate exondys eteplirsen negative opinion be expect follow oral explanation trend vote consequently sarepta request re examination opinion result assignment new rapporteur co rapporteur additionally sarepta request scientific advisory group sag dmd be call turn allow neuromuscular specialist provide expert guidance insight other thing validity external control used importance certain functional endpoint re examination be complete end finally look asco result celgene celg free report have multiple presentation oncology drug revlimid pomalyst other experimental therapy american society clinical oncology asco annual meeting chicago il result transcend study experimental cd direct car cell therapy candidate lisocabtagene maraleucel liso cel jcar patient relapse refractory aggressive cell hodgkin lymphoma nhl be encourage read more celgene present datum car therapy revlimid pomalyst regeneron regn free report partner sanofi also announce datum trial evaluate cemiplimab advanced cutaneous squamous cell carcinoma asco datum study show patient treat cemiplimab experience robust tumor effect cemiplimab treat patient show response rate median observed time response month datum cut date gilead gild free report kite also announce result ongoing phase study asco show clinical response be observed investigational cell receptor tcr cell therapy target human papillomavirus type hpv solid tumor cancer cause hpv meanwhile gilead have also collaborate hookipa biotech ag obtain exclusive right hookipa therat vaxwave arenavirus vector base immunization technology major chronic infectious disease indication hepatitis virus hbv human virus hiv gilead partner galapago nv also announce phase ii study equator pipeline candidate filgotinib achieve primary endpoint improvement sign symptom psoriatic arthritis week amgen amgn free report also announce result phase iii trial asco show kyproli administer once weekly mg dexamethasone achieve superior progression free survival pfs overall response rate orr compare twice weekly kyprolisat mg dexamethasone twice weekly kd patient relapse refractory multiple myeloma separately share amgen be fda approve biosimilar blockbuster drug neulasta biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock gilead gain past month celgene have lose alexion have gain see last biotech stock roundup here biotech stock roundup gild epclusa china approval bmrn palynziq fda nod next biotech stay tune regulatory update pipeline development news today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
27,BIIB,novartis ag nvs free report announce fda have approve label expansion multiple sclerosis ms drug gilenya fingolimod drug have be approve treatment child adolescent age relapse form multiple sclerosis rm drug be first disease modify therapy indicated individual age note gilenya be already approve unite state first line treatment rmsin adult europe adult patient highly active relapse remit ms rrm approval gilenya patient age be support datum phase iii paradigm study study meet primary endpoint show oral gilenya result significant clinically meaningful reduction number relapse annualize relapse rate child adolescentsover period year compare interferon beta intramuscular stock have lose year date compare industry decline apart gilenya novartis ms portfolio include interferon beta subcutaneous injection be approve treatment relapse form ms company also other pipeline candidate baf siponimod omb ofatumumab investigation relapse ms novartis generic division sandoz market glatopa generic version teva pharmaceutical teva free report copaxone mg note biogen inc biib free report hold strong position ms market wide range product include avonex tysabri tecfidera plegridy zack rank stock currently carry zack rank hold better rank stock same space be ligand pharmaceutical lgnd free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate moved past day company deliver positive earning surprise trail quarters average beat company share have rally year date novartis ag price novartis ag price novartis ag quote medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
28,BIIB,mylan myl free report be partner fujifilm kyowa kirin biologic co ltd commercialize biosimilar abbvie abbv free report blockbuster arthritis drug humira adalimumab adalimumab be develop fujifilm kyowa kirin biologic mylan intend seek approval commercialize product europe european medicine agency ema accept marketing authorization application review propose biosimilar humira company expect receive ema decision second half agreement mylan have exclusive license commercialize biosimilar europe receive upfront fee fujifilm kyowa kirin company also be responsible sale activity product european country other hand fujifilm kyowa kirin biologic be eligible receive subsequent milestone payment sale royalty year share mylan increase compare industry fall humira be tnf inhibitor aim treat multiple chronic inflammatory condition be approve europe treatment rheumatoid arthritis juvenile idiopathic arthritis psoriatic arthritis ankylose spondylitis crohn disease ulcerative colitis plaque psoriasis hidradenitis suppurativa uveitis note few day biogen inc biib free report partner samsung bioepis announce resolution ongoing patent dispute abbvie regard biogen biosimilar version imraldi abbvie humira eu settlement agreement biogen samsung bioepis plan launch imraldi europe oct also unite state samsung bioepis enter settlement agreement abbvie allow former bring humira biosimilar market jan notably imraldi be second biosimilar version humira be launch eu biotechnology company amgen amgn free report be also expect launch biosimilar version humira eu come october year amjevita settlement abbvie notably amjevita be approve eu last march approve unite state september unite state settlement abbvie amjevita be likely be launch jan mylan price mylan price mylan quote zack rankmylan carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
29,BIIB,biotech sector be bumpy ride week share spectrum surge positive datum phase ii study incyte plunge failure melanoma study effort bolster presence gene therapy space swiss giant novartis announce acquisition avexis inc spectrum surge lung cancer datum share spectrum pharmaceutical inc sppi free report surge company report encourage result phase ii study poziotinib egfr exon mutant small cell lung cancer patient result show confirm objective response rate be first patient better expectation early datum suggest poziotinib have meaningful impact outcome patient have limit treatment option median progression free survival rate have still not be reach median follow period month meanwhile original cohort egfr patient be fully enrolled expand cohort patient be near completion enrollment avexis skyrocket novartis deal avexis inc share sky-rocket news merger swiss pharma giant novartis nvs free report agreement novartis pay clinical stage gene therapy company avexis lead product candidate avxs be be evaluate time gene replacement therapy spinal muscular atrophy disease result early death life long disability considerable healthcare cost acquisition poise novartis promising gene therapy space acquisition be complete mid candidate enjoy breakthrough therapy designation unite state prime designation europe fda also grant avxs fast track status treatment sma type regulatory filing unite state be expect second half year launch anticipate read more novartis inks gene therapy deal buy avexis incyte plunge study failure share incyte corporation incy free report plunge external datum monitoring committee review phase iii study echo keynote evaluate incyte epacadostat combination merck keytruda patient unresectable metastatic melanoma determine study do not meet primary endpoint improve progression free survival overall population compare keytruda monotherapy moreover second primary endpoint overall survival be not expect reach statistical significance hence study be stop failure late stage candidate disappoint investor incyte have pin hope success give improve response rate mid stage study read more incyte epacadostat fail melanoma study share plunge conatus pharmaceutical sink study failure conatus pharmaceutical cnat free report plummet report pipeline candidate emricasan fail phase iib study polt hcv svr candidate do not achieve primary endpoint study evaluate patient fibrosis cirrhosis undergo liver transplant datum polt hcv svr study show emricasan do not achieve better overall response rate compare placebo overall patient population however patient subset advanced fibrosis early cirrhosis emricasan provide evidence fibrotic treatment effect patient compare placebo company evaluate emricasan further particular subset read more conatus emricasan fail phase ii study share sink biogen settle litigation abbvie humira biosimilar biogen inc biib free report partner samsung bioepis announce agreement abbvie abbv free report imraldi biosimilar humira term abbvie grant patent license use sale imraldi europe country country basis biogen samsung bioepis make royalty payment abbvie company have agree dismiss pending patent litigation biogen plan launch biosimilar europe october samsung bioepis enter settlement agreement abbvie allow former bring humira biosimilar market jan read more biogen crack case abbvie humira biosimilar biogen carry zack rank hold see complete list today zack rank strong buy stock here performance nasdaq biotechnology index lose last trading session major biotech stock alexion fall last month celgene lose vertex gain see last biotech stock roundup here biotech stock roundup edge fall alk fda amgn drug label expansion medical biomedical genetic industry yr return medical biomedical genetic industry yr return next biotech world stay tune more regulatory pipeline update medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
30,BIIB,abbvie inc abbv free report have announce pipeline candidate upadacitinib meet primary endpoint phase iii study select program evaluate candidate treatment patient rheumatoid arthritis ra upadacitinib be investigational oral jak selective inhibitor be be study once day oral therapy phase iii select compare study be design evaluate efficacy safety upadacitinib mg compare placebo abbvie market drug humira adalimumab week patient moderate severe ra be stable background methotrexate have inadequate response study upadacitinib meet primary well secondary endpoint compare placebo show superiority compare humira primary endpoint study register acr response clinical remission datum trial demonstrated patient receive oral once daily dose upadacitinib mg achieve acr response compare patient receive placebo week moreover subject treat upadacitinib achieve complete remission comparison placebo additionally datum study also show patient experience low disease activity secondary endpoint treat upadacitinib compare receive humira receive placebo week notably select compare be fourth ongoing phase iii study select ra clinical trial program conduct upadacitinib remind investor last december abbvie announce upadacitinib meet primary endpoint rd phase iii study select trial other research be also underway upadacitinib treat crohn disease ulcerative colitis atopic dermatitis share abbvie have rally past year outperform industry rise notably abbvie already have strong presence ra market blockbuster drug humira however several company be work develop biosimilar version humira induce competition market company also ra market be extremely crowd include drug johnson johnson simponi ucb cimzia other significantly eli lilly lly free report jak inhibitor olumiant be approve eu ra last february pfizer pfe free report xeljanz be market unite state same indication strong competition upadacitinib approval also late biogen biib free report have announce resolution ongoing patent dispute abbvie regard biogen biosimilar version humira eu settlement agreement biogen plan launch humira biosimilar europe october however upadacitinib be approve reduce potential negative impact humira generic abbvie top line abbvie inc price abbvie inc price abbvie inc quotezack rankabbvie carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
31,BIIB,novartis nvs free report announce have inked deal acquire base clinical stage gene therapy company avexis inc avexis be focuse develop novel treatment patient suffering rare life threaten neurological genetic disease pursuant agreement novartis execute acquisition subsidiary cash tender offer share avexis common stock represent premium culmination transaction be subject customary close condition novartis anticipate completion buyout second half board company have approve acquisition deal share novartis swiss drug maker inched pre market trading apr follow news release avexis stock also soar pre market trading session novartis stock have outperformed industry year date have lose comapr industry decline impending buyout add avexis lead candidate avxs acquirer portfolio strengthen latter presence gene therapy neuroscience space avxs be be develop treatment spinal muscular atrophy sma disease accounting highest genetic cause death infant notably fda european medicine agency ema have grant avxs orphan drug designation treatment sma fda have grant avxs fast track status treatment sma type regulatory agency have also grant breakthrough therapy designation avxs address sma type pediatric patient regulatory filing unite state be expect second half year launch anticipate company also secure prime sakigake designation candidate europe japan respectively significantly approve product cure sma unite state be biogen biib free report spinraza nusinersen first only treatment get fda nod country indication however approve avxs be first ever time gene replacement therapy sma unite state apart avxs deal also expand novartis pipeline other genetic disorder include rett syndrome amyotrophic lateral sclerosis initially acquisition be anticipate negatively impact novartis operate income due increase research development expense be later expect substantially contribute company bottom line onward remind investor january novartis enter licensing agreement spark therapeutic develop commercialize latter gene therapy luxturna voretigene neparvovec market outside unite state note luxturna be approve unite state last december time gene therapy restore functional vision child adult patient biallelic mutation rpe retinal pigment epithelial kda protein gene novartis ag price novartis ag price novartis ag quote zack rank key picknovartis carry zack rank hold better rank stock health care sector be ligand pharmaceutical incorporate lgnd free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved north last day company deliver positive surprise trail quarters average beat share price company have surge year zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
32,BIIB,biogen inc biib free report partner samsung bioepis have announce resolution ongoing patent dispute abbvie abbv free report regard biogen biosimilar version imraldi abbvie blockbuster arthritis drug humira eu settlement agreement biogen samsung bioepis plan launch imraldi europe oct also unite state samsung bioepis enter settlement agreement abbvie allow former bring humira biosimilar market jan imraldi sb be used whole range indication include rheumatoid arthritis axial ankylose spondylitis plaque psoriasis psoriatic arthritis crohn disease ulcerative colitis polyarticular juvenile idiopathic arthritis active enthesitis related arthritis hidradenitis suppurativa infectious uveitis notably imraldi be second biosimilar version humira be launch eu biotechnology company amgen amgn be also expect launch biosimilar version humira eu come october year amjevita settlement abbvie notably amjevita be approve eu last march approve unite state september unite state settlement abbvie amjevita be likely be launch jan share biogen have underperform industry year so far stock have lose compare industry decrease remind investor biogen have joint venture samsung biologic biosimilar call samsung bioepis already market couple biosimilar eu namely flixabi biosimilar reference merck mrk free report remicade benepali biosimilar reference amgen pfizer pfe free report enbrel development turn make imraldi third tnf biosimilar biogen receive marketing authorization eu biogen be also work samsung biologic introduce new biosimilar market importantly biogen gross biosimilar revenue month period end december compare logged upside be primarily drive benepali record revenue compare year figure increase market share biogen inc price biogen inc price biogen inc quote zack rankbiogen carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
33,BIIB,multiple sclerosis ms space hit headline once again follow biotech bigwig biogen biib free report partner abbvie abbv free report decision withdraw jointly own ms drug zinbryta voluntarily worldwide basis due risk liver injury company decide withdraw drug ground complex evolve benefit risk profile zinbryta give limit number patient treat november european medicine agency ema conclude review zinbryta review find unpredictable potentially fatal immune mediate liver injury occur treatment zinbryta month stopping treatment clinical trial patient receive zinbryta have serious liver reaction give complexity market ms drug have long history serious side effect make risky therapeutic area autoimmune inflammatory disease centrol nervous system ms disrupt normal function brain optic nerve spinal cord inflammation tissue loss be type ms widely know affect adult relapse remit ms rrm secondary progressive ms spms primary progressive ms ppms market ms change drastically introduction oral formulation be mostly prefer injection variety drug available ms come own set risk mostly biogen be dominant player ms market drug avonex tysabri tecfidera plegridy zinbryta however company have be scrutiny pricing ms drug earlier emergence progressive multifocal pml case type brain infection associate use tysabri tecfidera have mar prospect ms drug fda thereafter update label tecfidera nevertheless company be name reckon ms market earlier fda also issue warning novartis nvs free report gilenya pml drug be recently grant breakthrough therapy designation gilenya treatment child adolescent year age older relapse ms drug be already approve same adult novartis have ms drug portfolio glatopa generic version copaxone mg sandoz company generic arm recently win fda approval generic version copaxone mg israel base teva pharmceutical teva free report have long be ms market widely used drug copaxone be face stiff competition last few year meanwhile past seizure be know side effect ms drug ampyra seizure risk be see increase higher blood level drug result fda have update ampyra label clarify recommendation kidney function be checked patient start ampyra monitored least annually ampyra treatment continue nevertheless risk associate drug have not deter newer entrant claim better formulation lesser side effect consequently market have become too crowd march fda approve roche rhhby ocrevus treat adult relapse form ms primary progressive multiple sclerosis however be question ocrevus be new innovation reformulation roche older drug rituxan drug sale aren impressive yet fda recently issue refusal file letter celgene celg free report new drug application nda ozanimod be development treatment patient relapse form multiple sclerosis fda determine nonclinical clinical pharmacology section nda be insufficient permit complete review hence company be now gear meet fda determine future course action haven be safety issue report delay definitely open avenue competition give so much be happen space expect investor remain glue further update hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
34,BIIB,acorda therapeutic inc acor free report report adjust earning cent share fourth quarter miss zack consensus estimate however bottom line significantly increase year figure cent acorda share decrease almost follow earning release fact stock have dip year time compare favorably industry decline total revenue come surpass zack consensus estimate moreover top line improve year year owing higher net product well royalty revenue quarter detailmajority acorda net product revenue be generate company key drug ampyra rake sale quarter revenue grow year year sequentially ampyra be market ex market biogen inc biib free report trade name fampyra biogen pay royalty acorda outside sale fampyra fampyra royalty be year year notably fourth quarter royalty revenue massively surge year figure acorda research development expense decline year year selling general administrative sg expense also lower pipeline updatesin december acorda resubmit new drug application nda fda pipeline candidate inbrija treatment option address period symptom parkinson affected person udergo carbidopa levodopa regimen company expect response regulatory agency month remind investor last august company have receive refusal file letter fda connection nda inbrija regulatory body deem application incomplete preliminary review want additional support information reassess filing subsequently discuss fda resolve issue company resubmit same aforementioned period notably acorda have defer plan submit regulatory application inbrija eu first quarter earlier expect be file end november company announce have discontinue phase iii study lead parkinson disease candidate tozadenant decision be prompt serious safety issue detected study acorda expect report efficacy safety datum phase iii trial first quarter resultsfull year sale increase year year beating zack consensus estimate top line also surpass preliminary result full year earning share miss zack consensus estimate however bottom line be significantly higher year figure cent company maintain ampyra net sale guidance range be lower ampyra full year revenue due expect generic entry drug unite state july company continue project sg expense band respectively acorda await positive cash balance excess end acorda therapeutic inc price consensus ep surprise acorda therapeutic inc price consensus ep surprise acorda therapeutic inc quote zack rank key picksacorda carry zack rank sell better rank stock health care sector be exelixis inc exel free report xoma corporation xoma free report exelixis sport zack rank strong buy xoma carry zack rank buy see complete list today zack rank stock here exelixis earning share estimate have be revise upward cent cent last day company pull positive surprise trail quarters average beat share price company have surge year time xoma loss share estimate have narrow cent cent last day company come average beat stock have sky-rocket last month wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
35,BIIB,merck co inc mrk free report announce be discontinue study evaluate verubecestat treatment prodromal alzheimer disease success be unlikely apecs be phase iii study evaluate efficacy safety verubecestat oral amyloid precursor protein site cleave enzyme bace inhibitor versus placebo study be stop recommendation external datum monitoring committee assessed study overall benefit risk recent interim safety analysis committee say chance observe positive risk benefit profile study continue be slim share merck decline almost tuesday past year merck share have underperform industry merck share have decline period increase industry february last year merck have discontinue study epoch phase ii iii verubecestat be evaluate mild moderate alzheimer disease due lack efficacy time committee have recommend apecs study continue unchanged alzheimer disease market have attract lot attention several company however successful development therapy treatment alzheimer disease be challenge note several company have fail regard last month pfizer pfe free report reportedly say statement end effort alzheimer parkinson disease area result layoff long back pfizer shelved late stage alzheimer candidate bapineuzumab iv fail phase iii study december biogen biib free report announce alzheimer disease study ban fail show early positive result raise investor concern candidate chance success november lilly lly free report amyloid candidate solanezumab fail meet primary endpoint late stage ad study lilly decide drop development solanezumab lilly also suffer major setback august have halt development phase iii alzheimer candidate semagacestat alzheimer disease market represent huge commercial potential successfully develop product generate billion dollar sale once launch merck carry zack rank hold see complete list today zack rank strong buy stock here don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
36,BIIB,ionis pharmaceutical ion free report be schedule report first quarter result market open last report quarter company deliver positive earning surprise company have mixed track record miss estimate twice trail quarters beating same occasion deliver average positive earning surprise notably ionis share price have decrease so far year compare industry decline let see thing be shape announcement earning whispersour proven model do not conclusively show ionis be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp represent difference most accurate estimate loss cent zack consensus estimate loss cent be uncover best stock buy sell re report earning esp filter zack rank ionis zack rank increase predictive power esp however need have positive esp be confident earning surprise note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision factor considerionis earn revenue form upfront milestone other payment partnership lead health care company biogen biib free report ionis biogen have collaborate develop commercialize spinraza ionis earn royalty spinraza sale biogen last week biogen release first quarter result announce spinraza witness strong demand international market ionis earn first quarter license fee astrazeneca related licensing fatty liver candidate azd december ionis initiate phase study evaluate antisense drug candidate ionis jbi rx patient immune disorder likely increase cost soon be report quarter apart spinraza ionis be focuse late stage candidate inotersen volanesorsen regulatory application candidate be review unite state well europe candidate be expect receive approval second half ionis be also gear launch ionis also grant exclusive worldwide license inotersen akcea therapeutic leverage latter commercial infrastructure capability successful launch drug expect investor focus be launch plan inotersen volanesorsen first quarter conference call subsequent quarter ionis announce top line datum phase ii study antisense drug candidate ionis httrx demonstrated candidate significantly reduce disease cause protein also improve clinical measure huntington disease ionis have several mid stage pipeline candidate various indication expect company provide update different study include path forward inotersen volanesorsen first quarter earning call ionis pharmaceutical inc price ep surprise ionis pharmaceutical inc price ep surprise ionis pharmaceutical inc quotestock warrant lookhere be biotech stock want consider model show too have right combination element post earning beat quarter emergent biosolution inc ebs free report have earning esp zack rank company be schedule release first quarter result seethe complete list today zack rank stock here vanda pharmaceutical inc vnda free report have earning esp zack rank company be schedule release first quarter result wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
37,BIIB,plc alk free report report adjust loss cent share first quarter wider zack consensus estimate loss cent bottom line be however narrower adjust loss cent record year quarter company revenue quarter be year year top line beat zack consensus estimate result be drive strong growth company proprietary product vivitrol aristada so far year share have lose compare industry decline revenue risemanufacture royalty revenue risperdal consta invega sustenna xeplion invega trinza trevicta be year year same ampyra fampyra be year year vivitrol sale improve year year aristada sale come year year cost riseresearch development expense be year year selling general administrative sg expense be year year company expect total revenue range drive continuous growth vivitrol aristada vivitrol sale be expect range aristada sale be anticipate range zack consensus estimate be be guidance range provide company company expect expense range company now expect sg expense range reduce previous expectation reduction be drive shift certain launch related expenditure include hire alk sale force share base compensation expense related certain company wide performance base restrict stock unit award vest fda approval alk company expect loss share be range cent share earning range cent share compare previous expectation loss share range cent zack consensus estimate be be guidance range provide company pipeline fda accept company snew drug application nda alk adjunctive treatment major depressive disorder set action date jan company complete enrollment enlighten month weight study alk compare olanzapine patient stable schizophrenia top line result be expect fourth quarter november biogen biib free report announce global license collaboration agreement develop commercialize phase iii multiple sclerosis candidate biib alk biib preparation regulatory submission have begin company remain track submit nda year end plc price consensus ep surprise plc price consensus ep surprise plc quotezack rank other stock consideralkerme be zack rank buy stock other top rank stock same space be ligand pharmaceutical lgnd free report protagonist therapeutic ptgx free report themsport zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat company share have rally year date protagonist loss estimate narrow cent last day company deliver positive earning surprise trail quarters average beat look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
38,BIIB,roche hold ag rhhby free report announce encourage datum multiple sclerosis ms drug ocrevus american academy neurology aan annual meeting hold apr los angele datum reveal efficacy ocrevus relapse multiple sclerosis rm several measure underlie disease activity disability progression include magnetic resonance imaging mri cognitive function spinal fluid biomarker inflammation datum show year continuous treatment ocrevus show sustain reduction underlie disease activity rm open label extension period patient continue ocrevus maintain low number gadolinium enhance gd lesion pre ole gd lesion scan year year ole phase new enlarge et lesion pre ole et lesion scan year ole phase safety datum be consistent drug favorable benefit risk profile relapse primary progressive multiple sclerosis additonally second year analysis present poster aan also reveal patient stay ocrevus year ole period sustain low annualize relapse rate week confirm disability progression switch interferon beta ocrevus experience significant decline arr year be maintain year further ocrevus reduce risk week confirm cognitive decline defined confirm worsening symbol digit modality test least point respectively week period person rm compare interferon beta pooled datum phase iii study opera opera ii datum show patient rm increase risk progressive disease determine baseline expand disability status scale pyramidal kurtzke functional system score least point respectively treat ocrevus experience significant improvement cognitive function compare take interferon beta week march fda approve ocrevus treat adult relapse form ms primary progressive multiple sclerosis however be uncertainty ocrevus be new innovation reformulation roche older drug rituxan drug sale aren impressive yet roche stock have lose year industry gain last week novartis nvs free report also announce encourage datum phase iii study expand oral once daily siponimod baf patient secondary progressive multiple sclerosis spms give complexity market ms drug have long history serious side effect make risky therapeutic area autoimmune inflammatory disease centrol nervous system ms disrupt normal function brain optic nerve spinal cord inflammation tissue loss be type ms widely know affect adult relapse remit ms spms primary progressive ms competition be also stiff market biogen biib free report be dominant player ms market drug avonex tysabri tecfidera plegridy zinbryta fda recently issue refusal file letter celgene celg free report new drug application ozanimod be development treatment patient relapse form multiple sclerosis zack rankroche currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
39,BIIB,key highlight week include fda acceptance regeneron sanofi dupixent sbla asthma biogen abbvie decision withdraw multiple sclerosis drug zinbryta due risk liver failure celgene completion juno acquisition recap week most important sanofi dupixent sbla asthma accept fda regeneron regn free report partner sanofi sny free report announce fda have accept review supplemental biologic license application sbla dupixent dupilumab add maintenance treatment adult adolescent year age older moderate severe asthma fda have set target action date oct prescription drug user fee act sbla be support result pivotal trial liberty asthma clinical development program sanofi regeneron be study dupilumab broad range clinical development program disease drive type inflammation include pediatric atopic dermatitis phase iii nasal polyp phase iii eosinophilic esophagitis phase iii read more fda accept regeneron sanofi dupixent sbla asthma regeneron be zack rank strong buy stock see complete list today zack rank stock here biogen abbvie withdraw zinbryta biogen biib free report partner abbvie abbv free report announce company withdraw multiple sclerosis drug zinbryta voluntarily worldwide basis due risk liver injury company decide withdraw drug ground complex evolve benefit risk profile zinbryta give limit number patient be treat drug be currently available europe unite state switzerland canada australia abbvie distribute zinbryta unite state biogen distribute drug ex market european regulatory authority provisionally restrict use zinbryta adult patient highly active relapse disease full adequate course treatment least dmt rapidly evolve severe relapse ms be unsuitable treatment other dmts follow report case fatal fulminant liver failure well case serious liver injury gilead report new datum biktarvy gilead gild free report announce encourage result week phase iii study study virologically suppress adult woman hiv infection international workshop hiv woman conference retroviruse opportunistic infection croi boston poster biktarvy be find be statistically inferior regimen contain bpi boost elvitegravir demonstrated treatment emergent resistance week ongoing study biktarvy gilead latest triple therapy be approve fda february complete regimen treatment hiv infection adult have antiretroviral treatment history read more gilead announce positive datum new hiv therapy biktarvy celgene complete juno acquisition celgene corporation celg free report announce have complete previously announce acquisition juno therapeutic inc juno focus development car chimeric antigen receptor tcr cell receptor therapeutic promising pipeline evaluate multiple target cancer indication acquisition add jcar lisocabtagene maraleucel liso cel celgene lymphoma pipeline jcar be best class cd direct car currently pivotal program relapse refractory diffuse large cell lymphoma dlbcl candidate be expect obtain regulatory approval unite state potential global peak sale approximately biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock regeneron gain last month celgene lose vertex gain see last biotech stock roundup here biotech stock round celgene suffer setback gilead team sangamo next biotech world stay tune more regulatory pipeline update hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
40,BIIB,have be month last earning report biogen inc biib free report share have lose past month underperform market recent negative trend continue lead next earning release be biib due dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst biogen top sale miss earningsfourth quarter earning share be miss zack consensus estimate earning however rise year year higher revenue make higher operate cost sale come year period sale also surpass zack consensus estimate higher ms sale spinraza outperformance lead strong top line performance quarter sale quarter also benefit inventory build increase contract manufacturing other revenue top line exclude hemophilia revenue grow year year quarter detailbiogen ms revenue be quarter include approximately royalty sale roche ms drug ocrevus tecfidera sale increase year year sequentially include sale year year ex sale patient growth major european market strong emerge market growth drive international tecfidera sale inventory build quarter benefit sale fourth quarter tysabri revenue be decrease year year sequentially tysabri sale decline quarter biogen say ocrevus launch have witness decrease number patient start increase discontinuation tysabri unite state international revenue rise quarter help large order russia patient growth major european country follow label update combine interferon revenue avonex plegridy fourth quarter be year period avonex revenue decline year period plegridy contribute fourth quarter revenue flat year year well sequentially interferon revenue be experience decline trend due patient transition other oral high efficacy ms therapy well due higher discount allowance zinbryta launch collaboration abbvie contribute revenue fourth quarter compare third quarter newly launch spinraza bring revenue fourth quarter register growth sequentially expect spinraza sale fourth quarter be mainly drive ex market spinraza sale be fourth quarter slightly better third quarter biogen say sale fourth quarter be patient receive less intensive maintenance dose dose only once month versus third quarter accord biogen spinraza revenue be derive maintenance dose end help stabilize growth trajectory however biogen say number patient therapy unite state rise third quarter ex market spinraza record sale significantly higher third quarter almost double number commercial patient therapy company say germany turkey japan account third ex revenue quarter biogen record biosimilar revenue compare third quarter drive primarily benepali record revenue sequentially increase market share flixabi record revenue compare third quarter revenue cd therapeutic program include biogen share rituxan gazyva operate profit climb year period expect operate expense be higher fourth quarter company continue invest strategic priority spend rise year year sequentially sg spend rise year year sequentially resultsfull year sale top zack consensus estimate sale rise year year top line exclude hemophilia revenue grow year year adjust earning be share fall short zack consensus estimate earning rise year year outlookbiogen guide earning range share represent growth revenue be expect range represent year year growth biogen say ms franchise sale growth include ocrevus royalty be roughly flat level exclude ocrevus royalty ms sale be expect decline low single digit range far spinraza be concern significant portion revenue growth be expect come outside unite state expense be expect be approximately total revenue sg be expect range lower level first quarter outlookon call company say seasonality absence inventory build benefit fourth quarter result hurt performance ms franchise first quarter meanwhile operate expense be expect be lower first quarter compare fourth quarter however earning growth be expect be higher second fourth quarters year have estimate be move then turn fresh estimate flatlined past month have be revision higher current quarter compare lower look back additional day see even more upward momentum have be move higher compare lower month biogen inc price consensus biogen inc price consensus biogen inc quote vgm scoresat time biib have nice growth score grade same score momentum front follow exact same course stock be also allocate grade value side putt second quintile investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested base score stock be equally suitable value growth momentum investor outlookbiib have zack rank hold expect line return stock next few month
41,BIIB,earning season be fly start owing slew upbeat economic datum strong corporate performance president donald trump tax reform sign law however equity market have be suffering sell owing fear rise rate come performance biotech giant have be mixed bag biotech company beating market expectation few fail do so read follow etf move finally selloff set now discuss performance few biotech giant such amgen inc amgn free report gilead science gild free report biogen inc biib free report alexion pharmaceutical alxn free report earning focusamgen report fourth quarter adjust earning share miss zack consensus estimate unchanged year quarter company also miss zack consensus estimate revenue amgen report revenue miss zack consensus estimate decrease year quarter full year company report decrease revenue however gaap ep increase company expect gaap ep be range also expect revenue be range moreover amgen expect adjust tax rate be owing tax reform gilead science report fourth quarter adjust earning share surpass zack consensus estimate decrease share year quarter moreover company also beat zack consensus estimate revenue company report revenue surpass zack consensus estimate decrease more year quarter full year company report decrease revenue moreover gaap ep decrease period company expect full year revenue be range adjust expense adjust sg expense be project range respectively biogen inc report fourth quarter adjust earning share miss zack consensus estimate increase share year quarter company report revenue surpass zack consensus estimate increase roughly year quarter full year company report increase revenue moreover gaap ep increase biogen expect earning be range share company expect full year revenue be range alexion pharmaceutical inc report fourth quarter adjust earning share surpass zack consensus estimate increase roughly share year quarter company report revenue beat consensus estimate increase roughly year quarter full year company report increase revenue moreover gaap ep increase company expect full year revenue be range company expect gaap ep be range now discuss few etfs high exposure company discuss ishare nasdaq biotechnology etf ibb free report fund seek provide exposure biotech industry have aum charge fee basis point year fund have exposure amgen biogen gilead alexion feb fund have return year have zack etf rank hold high risk outlook vaneck vector biotech etf bbh free report fund have aum charge fee basis point year fund have exposure amgen gilead biogen alexion feb fund have return year have zack etf rank high risk outlook proshare ultra nasdaq biotechnology etf bib free report fund have aum charge fee basis point year fund have exposure amgen biogen gilead alexion dec fund have return year want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
42,BIIB,fourth quarter earning season be full swing financial figure member index already jan latest earning preview total earning index member jump year quarter drive improvement revenue beat ratio be bottom line top line positive note ongoing earning phase seem have begin well drug biotech sector major large cap player johnson johnson jnj free report kick season earning beating estimate sale slightly miss same few other large pharma company release earning result last week picture look quite encourage pharma bigwig have report last week be novartis nvs free report abbvie abbv free report surpass earning sale estimate quarter review novartis raise sale guidance abbvie increase previously issue earning expectation year major player biotech sector biogen biib free report announce mixed performance report period earning lag estimate sale exceed same however celgene corp celg free report outpaced metric expectation fourth quarter drug biotech stock remain growth trajectory courtesy slew fda approval rise demand new product sale successful innovation product line expansion strong clinical report well continue robust performance legacy product moreover impressive factor regular acquisition be expect drive sector growth well also earning preview broader medical sector inclusive drug biotech well medical device company be likely record year year growth revenue rise earning period discussion pharma biotech giant be schedule report earning number jan let see thing be shape company upcoming release eli lilly company lly free report lilly be schedule release fourth quarter earning market open company deliver positive surprise last quarter lilly earning performance have be modest earning miss expectation last quarters beating same remain thus bring average beat proven model show lilly be likely beat earning quarter combination lilly zack rank increase predictive power esp solid zack rank positive earning esp make confident earning beat impending report zack consensus estimate quarter be report be peg share uncover best stock buy sell re report earning esp filter expect sturdy uptake new product trulicity taltz basaglar cyramza jardiance lartruvo upside be likely make decline sale establish product zyprexa alimta ciali strattera effient fourth quarter read more lilly report earning card vertex pharmaceutical inc vrtx free report vertex be slate release fourth quarter earning market close company track record have also be impressive so far deliver positive surprise trail quarters average beat third quarter vertex come positive surprise however proven model do not conclusively show vertex be likely beat earning quarter company favorable zack rank hold increase predictive power esp earning esp leave surprise prediction inconclusive zack consensus estimate be peg cent share see complete list today zack rank strong buy stock here vertex cystic fibrosis cf drug kalydeco orkambi perform consistently first quarters expect uptrend be reflect result soon be report quarter read more vertex report earning card don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
43,BIIB,biogen inc biib free report well know name multiple sclerosis ms market report fourth quarter result jan market open last quarter company deliver positive earning surprise biogen share have rise year better industry growth same time frame biogen earning performance have be pretty impressive so far have deliver positive surprise last quarters average earning beat last quarters be biogen inc price ep surprise biogen inc price ep surprise biogen inc quote let see thing be shape announcement factor consideron third quarter call company have warn seasonality continue competitive pressure roche rhhby free report newly launch ms drug ocrevus hurt performance ms franchise fourth quarter meanwhile combine number patient used avonex plegridy continue decline patient transition other oral ms therapy well due higher discount allowance spinraza approve spinal muscular atrophy december witness faster anticipate adoption unite state first half backed robust underlie demand however spinraza sale be slow third quarter due unfavorable timing induction dose patient transition intensive spinraza treatment less intensive maintenance schedule third quarter call company have say due impact dose scheduling spinraza sale fourth quarter mainly be drive ex market biogen biosimilar product flixabi biosimilar reference remicade benepali biosimilar reference enbrel be also generate higher revenue trend continue quarter well third quarter call company have also say operate expense be higher fourth quarter compare third company investing strategic priority investor focus fourth quarter call remain management comment impact ocrevus competition tecfidera sale prescription trend performance spinraza pipeline progress acquisition plan earning whispersour proven model do not conclusively show biogen be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be most accurate estimate stand zack consensus estimate be peg higher uncover best stock buy sell re report earning esp filter zack rank biogen zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considerbiotech stock have positive esp favorable zack rank include alexion pharmaceutical inc alxn free report schedule release result feb have earning esp zack rank see complete list today zack rank stock here emergent biosolution inc ebs free report have earning esp zack rank company be expect release result next month hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
44,BIIB,sanofi sny free report bid strengthen blood disorder portfolio be acquire bioverativ inc be focuse develop therapy hemophilia other rare blood disorder sanofi have offer share premium almost close price bioverativ jan acquire outstanding share cash deal amount transaction be approve board remind investor bioverativ be part biogen inc biib free report latter spun february bioverativ begin trading nasdaq feb share sanofi be almost pre market trading jan presumably due high cost acquisition share be meanwhile company share have increase past year underperform industry gain same time frame acquisition be beneficial sanofi leverage expertise bioverativ rare blood disorder therapy especially haemophilium moreover deal be line sanofi long term outlook strengthen presence specialty care leadership rare disease bioverativ eloctate alprolix be standard care treatment hemophilia respectively company generate sale deal also strengthen sanofi pipeline add phase iii candidate cold agglutinin disease other early stage candidate hemophilia other rare blood disorder include sickle cell disease beta thalassemia sanofi be currently develop rna base therapy fitusiran treat haemophilium company now use bioverativ clinical expertise exist commercial platform advance candidate development note sanofi earlier month gain global development right fitusiran restructure rare disease alliance alnylam pharmaceutical inc alny free report press release current haemophilium market stand be expect grow annually add standard care product portfolio certainly boost sanofi prospect lucrative market sanofi expect acquisition be accretive earning share addition add sanofi price sanofi price sanofi quote zack ranksanofi carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
45,BIIB,biogen inc biib free report report fourth quarter earning share miss zack consensus estimate earning however rise year year higher revenue make higher operate cost sale come year period sale also surpass zack consensus estimate remind investor last year biogen spun hemophilia business new company call bioverativ sanofi sny free report earlier week announce have offer buy bioverativ quarter detailbiogen multiple sclerosis ms revenue be quarter include approximately royalty sale roche rhhby free report ms drug ocrevus deal roche biogen be entitle receive royalty sale ocrevus quarter ms sale unite state include inventory buildup benefit revenue oral ms drug tecfidera sale increase year year sequentially other ms drug tysabri sale decrease year year sequentially combine interferon revenue avonex plegridy fourth quarter be year period avonex revenue decline year period plegridy contribute fourth quarter revenue flat year year well sequentially interferon revenue be experience decline trend due patient transition other oral ms therapy well due higher discount allowance zinbryta launch collaboration abbvie contribute revenue fourth quarter compare third quarter newly launch spinraza bring revenue fourth quarter register growth sequentially spinraza sale be fourth quarter much better third quarter inventory level be flat fourth quarter ex market spinraza record sale significantly higher third quarter company say spinraza international revenue be mainly germany turkey japan quarter biogen record biosimilar revenue compare third quarter revenue cd therapeutic program include biogen share rituxan gazyva operate profit climb year period expect operate expense be higher fourth quarter company continue invest strategic priority spend rise year year sequentially sg spend rise year year sequentially resultsfull year sale top zack consensus estimate sale rise year year top line exclude hemophilia revenue grow year year adjust earning be share fall short zack consensus estimate earning rise year year outlookbiogen guide earning range share zack consensus estimate share revenue be expect range zack consensus estimate be peg expense be expect be approximately total revenue sg be expect range takebiogen have mixed fourth quarter beat estimate earning miss same sale higher ms sale strong spinraza performance lead strong top line performance quarter revenue beat upbeat outlook lead share rise more pre market trading biogen share have rise past year better industry growth same time frame biogen have strong portfolio ms product however overall growth trend multiple sclerosis market be gradually slow tecfidera patient demand have be decline due increase competition oral medicine slowdown overall ms market competition ms market intensify biogen be diversify ms other area alzheimer parkinson stroke other company say have make addition neuroscience pipeline expect several important datum readout biogen carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
46,BIIB,have complete just week biotech sector be already see significant pickup merger acquisition deal year start celgene corporation celg free report announce intention acquire impact biomedicine soon thereafter nordisk nvo free report confirm be look acquire belgium base biopharma company ablynx nordisk have initially propose acquire ablynx share cash however company come back revise offer ablynx reject first proposal nordisk latest offer include upfront cash payment share contingent value right cvr worth share total equity valuation approximately offer too have be reject ablynx company board announce proposal fundamentally undervalue ablynx growth prospect last week celgene be once again news rumor be look acquire immuno oncology focuse juno therapeutic yesterday rumor be confirm company say be acquire juno approximately acquisition announcement be make yesterday french pharma giant sanofi sny free report say be buy biopharma company bioverativ celgene be look strengthen presence cancer space impact juno acquisition sanofi be look expand presence specialty care strengthen leadership rare disease bioverativ acquisition more deal follow announcement be make expectation be pretty high more such deal fact last week acorda therapeutic share be rumor biogen biib free report be interested acquire company factor grow biosimilar competition slowdown growth legacy product major pipeline setback loom patent expiry pricing challenge grow competition have force big player seek deal acquisition grow pipeline boost revenue stream tax reform expect lead increase cash repatriation seem set more announcement company pfizer amgen amgn free report biogen merck johnson johnson gilead be expect be lookout suitable deal year end third quarter gilead have acquire kite approximately have cash equivalent balance include overseas cash amgen cash balance be also sep be hold overseas meanwhile merck exit third quarter cash equivalent worth be hold overseas bristol myer squibb overseas cash holding be approximately end third quarter biogen overseas cash balance be approximately end third quarter cash be likely be used share buyback dividend payment company be also expect use fund acquisition deal most company be lookout asset technology be potentially address unmet need immuno oncology be currently very much demand company be also focuse rare disease orphan disease area valuation look high cancer focuse company especially one involved immuno oncology valuation appear be more reasonable specialty pharma company company be focuse central nervous system disease other such area many large cap player have expressed interest pursue deal have also point deal make sense financial perspective high valuation bidding war keep key player sideline company avexis bluebird biomarin puma biotechnology incyte exelixis exel free report be often consider acquisition target exelixis be zack rank strong buy stock see complete list today zack rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
47,BIIB,turn be pretty good year pharma biotech stock nasdaq biotechnology index nyse arca pharmaceutical index gain respectively industry continue face headwind form drug pricing scrutiny pricing pressure increase competition concern regard amazon interest enter healthcare arena fewer expect acquisition deal major pipeline setback be positive development well be significant surge fda approval investor appear more comfortable drug pricing controversy innovation win day fda grant approval gene therapy cancer well rare form blindness tax reform be also expect work sector favor merger acquisition expect pick come quarters new product sale ramp success innovation continue strong performance key product grow demand drug especially rare treat disease age population increase health care spending be factor keep momentum start new year here be look drug stock look well position be witness upward estimate revision have favorable zack rank zack rank strong buy buy plc alk free report be focuse development marketing treatment central nervous system cns disease key disease area include schizophrenia depression addiction multiple sclerosis earlier year company say current commercial business have potential generate revenue excess also strong late stage pipeline represent catalyst company gain fda approval june nanocrystal dispersion aristada schizophrenia meanwhile expect complete filing roll submission alk major depressive disorder january potential advisory committee meeting fda decision second half year company also expect submit new drug application nda alk multiple sclerosis second half year datum alk schizophrenia be also due year metabolic study datum first half enlighten datum fall nda submission candidate be schedule first half have global license collaboration agreement biogen biib free report alk treatment multiple sclerosis have see zack consensus estimate earning be revise upward last day company also beat expectation last quarters average surprise have earning esp fourth quarter zack rank stock have see share gain last year compare rally industry belong xoma corporation xoma free report xoma be focuse discovery development licensing therapeutic antibody company have several licensing agreement other biotech pharma company provide fund form upfront milestone payment potential royalty payment xoma share have be upward trajectory august follow signing licensing agreement novartis nvs free report gevokizumab intellectual property cover use il beta target antibody treatment cardiovascular disease deal result xoma receive upfront payment include equity investment agreement term also result reduction xoma outstanding debt repayment obligation laboratoire servier extension company maturity date debt novartis couple year xoma also stand earn significant milestone payment tiered royalty sale gevokizumab additional such licensing deal rest pipeline be major boost stock have see share soar past year moreover zack consensus estimate loss have be lower last day xoma be zack rank stock see complete list today zack rank stock here xoma have earning esp fourth quarter eiger inc eigr free report clinical stage company eiger be focuse development therapy rare disease disease be address company pipeline include hepatitis delta virus lonafarnib lambda pulmonary arterial hypertension ubenimex post bariatric hypoglycemia exendin lymphedema ubenimex regulatory clinical announcement program be expect zack consensus estimate loss zack rank stock have be lower last day eiger share be last year eiger have surpass expectation last quarters earning esp fourth quarter be wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
48,BIIB,quite few pharmaceutical industry merger include large deal be card now tax reform be place tax bill be sign law president donald trump december last tax rate corporate now go boost profit large drug biotech company meanwhile change tax code also allow company bring back huge cash hold overseas time tax rate also tax cut be expect prevent inversion be rampant drug industry change definitely leave more cash hand drug biotech company cash be invest merger acquisition have be few compare gilead gild free report nearly acquisition kite pharma johnson johnson jnj free report acquisition swiss biotech actelion be only noteworthy deal week senior executive largest pharmaceutical biotech company discuss impact tax reform merger acquisition plan use excess cash jp morgan healthcare conference ceo say brent saunder chief executive officer ceo allergan agn free report say first half year be likely see smaller deal such celgene celg free report bigger high profile merger large pharmaceutical biotech company probably happen latter half year next year last week celgene announce have offer buy small cancer drug developer impact biomedicine read more celgene acquire impact biomedicine boost pipeline lilly lly free report ceo dave rick chief financial officer dominic caruso say tax cut american company compete better foreign counterpart operate better tax environment caruso say new tax law provide more flexibility ease analysis term get transaction do same line merck mrk free report ceo meg tirrell say have access overseas cash give more financial flexibility think different way go transaction tirrell however confidently say even new tax law be implement company have enough power balance sheet make bolt acquisition want do michel vounatsos biogen biib free report ceo smartly argue tax overhaul spur activity rationale activity not be cash available go say be look set potential target gilead ceo john milligan say tax reform be good company allow plan long term fda approval process be quite lengthy meanwhile maintain goal investing replenish pipeline also say excess cash allow clean balance sheet repay debt conclusion overall be quite clear drug industry be optimistic tax reform fuel greater activity be major drug biotech player struggle organic growth need infusion new growth driver pipeline product portfolio internal development buyout strategic licensing deal be therefore inevitable innovation starve drug biotech company look growth highly competitive global marketplace give take several year million dollar develop new therapeutic scratch large pharmaceutical company sit huge pile cash prefer buy innovative small mid cap biotech company build pipeline matter company look buy drug biotech stock be current sale performance latter drug product prospect sale growth quality pipeline wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
49,BIIB,key highlight week include regeneron announce positive datum praluent sarepta seek rapid approval second dmd drug orexigen filing bankruptcy recap week most important sanofi announce positive datum praluent cut price regeneron pharmaceutical regn free report partner sanofi sny free report announce positive result odyssey outcome trial praluent late breaker session american college cardiology annual scientific session orlando fl trial meet primary endpoint result show praluent significantly reduce risk major adverse cardiovascular event mace patient recent acute coronary syndrome acs event such heart attack june regeneron sanofi announce phase iiib iv odyssey dm trial patient diabetes meet primary endpoint uptake drug hasn be encourage cholesterol management market hold huge commercial potential company also announce reduction net price praluent alignment new value assessment high risk patient institute clinical economic review meanwhile phase iii study evaluate praluent homozygous familial be initiate fourth quarter read more regeneron sanofi announce positive datum praluent regeneron be zack rank strong buy stock see complete list today zack rank stock here sarepta seek rapid approval second dmd drug sarepta therapeutic srpt free report stock scale fresh week high company announce accelerate approval second drug golodirsen treat duchenne muscular dystrophy dmd most common type muscular dystrophy sarepta have meet fda division neurology product february obtain guidance regulatory pathway golodirsen sarepta file roll new drug application nda fda seek accelerate approval golodirsen dmd patient have confirm mutation dmd gene susceptible exon skip sarepta intend complete roll nda submission golodirsen year end sarepta only approve drug exondys be approve unite state once weekly intravenous infusion specifically target patient have confirm mutation dmd gene susceptible exon skip read more sarepta seek rapid approval second dmd drug stock orexigen file bankruptcy orexigen therapeutic announce have decide file voluntary petition chapter bankruptcy code bankruptcy court district delaware company also plan file motion seek authorization pursue auction sale process section bankruptcy code bidding process be expect conclude news come wake unimpressive performance weight loss drug contrave be market mysimba european union orexigen have file series motion court thereby seek ensure continuation normal operation tenure read more orexigen plummet filing chapter bankruptcy code biogen buy cognitive impairment asset pfizer biogen biib free report announce acquire phase iib ready ampa receptor potentiator cognitive impairment associate schizophrenia pfizer pfe free report upfront payment milestone payment well tiered royalty low mid percentage company be look diversify portfolio core therapeutic area multiple sclerosis disorder biogen initiate phase iib study pf determine ampa receptor potentiator be safe effective treatment cognitive dysfunction schizophrenia patient second half read more biogen buy mid stage neuropsychiatry asset pfizer biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index lose last trading session major biotech stock vertex gain last month celgene lose vertex gain see last biotech stock roundup here biotech stock round regeneron submit sbla biogen withdraw zinbryta next biotech world stay tune more regulatory pipeline update ongoing cowen healthcare conference breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
50,BIIB,biogen inc biib free report have agree acquire phase iib ready candidate pf be be develop cognitive impairment associate schizophrenia cia pharma giant pfizer inc pfe free report deal biogen make upfront payment pfizer latter also be entitle development milestone payment potential royalty latter half year biogen initiate phase iib study pf determine ampa receptor potentiator be safe effective treatment cognitive dysfunction schizophrenia patient schizophrenia patient often experience significant deficit cognitive function ability make sense majority more person live schizophrenia worldwide witness degree cognitive dysfunction accord biogen press release however negative symptom schizophrenia have be particularly difficult treat biogen share have decline year so far underperform industry rise same time frame deal mark biogen entry emerge market neuropsychiatry be sync strategy diversify pipeline core therapeutic area multiple sclerosis disorder last year biogen add new clinical stage program neuroscience pipeline advance internal pipeline candidate well external deal biogen alzheimer disease ad pipeline comprise candidate different mechanism action include tau candidate biib potential ad well progressive supranuclear palsy psp amyloid aducanumab candidate well bace inhibitor elenbecestat program meanwhile biogen spinal muscular atrophy sma treatment spinraza nusinersen approve late have consolidated position neurological disease market drug be first only treatment be approvedin unite state sma market potential disease be huge drug have perform expectation so far witness strong patient uptake unite state internationally december last year biogen form new collaboration ionis pharmaceutical inc ion free report identify antisense oligonucleotide drug candidate treatment sma biogen have option license therapy arise collaboration also biogen plan start phase study gene therapy asset sma mid biogen be also build portfolio best class treatment stroke acute neurology maylast year biogen purchase phase iii candidate biib cirara remedy pharmaceutical be be study treatment large hemispheric stroke lhi severe form stroke available therapy biogen carry zack rank hold better rank stock biotech sector be ligand pharmaceutical incorporate lgnd free report carry zack rank buy see complete list today zack rank stock here ligand earning share estimate have moved last day company deliver positive surprise trail quarters average beat share price company have surge past year zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
51,BIIB,earning season pharma biotech sector be scatter few small biotech company yet report release so far provide clear picture sector performance overall sector perform reasonably well biotech pharma bigwig gilead gild free report celgene celg free report vertex vrtx free report beat earning revenue estimate meanwhile biogen biib free report announce mixed result earning beating estimate sale lag same however amgen amgn free report have rather weak quarter miss expectation earning sale also issue lower expect sale guidance drug biotech stock remain growth trajectory ramp new product sale successful innovation product line expansion favorable clinical study result frequent fda approval strong performance key product grow demand drug especially rare treat disease age population increase health care spending be factor keep drive sector faster drug approval process propose removal outdated regulation push cost slowdown innovation also prove beneficial year start expectation pick activity new tax law cut corporate tax rate encourage company bring back huge cash hold overseas time tax rate be expect spur merger activity year sanofi sny free report earlier year announce deal buy belgian biotech company ablynx haemophilium focuse biotech firm bioverativ banking positive trend impressive performance be perfect time cash bountiful prospect grow market here have picked biotech stock see positive estimate revision post earning release also flaunt zack rank strong buy buy see complete list today zack rank stock here earning estimate revision have greatest impact stock price stock rise estimate have significantly outperformed index year year hence investor safely bet stock have be see upward movement earning estimate company have also see steady rally share price post result ligand pharmaceutical incorporate lgnd free report san diego base biotechnology company ligand carry zack rank stock witness positive estimate revision last day company release fourth quarter earning feb have see zack consensus estimate earning rise company surpass earning revenue estimate fourth quarter mainly higher royalty revenue additionally share company have rally post earning release regeneron pharmaceutical inc regn free report tarrytown ny base company regeneron witness positive estimate revision last day company release fourth quarter earning feb zack rank stock have see zack consensus estimate earning rise respectively regeneron fourth quarter result be impressive earning sale beat estimate strong sale company key market drug eylea share company have rally release earning release horizon pharma plc hznp free report base dublin ireland horizon pharma carry zack rank company have see zack consensus estimate earning move last day company release fourth quarter earning feb share company have gain post earning announcement horizon pharma also beat earning sale estimate fourth quarter backed strong performance orphan unit company sale guidance be encourage well outlookwhile be strong year be expect be vital biotech sector company continue invest pipeline build global business drive new product growth zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
52,BIIB,pdl biopharma inc pdli free report have report earning cent share fourth quarter substantially surpass zack consensus estimate cent however company report loss cent year quarter company generate total revenue quarter register year earlier upside be mainly attributable rise royalty right primarily back increase fair value depome royalty asset report period notably company receive cash payment royalty right acquire depome primarily related glumetza product market valeant pharmaceutical international inc vrx free report authorize generic version glumetza be also launch valeant subsidiary february pdl biopharma get royalty same term brand glumetza agreement pdl biopharma share rally hour trading mar owing higher earning moreover company have outperformed industry year time stock have jump industry decrease quarter detailrevenue include royalty license queen et al patent interest revenue product revenue sale noden product tekturna tekturna hct unite state lease lensar laser system revenue queen et al license be lower prior year figure downside be mainly due expiration patent license agreement pdl biopharma roche rhhby free report subsidiary genentech humanize antibody product queen et al license royalty include royalty sale biogen biib free report multiple sclerosis drug tysabri also decline quarter review lower sale product research development expense fourth quarter come level record year general administrative expense also decrease nearly figure comparable quarter last year resultswhile full year sale surge year year full year earning cent share be lower year tally cent pdl biopharma inc price consensus ep surprise pdl biopharma inc price consensus ep surprise pdl biopharma inc quote zack rankpdl biopharma carry zack rank hold see complete list today zack rank strong buy stock here don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
53,BIIB,spite increase incidence alzheimer be recognize drug cure slow progress disease alzheimer association claim second american develop alzheimer person live alzheimer find extremely difficult carry daily function hence need be supervision round clock come other life threaten condition cnbc report death related alzheimer have sky-rocket follow heart disease have drop turn century detection year onset alzheimer sa blood test have be introduce detect alzheimer almost decade patient show noticeable symptom last year dr randall bateman washington university announce test be able detect accumulation amyloid beta brain buildup toxic protein be first sign deadly disease also january team researcher japan australia introduce blood test accuracy high detection disease dr bateman employ mass spectrometry testing identify protein accord email bateman cnbc scientist japan have develop identical mass spectrometry investigative procedure protein detection come similar result blood test speed drug trial drug delay start disease fail number time thank unavailability decent number qualify patient reveal dr jeff cumming cleveland clinic hence wider patient base higher be possibility meaningful clinical trial new blood test doctor be able detect patient early include clinical trial development effective preventive treatment also be proper utilization million dollar federal government funding preventive treatment importantly blood test be most efficient way detect alzheimer other alternative be quite expensive lumbar puncture early diagnosis be alternative collect cerebrospinal fluid process needle be insert lower back patient give rise need local anesthetic positron emission tomography be process cost least also accuracy pet scan be significantly lower blood test dr robert vassar northwestern university have also backed efficiency blood test other method diagnosis alzheimer meanwhile dr bateman add blood test be more demand once proper preventive measure have be establish stock gainpeople world likely gain access test come few year dr bateman however question loom large be be next course action find be risk develop alzheimer meanwhile launch blood test pave way advanced clinical trial more person be estimate be live disease unite state alzheimer association notably health organization expect number rise more time alzheimer be press concern be massive business potential space hence launch blood test help company focuse develop preventive treatment make billion base cambridge biogen inc biib free report have be pay particular attention step research work alzheimer company surpass zack consensus estimate last quarters average positive earning surprise be also expect company witness earning growth respectively have be almost year eli lilly company lly free report headquarter indianapoli be fight alzheimer company beat zack consensus estimate last quarters also expect company post earning growth respectively fact treat patient early alzheimer symptom astrazeneca plc azn free report eli lilly be jointly develop lanabecestat small molecule therapy candidate merck co inc mrk free report headquarter kenilworth nj have be focuse research treat alzheimer company be expect post earning growth respectively merck also manage beat zack consensus estimate last quarters biogen eli lilly merck carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
54,BIIB,ionis pharmaceutical ion free report be schedule report fourth quarter result feb market open last quarter company deliver negative earning surprise company have disappointing track record miss estimate twice trail quarters beating same occasion deliver average negative earning surprise notably ionis share price have increase past year compare zack classify industry decline let see thing be shape announcement earning whispersour proven model do not conclusively show ionis be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate zack consensus estimate stand loss cent uncover best stock buy sell re report earning esp filter zack rank ionis zack rank increase predictive power esp esp make surprise prediction difficult note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision factor considerionis earn revenue form upfront milestone other payment partnership lead health care company biogen biib free report ionis biogen receive fda approval spinraza december treat spinal muscular atrophy sma drug be approve europe june first treatment sma ionis biogen have collaborate develop commercialize spinraza ionis earn royalty spinraza sale biogen last week biogen release fourth quarter result announce spinraza have witness strong demand globally drive sale company be evaluate drug clinical study reinforce favorable efficacy safety profile ionis earn quarter milestone license fee several drug company related initiation clinical study license transfer pipeline candidate december ionis biogen enter collaboration agreement identify new antisense oligonucleotide drug candidate treat sma apart spinraza expect investor focus be pipeline update fourth quarter conference call quarter ionis akcea submit regulatory application european medicine agency ema fda inotersen treatment patient hereditary ttr amyloidosis hattr regulatory application europe be review accelerate assessment program fda have also grant priority review january suggest faster review application marketing application pipeline candidate volanesorsen treatment patient familial chylomicronemia syndrome fcs be review unite state europe canada ionis have several mid stage pipeline candidate various indication expect company provide update different study include path forward inotersen volanesorsen fourth quarter earning call ionis pharmaceutical inc price ep surprise ionis pharmaceutical inc price ep surprise ionis pharmaceutical inc quotestock warrant lookhere be couple health care stock want consider model show have right combination element post earning beat quarter atara biotherapeutic inc atra free report be expect release result mar company have earning esp zack rank see complete list today zack rank stock here gemphire therapeutic gemp free report be expect release result mar company have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
55,BIIB,fda have propose new guideline be aim lower clinical study goal alzheimer disease drug treat earlier stage patient have not yet display functional disability clinical abnormality strategy part fda ongoing effort expand access safe effective treatment option many serious condition suggest agency be open accelerate approval process such drug fda propose guideline come week major disappointment field be announce company develop drug treat deadly brain disease earlier week merck mrk free report announce be discontinue study evaluate verubecestat treatment prodromal alzheimer disease success be unlikely biogen biib free report also announce have decide increase number patient enrolment study be conduct crucial alzheimer disease candidate aducanumab raise concern regard chance success treatment december biogen alzheimer disease study candidate ban fail show early positive result raise investor concern candidate chance success alzheimer disease market have attract lot attention several company however successful development therapy treatment alzheimer disease be challenge be somewhat underlie cause severe neurological ailment alzheimer not be clear disease cancer also alzheimer progress go unnoticed year time symptom ailment become evident significant function already be lose make develop drug treat disease difficult note several company have fail regard last month pfizer pfe free report reportedly announce termination effort alzheimer parkinson disease area result layoff long back pfizer shelved late stage alzheimer candidate bapineuzumab iv fail phase iii study november lilly lly free report amyloid candidate solanezumab fail meet primary endpoint late stage ad study lilly decide drop development solanezumab lilly also suffer major setback august have halt development phase iii alzheimer candidate semagacestat alzheimer disease market represent huge commercial potential successfully develop product generate billion dollar sale once launch fda latest effort reinvigorate research effort alzheimer drug repeat failure wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
56,BIIB,biogen inc biib free report announce multiple sclerosis ms product tysabri natalizumab fail meet primary secondary endpoint phase iib study evaluate medicine indication acute ischemic stroke ais tysabri be presently approve treat multiple sclerosis crohn disease drug record sale top line result phase iib dose range action study show treatment natalizumab do not lead improvement clinical outcome patient independence ability perform daily task compare placebo patient ais ischemic stroke be condition sudden loss blood circulation brain lead loss neurologic function biogen have decide not pursue development natalizumab ais share decline slightly wednesday response news biogen share have rise past year better industry rise same time frame however biogen believe failure not affect pipeline effort acute neurological condition include stroke biogen be develop biib treatment large hemispheric stroke lhi severe form stroke available therapy have acquire biib remedy pharmaceutical last year phase iii study candidate be expect be initiate mid fourth quarter conference call hold last month biogen say launch roche rhhby free report ms drug ocrevus have witness decrease number patient start increase discontinuation tysabri unite state moreover treatment novartis gilenya sanofi sny free report aubagio competitive threat tysabri have tysabri be successfully develop stroke indication have improve drug prospect competitive market competition ms market intensify biogen be look diversify alzheimer disease ad other disorder area biogen add new clinical stage program neuroscience pipeline advance internal pipeline candidate well external deal biogen ad pipeline comprise candidate different mechanism action include tau candidate biib amyloid aducanumab candidate well bace inhibitor elenbecestat program biogen ionis pharmaceutical inc ion free report spinal muscular atrophy sma treatment spinraza nusinersen be first only treatment be approve unite state sma drug have perform expectation so far witness strong patient uptake unite state carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
57,BIIB,government shutdown unite state guide stock europe asia last week meanwhile world leader continue deliberate crucial issue such trade world economic forum davos stock asia also gain direction dollar plunge meanwhile stock brazil argentina breach key level follow encourage legal development earning corporate development guide europe stocksstock europe finished green last monday investor attempt shrug fear emanate government shutdown stoxx gain major sector end mixed most index close black cac dax end higher however ftse decline travel leisure stock be lead loser close lower bank telecom stock close session higher stoxx increase last tuesday nearly sector finishing green stock region be guide corporate development follow end government shutdown unite state dax close ahead other index cac end slightly lower market europe close red last wednesday investor continue receive news individual stock stoxx decline nearly major sector close loss day worst performer be utility stock meanwhile number employ individual increase september november period take number employ record even ftse close loss stoxx lose last thursday nearly major sector close red investor assessed latest comment ecb even region central bank refrain raise rate ecb chairman mario draghi say recently observed exchange rate volatility be source uncertainty require constant monitoring investor also continue receive news world economic forum be hold davos bullish earning number help most europe stock close green last friday stoxx gain nearly most sector finishing green cac emerge best performer counterpart power strong earning number meanwhile gdp increase last quarter exceed most analyst estimate additionally president trump address world leader davos say unite state desire fair reciprocal trade even several country be exploit other trade agreement dollar slide government shutdown guide asia stocksstock asia end mixed last monday even investor digest political development surround government shutdown unite state nikkei end mostly unchanged gain mere south korea manufacturing finance retail stock close mixed even kospi end lower asx also close red lose shanghai composite shenzhen composite advanced respectively asia market rebound last tuesday wall street chalk gain follow end government shutdown meanwhile bank japan opted keep interest rate unchanged nikkei add reach highest level year earlier trading session kospi asx add respectively shanghai composite shenzhen composite increase respectively meanwhile csi advanced dollar continue slide versus basket currency last wednesday even asia market finished mostly black nikkei lose even kospi finished higher asx gain even australia major bank end gain meanwhile major mining company end loss shanghai composite shenzhen composite add respectively stock asia close red last thursday even dollar remain weigh slide last session nikkei lose kospi gain nearly asx inched even gain make material stock be outweighed loss suffer industrial utility shanghai composite shenzhen composite lose respectively comment president trump lead asia market close mixed last friday nikkei lose early gain end session lower contrast kospi overcome early loss gain market india australia be close republic day australia day respectively shanghai composite shenzhen composite add respectively bovespa surge lula conviction be upheld merval breach barrierstock brazil trade tight range last monday investor be wary bet big trial former president luiz inácio lula da silva major contender year election even so bovespa gain meanwhile mexico benchmark bmv ipc index also gain last tuesday bovespa lose trader indulge profit take follow recent gain share mining company vale sa vale free report drop brazil benchmark index hit time high last wednesday bovespa gain surge mark appellate court upheld conviction former president lula bribery money launder lula be opposed current president michel temer reform agenda lead gainer session be like itaú unibanco itub free report banco bradesco bbd free report petrobra pbr free report argentina stock also enjoy considerable gain benchmark merval index gain hit record level merval gain last thursday surge mark first time even mixed signal dollar emerge brazil market be close sao paulo anniversary holiday bovespa reopen strong note last friday gain hit time high index gain more last week appeal court upheld former president lula conviction blue chip stock such petrobra mop gain vale suffer loss follow drop iron ore price mexico bmv ipc index gain close highest level early september stock newsubs group ag ub free report report fourth quarter net profit attributable shareholder chf adjust basis prior year quarter result exclude defer tax expense ub have zack rank hold include defer tax expense net loss attributable shareholder come chf compare net income record prior year quarter result display rise net fee commission income year year higher trading income year year partially offset decrease net interest income year year notably quarter benefit company continue focus expense management net profit attributable shareholder be chf adjust basis prior year include time adjustment net income come chf prior year read ub group ag earning impress tax expense record novartis ag nvs free report report encourage result fourth quarter earning revenue beat estimate drive strong performance cosentyx entresto fourth quarter core earning share beat zack consensus estimate be record year quarter revenue increase volume growth drive cosentyx entresto be partially offset negative impact generic competition pricing revenue also beat zack consensus estimate full year sale come beat zack consensus estimate earning share come beating zack consensus estimate share zack rank novartis expect net sale grow low mid single digit innovative medicine be project grow mid single digit revenue sandoz be expect be broadly line decline slightly alcon sale be estimate grow low mid single digit read novartis earning sale top cosentyx entresto posco report impressive result net income increase year year krw drive primarily increase operate profit benefit selling investment security net earning be krw share american depository receipt adr significantly krw share adr report year however bottom line lag zack consensus estimate posco generate revenue krw reflect growth previous year crude steel production slip year year approximately ton due revamp pohang work blast furnace rationalization pohang work gwangyang work facility product manufacturing year be ton product sale fall year year roughly ton note posco domestic sale ratio grow basis point bps posco anticipate consolidated revenue be approximately krw krw record finished product sale be estimate be roughly ton crude steel production be project be nearly ton stock have zack rank buy see complete list today zack rank strong buy stock here sanofi sny free report bid strengthen blood disorder portfolio be acquire bioverativ inc be focuse develop therapy hemophilia other rare blood disorder zack rank sanofi have offer share premium almost close price bioverativ jan acquire outstanding share cash deal amount transaction be approve board bioverativ be part biogen inc biib free report latter spun february bioverativ begin trading nasdaq feb share sanofi be almost pre market trading jan presumably due high cost acquisition share be meanwhile company share have increase past year underperform industry gain same time frame read sanofi acquire haemophilium focuse bioverativ stock dip shire plc shpg free report announce have receive fda approval transfer product manufacturing technology hereditary angioedema hae drug cinryze esterase inhibitor house manufacturing site vienna austria company expect start commercial manufacturing cinryze give site first quarter notably zack rank sell shire have be face consistent supply challenge cinryze be produce single third party supplier third quarter company genetic disease portfolio sale be primarily due lower sale cinryze have plunge result supply shortage arise manufacturing interruption fda approval tech transfer company be able address supply disruption cinryze demand drug have periodically exceed supply company single third party partner read shire get fda nod cinryze tech transfer new site performance lead foreign table give show price movement largest stock list index worldwide last day last month next week outlookearning news stock specific development have largely guide stock last week dollar plunge have also make presence feel have have major impact asia stock meanwhile latin america stock be mop record gain phenomenon lead round profit take factor possibly continue influence market direction week ahead well zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
58,BIIB,be still few day left year end have turn be pretty good pharma biotech sector fda approval be concern date regulatory agency have give nod novel drug well drug approve last year immuno oncology be key focus area be do scientific conference clinical trial collaboration acquisition fda approval approval novartis nvs free report kymriah gene cell therapy gilead gild free report yescarta car chimeric antigen receptor cell cell treatment ensure highly lucrative immuno oncology market remain limelight acquisition immuno oncology focuse kite gilead also increase interest category investor expect more acquisition announcement area see year focuse immuno oncology here be look therapeutic area think garner lot interest immuno oncologyimmuno oncology remain key focus area well basic concept cancer immunotherapy immuno oncology be utilize certain part immune system fight disease be do stimulating immune system attack cancer cell introduce immune system component body immuno oncology treatment have potential be effective monotherapy other be more effective combine other treatment different type immunotherapy include monoclonal antibody mab man make version immune system protein be design attack very specific part cancer cell immune checkpoint inhibitor recognize attack cancer cell vaccine help prevent treat cancer other boost overall immune system encourage result generate company demonstrate partial complete response late stage cancer patient recent fda approval kymriah yescarta have raise hope cancer patient increase interest segment cancer market immuno oncology set change treatment paradigm cancer area represent huge commercial potential company have progressed quite bit area include juno therapeutic incyte bluebird bio blue free report company often consider be acquisition target alzheimer disease be area many company have try luck not much success last several year big player merck lilly lly free report pfizer have face setback quest find treatment alzheimer company be currently work alzheimer disease treatment include player biogen biib free report novartis astrazeneca eisai amgen biogen aducanumab be most important candidate company pipeline candidate currently couple late stage study biogen be also work elenbecestat bace inhibitor phase iii program ban humanize beta amyloid antibody phase ii development top line result expect end january candidate be be develop collaboration eisai lilly also have quite few alzheimer disease candidate pipeline include lanabecestat be be develop collaboration astrazeneca datum readout expect meanwhile novartis amgen be collaborate bace inhibitor cnp have fast track status unite status roche be also collaborate ac immune development alzheimer disease treatment alzheimer have historically be very challenge therapeutic area quite few stock stumbling effort find treatment market be highly lucrative result several company continue invest heavily develop alzheimer disease treatment accord alzheimer association year drug be test alzheimer study register clinicaltrial gov only succeed go gain fda approval number be far encourage success area mean huge return consider more american be live alzheimer disease number expect increase much datum alzheimer association be consider be biggest burden society be sixth lead cause death age unite state market have immense commercial potential company come new treatment rake billion dollar sale medical segment pharma biotech industry remain limelight next year be medical marijuana industry industry get first exchange trade fund etf earlier year have be attract interest investor last few quarters industry be expect grow rapidly legislator allow look allow more legal used marijuana marijuana related product especially medical life science industry key player area include gw pharmaceutical plc gwph free report insys therapeutic corbus pharmaceutical holding zynerba pharmaceutical gw pharma commercialize world first plant derive cannabinoid prescription drug sativex be approve treatment spasticity due multiple sclerosis however company have be news lead cannabinoid pipeline candidate epidiolex cannabidiol cbd be development number rare childhood onset epilepsy disorder company be currently seek fda approval epidiolex dravet syndrome lennox gastaut syndrome approval come early mid priority review be grant epidiolex represent blockbuster potential especially be approve possible indication gw pharma have several new formulation cbd development include improve liquid formulation solid dose form intravenous formulation specialty pharma company insys used proprietary spray technology capability development pharmaceutical cannabinoid wide range indication include treat addiction opioid opioid overdose epilepsy other disease area significant unmet need gw pharma insys be zack rank hold stock see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
59,BIIB,key highlight week include fda approval luxturna first gene therapy genetic disease first only pharmacologic treatment inherited retinal disease ird first adeno associate virus aav vector gene therapy earlier expect label expansion exelixis exel free report cabometyx recap week most important storiesearlier expect label expansion exelixis cabometyx exelixis receive boost earlier expect fda approval cabometyx first line treatment advanced renal cell carcinoma rcc patient cabometyx be previously approve use advanced rcc patient have receive angiogenic therapy approval first line indication expand patient population significantly approval be base result show cabometyx demonstrated clinically meaningful statistically significant reduction rate disease progression death median progression free survival pfs cabometyx be month compare month sunitinib accord information provide company press release patient country need first line treatment advanced kidney cancer year almost many patient second third line take together represent significant opportunity company grow cabometyx sale exelixis share be year date compare gain record industry belong spark gene therapy get fda nod spark therapeutic once free report gain fda approval time gene therapy luxturna patient confirm biallelic rpe mutation associate retinal dystrophy make luxturna first gene therapy genetic disease first only pharmacologic treatment ird first aav vector gene therapy be approve unite state accord fda biallelic rpe mutation associate retinal dystrophy affect approximately patient unite state approval be expect consider favorable fda advisory panel vote october decision come ahead jan prescription drug user fee act pdufa date spark be yet provide information pricing be key factor influence treatment uptake company say luxturna be available administration treatment center late first quarter pricing other detail be provide early january spark also get rare disease priority review voucher be used gain priority review subsequent drug application be not eligible priority review company also sell voucher million dollar other company want fasten review process candidate biomarin unite therapeutic knight therapeutic be company sell priority review voucher million dollar new sma collaboration biogen ionis biogen biib free report have enter new collaboration agreement ionis pharmaceutical inc ion free report new antisense oligonucleotide drug candidate be identify treatment spinal muscular atrophy sma new agreement allow biogen license therapy arise collaboration company be responsible development biogen make upfront payment well payment achievement development regulatory milestone tiered royalty company already have sma treatment spinraza market be develop collaboration agreement inception september ionis have receive collaboration agreement biogen biogen ionis be zack rank hold stock see complete list today zack rank strong buy stock here regeneron sign isa immuno oncology collaboration regeneron pharmaceutical inc regn free report be collaborate isa pharmaceutical clinical stage immunotherapy company evaluate isa immunotherapy target human papillomavirus type hpv induced cancer combination cemiplimab regn pd antibody company jointly fund conduct study evaluate combination cervical cancer head neck cancer regeneron make upfront payment well equity investment isa gain option exclusive global license isa regeneron decide exercise option be liable make milestone well royalty payment isa regeneron be develop cemiplimab sanofi read more regeneron strategic immuno oncology collaboration isa clinical hold lift alnylam sanofi fitusiran fda have lift clinical hold be place study be conduct alnylam pharmaceutical alny free report sanofi fitusiran company expect resume dose year end study include phase ii open label extension ole study atla phase iii program dose have be suspend follow observation fatal thrombotic serious adverse event sae patient hemophilia inhibitor be receive fitusiran ole study read more sanofi alnylam say fda lift clinical hold fitusiran alnylam sanofi also announce have submit regulatory application eu approval patisiran treatment adult hereditary transthyretin mediate amyloidosis read more alnylam sanofi submit maa europe rnai candidate biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock vertex vrtx free report gain celgene decline last month biogen be regeneron lose see last biotech stock roundup here ash datum focus gilead buy cell design lab next biotech world watch usual pipeline regulatory update medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
60,BIIB,ionis pharmaceutical inc ion free report announce have license ionis az rx generation antisense drug astrazeneca azn free report candidate be develop treat genetically associate form kidney disease astrazeneca be responsible development candidate go forward ionis enter strategic collaboration astrazeneca develop treatment cardiovascular metabolic renal disease be second drug enter development agreement term deal ionis receive upfront payment astrazeneca be eligible receive form milestone payment royalty payment potential sale ionis share have rise past year outperform industry gain period ionis have collaboration agreement several pharma company license sell technology exclusive exclusive basis fee payment ionis earn majority revenue form royalty biogen biib free report sale spinal muscular atrophy drug spinraza drug be develop used ionis antisense technology several other candidate be development collaboration biogen note august ionis retain right lead pipeline candidate inotersen glaxo gsk free report decline option develop drug investor cheer news ionis record full sale instead royalty successful be expect ionis be schedule report fourth quarter full year result feb expect get update various pipeline candidate ionis pharmaceutical inc price ionis pharmaceutical inc price ionis pharmaceutical inc quotezack rankionis pharma carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
61,BIIB,plc alk free report report adjust earning cent share fourth quarter beating zack consensus estimate cent bottom line also exceed adjust earning cent record year quarter company revenue quarter be year year top line also beat zack consensus estimate result be drive strong growth company proprietary product vivitrol aristada higher manufacturing royalty revenue upfront payment biogen biib free report related collaboration biib share company rise post earning release base strong fourth quarter result so far year share price have improve industry decline revenue risemanufacture royalty revenue risperdal consta invega sustenna xeplion invega trinza trevicta be year year same ampyra fampyra be year year vivitrol sale improve year year aristada sale come year year cost rise research development expense be year yearselling general administrative sg expense be year year company generate revenue increase year year adjust earning be cent share loss cent company expect total revenue range drive continuous growth vivitrol aristada vivitrol sale be expect range aristada sale be anticipate range company expect expense range sg expense be forecast band increase be attribute plan investment expansion commercial organization preparation expect launch alk treatment major depressive disorder company expect loss share range cent pipeline updatein january company submit new drug application nda fda alk adjunctive treatment major depressive disorder november biogen announce global license collaboration agreement develop commercialize phase iii multiple sclerosis ms candidate biib alk deal biogen be grant worldwide right alk upfront payment return biogen pay royalty mid teen percentage rate global sale alk deal be beneficial company lower cost bring strong partner also receive milestone payment various clinical regulatory achievement november nda aripiprazole lauroxil nanocrystal dispersion alncd be accept filing fda alncd be novel investigational product design initiation aristada extend release injectable suspension treatment schizophrenia fda issue target action date alncd nda june prescription drug user fee act plc price consensus ep surprise plc price consensus ep surprise plc quote zack rank stock consideralkerme be zack rank hold stock better rank stock health care space be xoma corp xoma free report exelixis exel free report carry zack rank buy see complete list today zack rank stock here xoma loss share estimate have narrow cent cent last day company pull positive earning surprise last quarters average beat share price company sky-rocket year exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average beat share price company surge year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
62,BIIB,fourth quarter earning season have crossed halfway mark so far result reflect favorable trend average proportion company beating top bottom line expectation latest earning preview total earning member have release result be year quarter rise revenue beat ratio bottom line be top line be proportion company beating ep revenue estimate be biotech company alexion pharmaceutical inc alxn free report regeneron pharmaceutical inc regn free report be expect report number feb let take look biotech company have edge other ahead release however look number let have look biotech industry glance biotech industry be see significant pickup merger acquisition deal late year start celgene celg free report announce plan acquire impact biomedicine company reveal plan acquire juno therapeutic approximately french pharma giant sanofi sny free report also announce buy biopharma company bioverativ january same month sanofi also announce plan acquire belgian biotech company ablynx fourth quarter biotech sector be well poise major player biotech sector biogen biib free report put mixed show report period earning lag estimate sale exceed same however celgene vertex vrtx free report outpaced metric expectation alexion new haven ct base alexion blockbuster drug soliris continue perform well alexion continue identify treat high number new patient paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus soliris country operate platform alexion be work expand soliris label additional indication fda recently approve drug treatment refractory gmg patient be acetylcholine receptor antibody positive drug be approve europe indication label expansion additional indication give soliris access higher patient population increase commercial potential drug significantly company also announce restructure initiative context alexion plan focus rare disease business core area hematology nephrology neurology metabolic disorder enhance productivity zack consensus estimate fourth quarter revenue be peg mark increase year year zack consensus estimate fourth quarter earning be peg share mark increase year year alexion track record be excellent have top estimate last quarters average positive earning surprise alexion have earning esp most accurate estimate be zack consensus estimate be peg uncover best stock buy sell re report earning esp filter alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc quoteregeneron regeneron key growth driver eylea be likely continue contribute company top line growth regeneron be work expand eylea label additional indication phase iii study panorama be evaluate eylea treatment moderately severe severe proliferative diabetic retinopathy patient dme phase iii study japan be evaluate neovascular glaucoma label expansion additional indication give eylea access higher patient population increase commercial potential drug apart eylea investor remain focuse uptake new drug kevzara dupixent fda also approve dupixent dupilumab injection treatment adult moderate severe atopic dermatitis initial uptake drug be encourage drug be approve europe also company be also evaluate drug treat asthma adult liberty asthma quest study hence focus be company performance particularly eylea dupixient uptake fourth quarter earning call investor be also expect await update company pipeline earning esp regeneron be company currently carry zack rank sell zack consensus estimate fourth quarter revenue be peg mark increase year year zack consensus estimate fourth quarter earning be peg share mark increase year year company performance have be mixed so far last quarters surpass earning estimate occasion miss average positive surprise regeneron pharmaceutical inc price ep surprise regeneron pharmaceutical inc price ep surprise regeneron pharmaceutical inc quoteour takedure fourth quarter alexion price decline compare regeneron fall however alexion zack rank combine positive esp make reasonably confident earning beat see complete list today zack rank strong buy stock here regeneron caution stock zack rank strong sell go earning announcement especially company be see negative estimate revision therefore proprietary model believe alexion be poise better performance upcoming quarter zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
63,BIIB,cambridge base biogen inc biib free report hold strong position multiple sclerosis ms market wide range product include avonex tysabri tecfidera plegridy however competition ms market intensify biogen be try diversify ms other area alzheimer parkinson stroke other meanwhile feb company spin hemophilia business allow focus neurology key area expertise biib have pretty good earning track record company deliver positive earning surprise last quarters average surprise currently biogen have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning miss biogen fourth quarter earning miss expectation company post earning share consensus call ep revenue beat biogen post revenue beating consensus estimate revenue increase year year key statistic oral ms drug tecfidera sale increase year year sequentially other ms drug tysabri sale decrease year year sequentially pre market trading share be more pre market trading check back later full biib earning report later biogen inc price consensus biogen inc price consensus biogen inc quotetoday stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
64,BIIB,market finished mostly higher monday even safe haven stock such utility real estate gain traction further optimism strong market rally begin continue push benchmark higher nasdaq post record close however dow decline due fall bank share snap winning run dow jone industrial average dji decrease almost close rise close nasdaq composite index close gain fear gauge cboe volatility index vix increase almost close advancer outnumber decliner nyse ratio nasdaq ratio favore advance issue nasdaq post record gain almost point finish record broader index also hit intraday record majority gain come industrial energy stock major segment end positive territory utility real estate lead gainer real estate select sector spdr xlre utility select sector spdr etf xlu gain respectively meanwhile nasdaq gather point also finish record level gain tech laden index be buoy surge share major tech stock share facebook fb free report amazon amzn free report alphabet googl free report netflix nflx free report gain respectively see complete list today zack rank strong buy stock here nasdaq also hit intraday record decline biotech share pare gain index nasdaq biotechnology nbi decline monday nearly biggest decline mid december such loss be lead decline regeneron pharmaceutical inc regn free report biogen inc biib free report share tank respectively dow decline end impressive rundow defy trend day lose almost point end red marked end day winning streak gain however blue chip index hit intraday record earlier session suffer broad base loss finish negative territory further share major bank such goldman sachs gs free report jp morgan jpm free report decline respectively weigh dow bank share decline analyst estimate be time charge fourth quarter earning bank suffer due implementation tax reform fed president speak rate hikesatlanta fed president raphael bostic comment monday fed continue raise interest rate slower pace compare last year further san francisco fed president john william comment central bank consider hold rate lower longer period allow inflation grow come year stock make headlineskohl rally solid holiday sale more upside store landscape many retailer be still struggle consumer change shopping pattern soft traffic kohl corporation kss free report surprised investor impressive holiday sale datum read more lululemon lift outlook successful holiday featlululemon athletica inc lulu free report be retailer emerge strong holiday season have lift overall outlook retail sector read more big topple soft sale lower ep viewbig sporting good corp bgfv free report report dismal sale number fourth quarter full year due extremely challenge performance december read more nvidia hit time high strength autonomous vehiclesshare nvidia corporation nvda free report yesterday craft time high company recent announcement ahead consumer electronic show ce make investor more optimistic autonomous vehicle opportunity read more zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
65,BIIB,pfizer inc pfe free report reportedly say statement end effort alzheimer parkinson disease area result layoff decision end neuroscience discovery program mainly affect employee facility andover cambridge groton ct pfizer however intend continue development pain candidate tanezumab be develop late stage study partnership eli lilly lly free report label expansion effort pain drug lyrica rare disease program share pfizer have rise past year compare unfavorably increase industry successful development therapy treatment alzheimer disease be challenge note several company have fail regard fact pfizer shelved late stage alzheimer candidate bapineuzumab iv fail phase iii study pfizer be develop candidate collaboration johnson johnson jnj free report elan corporation november lilly amyloid candidate solanezumab fail meet primary endpoint late stage ad study lilly decide drop development solanezumab lillyalso suffer major setback august have halt development phase iii alzheimer candidate semagacestat last month biogen inc biib free report announce alzheimer disease study ban fail show early positive raise investor concern candidate chance success pfizer plan use saving terminate program re allocate spend potentially more fruitful pipeline project pfizer expect approximately drug approval next year product have blockbuster potential include line extension cancer drug xtandi ibrance well rheumatoid arthritis drug xeljanz half potential blockbuster be expect receive approval pfizer carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
66,BIIB,week company amgen amgn free report revance therapeutic inc rvnc free report abbvie abbv free report be news amgen get fda approval inclusion cardiovascular outcome datum pcsk inhibitor abbvie revance provide datum pipeline candidate recap week most important storiesrevance soar rt datum revance share shot positive top line datum late stage study evaluate company next generation neuromodulator rt rt meet primary well secondary endpoint study be conduct reduction moderate severe glabellar line frown line wrinkle brow long term safety study be currently ongoing study schedule complete second half successful completion study allow revance file fda approval first half potentially launch product company believe fda approval make rt first neuromodulator long act duration month currently market neuromodulator have show duration month treat glabellar line rt approval well change neuromodulator treatment landscape be need only twice year accord information provide company treatment glabellar line be most popular aesthetic procedure injectable neuromodulator almost third global neuromodulator sale come area currently approve treatment include botox dysport amgen pcsk inhibitor label approve cardiovascular outcome datum amgen pcsk inhibitor repatha get bit boost fda grant approval company request add cardiovascular outcome datum drug label make repatha first pcsk inhibitor prevent heart attack stroke coronary adult establish cardiovascular disease repatha be also approve use adjunct diet alone combination other lipid lower therapy statin treatment adult primary hyperlipidemia reduce low density lipoprotein cholesterol ldl update label provide physician new treatment option prevent cardiovascular event dramatically lower ldl cholesterol repatha especially case patient be already maximally tolerate statin therapy need lower ldl cholesterol level further cardiovascular outcome datum help drive repatha sale be yet take expect factor strict utilization management criterium process employ insurer pharmacy benefit manager pbms impact sale however amgen have be work payer improve access appropriate patient repatha remain growth brand company read more amgen pcsk inhibitor get fda nod stroke prevention amgen be zack rank hold stock see complete list today zack rank strong buy stock here positive datum abbvie risankizumab imbruvica abbvie risankizumab meet primary endpoint fourth pivotal phase iii study conduct treatment patient moderate severe plaque psoriasis week treatment almost half risankizumab patient achieve complete skin clearance pasi compare patient placebo risankizumab be be develop collaboration boehringer ingelheim read more abbvie psoriasis candidate succeed phase iii study abbvie also present datum combination btk inhibitor imbruvica rituxan treatment newly previously treat patient waldenström wm primary endpoint progression free survival pfs be achieve late stage study imbruvica be approve different indication include chronic lymphocytic leukemia previously treat mantle cell lymphoma wm well chronic graft versus host disease abbvie expect imbruvica revenue priority review clovis snda clovis oncology clvs free report supplemental new drug application snda use parp inhibitor rubraca rucaparib have be grant priority review status fda company be look get rubraca approve use maintenance treatment woman recurrent ovarian cancer be platinum sensitive complete partial response platinum chemotherapy requirement diagnostic testing fda grant priority review response be apr clovis share be year date compare gain record industry belong galectin nash datum galectin therapeutic inc share fall datum phase iib study gr md candidate show statistically significant clinically meaningful result sub group alcoholic steatohepatitis nash cirrhosis patient fail achieve statistical significance total group patient positive week datum ultragenyx drug ultragenyx pharmaceutical inc rare free report partner kyowa kirin announce positive week datum late stage study burosumab krn adult link xlh company say further improvement disease symptom fracture heal be observed week treatment burosumab burosumab be currently priority review treatment pediatric adult patient xlh response fda expect apr biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline slightly last trading session major biotech stock amgen be vertex decline last month biogen biib free report be regeneron regn free report lose see last biotech stock roundup here regeneron eylea datum biogen ms deal next biotech world watch usual pipeline regulatory update wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
67,BIIB,be good year pharma biotech stock sector witness positive development lead much await recovery key reason sector improve performance be willingness investor look drug pricing controversy focus more fundamental instead drug pricing controversy be major overhang remain headline risk investor seem more comfortable issue moreover significantly higher number fda approval have restore investor confidence sector approval first gene cell therapy last year be major breakthrough sector hope more merger acquisition have also go tax reform place big player lookout company innovative pipeline technology have already be quite bit buzz year potential deal celgene rumore be interested buy juno biogen biib free report acorda sanofi sny free report bioverativ meanwhile nordisk recently confirm be look acquire belgium base biopharma company ablynx ablynx reject nordisk offer look forward new product sale ramp success innovation continue strong performance key product more activity grow demand drug especially rare treat disease age population increase health care spending be factor keep momentum headwind include drug pricing scrutiny pricing pressure increase competition grow presence biosimilar generic competition slowdown growth legacy product concern regard amazon interest enter healthcare arena major pipeline setback biotech pharma stock keep eye earning seasonaccording zack earning trend article medical sector have be better perform sector last several quarters be expect record earning growth revenue growth fourth quarter give scenario medical sector earning round corner make sense look pharma biotech stock be expect report positive earning surprise quarter investing such stock prove beneficial investor earning beat usually lead significant share price appreciation help zack stock screener have zero pharma biotech stock sport zack rank strong buy buy hold have positive earning esp earning esp be very valuable tool investor look stock be most likely beat earning estimate moreover add zack rank have produce positive surprise time see complete list today zack rank stock here uncover best stock buy sell re report earning esp filter alexion pharmaceutical inc alxn free report alexion have strong presence rare disease market market drug include soliris treatment patient paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus acetylcholine receptor achr antibody positive generalized myasthenia gravis gmg strensiq enzyme replacement therapy patient hpp kanuma enzyme replacement therapy patient lysosomal acid lipase deficiency lal alexion be focuse grow maximize presence rare disease business core area focus include hematology nephrology neurology metabolic disorder alexion have consistently surpass earning expectation last quarters average surprise zack rank stock report fourth quarter result february have earning esp quarter soliris revenue be expect range metabolic revenue be expect range celgene corporation celg free report celgene be focuse discovery development treatment cancer inflammatory disease next generation solution protein homeostasis immuno oncology epigenetic immunology neuro inflammation earlier month company announce preliminary result fourth quarter revenue expect be earning be approximately share celgene have surpass earning last quarters average surprise zack rank stock be report fourth quarter result january have earning esp abbvie abbv free report abbvie be know blockbuster drug humira be focuse development treatment primary therapeutic area immunology oncology virology neuroscience earning be expect be share revenue growth approximately humira be expect remain key growth driver sale expect cross abbvie be report fourth quarter result january company have decent track record have surpass earning expectation last quarters average surprise zack rank stock have earning esp fourth quarter abbvie share be last year significantly surpass rally industry belong merck mrk free report merck be report fourth quarter result february company have strong earning track record be expect deliver surprise fourth quarter growth driver include keytruda gardasil few hospital specialty product animal health division help offset impact genericization zetia vytorin merck be also zack rank stock hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
68,BIIB,roche holding rhhby free report announce european commission ec have grant marketing authorization multiple sclerosis ms drug ocrevus drug be approve patient suffering active relapse form multiple sclerosis defined clinical imaging feature patient early primary progressive multiple sclerosis term disease duration level disability imaging feature characteristic inflammatory activity approval be base datum pivotal phase iii study orchestra trial program meet primary nearly key secondary endpoint drug also demonstrated favorable benefit risk profile demonstrated large phase iii study diverse patient population include early disease remind investor drug be also approve unite state march relapse primary progressive form multiple sclerosis approval boost roche neuroscience portfolio roche have more dozen pipeline candidate neuroscience portfolio disease include multiple sclerosis alzheimer disease spinal muscular atrophy parkinson disease autism roche stock have rally past year compare industry gain ms market have immense potential europe disease affect approximately person europe have highly disable primary progressive form however competition be stiff ms space august european commission merck approve kgaa mavenclad treatment ms unite state biogen inc biib free report have strong position ms market backed wide range product include avonex tysabri tecfidera plegridy meanwhile roche have strong presence oncology market company dominate breast cancer space strong demand franchise drug herceptin perjeta kadcyla be also impressed company effort develop portfolio oncology immunology new drug launch such tecentriq cotellic alecensa boost sale be expect continue do so upcoming quarters zack rank key pick roche carry zack rank hold better rank stock healthcare sector be exelixis inc exel free report zack rank strong buy see complete list today zack rank stock here exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average beat wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
69,BIIB,be slow week few company announce collaboration agreement meanwhile ligand pharmaceutical lgnd free report raise guidance gw pharmaceutical gwph free report get priority review unite state epidiolex recap week most important storiesgw epidiolex submit eu approval gw pharmaceutical have be news lead cannabinoid pipeline candidate epidiolex cannabidiol cbd say have submit regulatory application european medicine agency ema epidiolex adjunctive treatment seizure associate lennox gastaut syndrome lgs dravet syndrome be highly treatment resistant form childhood onset epilepsy company have orphan designation eu epidiolex indication well west syndrome tuberous sclerosis complex company be also seek approval unite state lgs dravet syndrome indication regulatory agency grant priority review response be expect jun epidiolex represent blockbuster potential especially be approve possible indication ligand up view payment omniab partner ligand raise guidance company earn partner hanall biopharma hanall say have license antibody project be discover company used ligand omniab antibody discovery platform ligand say now expect earn share total revenue approximately company be previously expect earning share revenue priority review label expansion seattle genetic adcetris seattle genetic sgen free report get priority review supplemental biologic license application bla adcetris chemotherapy front line treatment patient advanced classical hodgkin lymphoma give priority review status response be expansion front line set boost product sale first month adcetris sale record seattle genetic be sangamo pfizer sign collaboration agreement sangamo therapeutic sgmo free report pfizer be collaborate development potential gene therapy used zinc finger protein transcription factor zfp tfs treatment amyotrophic lateral sclerosis al frontotemporal lobar degeneration ftld link mutation orf gene agreement see sangamo receive upfront payment pfizer well milestone payment worth tiered royalty net sale sangamo be responsible development zfp tf candidate pfizer be operationally financially responsible subsequent research development manufacturing orf zfp tf program other result product sangamo pfizer already have collaboration agreement be announce last year development gene therapy product hemophilia include sb sangamo share be last year compare gain record industry belong uthr licensing agreement corsair pharma unite therapeutic uthr free report key player pulmonary arterial hypertension pah market announce exclusive license agreement corsair pharma latter portfolio patent cover treprostinil prodrug addition get upfront payment corsair receive royalty payment treprostinil prodrug product unite therapeutic be cover corsair patent agreement term also include equity investment unite therapeutic corsair spark provide update luxturna spark therapeutic once free report have price time gene therapy treatment luxturna however company also announce new payer program be expect lower financial burden patient well treatment center company have be work health insurer ensure access luxturna read more spark therapeutic hope cure rare blindness pop luxturna be approve december patient confirm biallelic rpe mutation associate retinal dystrophy accord fda biallelic rpe mutation associate retinal dystrophy affect approximately patient unite state spark be zack rank hold stock see complete list today zack rank strong buy stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock biogen biib free report gain last month biogen be celgene lose see last biotech stock roundup here biib celg hit pipeline news acquisition deal ignyta sucampo next biotech world watch update outlook be provide several company next week annual morgan healthcare conference wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
70,BIIB,key highlight week include announcement couple acquisition agreement well pipeline news biogen biib free report celgene celg free report announcement relate acquisition ignyta roche sucampo pharmaceutical mallinckrodt recap week most important storiescelgene revlimid combo datum celgene share be disappointing datum combination evaluate company blockbuster cancer drug revlimid treatment naïve follicular lymphoma patient late stage relevance study evaluate revlimid rituxan follow maintenance compare standard care rituxan chemotherapy chop bendamustine cvp follow rituxan maintenance treatment arm fail achieve superiority co primary endpoint complete response unconfirmed complete response cr cru week progression free survival read more celgene discourage datum revlimid celgene share be year date compare gain record industry belong acquisition agreement announce couple acquisition deal be announce week first agreement see ignyta be acquire swiss pharma giant roche cash deal value share ignyta be focuse develop precisely target therapeutic guide diagnostic patient rare cancer acquisition slate close first half roche add entrectinib portfolio entrectinib be currently mid stage development second agreement see sucampo be acquire mallinckrodt share approximately acquisition mallinckrodt get source term net sale earning accretion amitiza boost rare disease pipeline vts cpp sulindac deal be expect close first quarter sucampo be zack rank strong buy stock see complete list today zack rank stock here biogen share alzheimer datum biogen share decline datum ongoing alzheimer disease study ban be be develop collaboration eisai independent datum monitoring committee say ban do not meet criterium success base bayesian analysis month primary endpoint phase ii study study fail show early positive result company say blind study be be conduct patient prodromal mild alzheimer disease collectively know early alzheimer disease continue comprehensive final analysis be conduct month result be expect be obtain second half study datum come disappointment positive datum have be major boost moreover result have raise concern candidate chance success give high rate failure experience other company bring alzheimer disease treatment market read more biogen alzheimer drug miss goal interim analysis biomarin pdufa date extend fda have extend prescription drug user fee act pdufa goal date biomarin pharmaceutical bmrn free report pegvaliase month biomarin be look get investigational therapy approve reduction blood phenylalanine phe level adult patient pku have uncontrolled blood phe level exist management extension be expect agency have ask company submit additional chemistry manufacturing control cmc information company say due memorial day weekend action goal date be read more biogen alzheimer drug miss goal interim analysis agio submit ivosidenib nda agio pharmaceutical agio free report have submit new drug application nda seek fda approval ivosidenib ag investigational oral treatment patient relapse refractory acute myeloid leukemia aml isocitrate dehydrogenase idh mutation company have ask priority review cut review period month agio also announce have receive permission fda move pipeline candidate ag clinical study company intend commence phase study first quarter biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock vertex vrtx free report gain biogen decline last month biogen be regeneron lose see last biotech stock roundup here label expansion exelixis cabometyx fda nod spark gene therapy next biotech world watch usual pipeline regulatory update wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
71,BIIB,share biogen inc biib free report decline almost company alzheimer candidate ban fail meet criterium success base month interim analysis primary endpoint mid stage trial company be develop candidate collaboration eisai co ltd so far year share biogen have gain compare industry growth phase ii study study involve patient prodromal mild alzheimer disease positive biomarker brain amyloid pathology study used bayesian adaptive randomization design allow automatic change design study early success study explore efficacy dose response ban interim analysis month evaluation base eisai house develop alzheimer disease composite score adcom month comprehensive assessment treatment placebo active arm bayesian analysis month indicated success be judge higher probability achieve least reduction rate decline adcom versus placebo interim analysis assessed potential futility stopping safety neither condition be meet study continue full analysis month biogen state month blind study continue further analysis follow predefined study protocol comprehensive final analysis be conduct month look demonstrate clinically significant result datum study be expect second half biogen be look strengthen ad other disorder pipeline notably company alzheimer disease ad pipeline comprise candidate different mechanism action include tau candidate biib bms potential ad well progressive supranuclear palsy psp amyloid aducanumab candidate well bace inhibitor elenbecestat program however successful development therapy treatment alzheimer disease be challenge note several company have fail develop treatment same november eli lilly company lly free report amyloid candidate solanezumab fail meet primary endpoint late stage ad study consequently lilly decide drop development candidate meanwhile pfizer pfe free report shelved late stage alzheimer candidate bapineuzumab iv fail phase iii study pfizer be develop candidate collaboration johnson johnson jnj free report elan corporation alzheimer disease market represent huge commercial potential successfully develop product generate billion dollar sale once launch biogen inc price biogen inc price biogen inc quotezack rankbiogen carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
72,BIIB,biogen inc biib free report have expand collaboration ionis pharmaceutical inc ion free report enhance portfolio medicine treat spinal muscular atrophy sma devastate neuromuscular disease latest deal company have collaborate identify new antisense oligonucleotide drug candidate treatment sma biogen have option license new therapy emerge deal thereafter develop commercialize product collaboration biogen make upfront payment ionis latter also be entitle development regulatory well royalty payment new therapy be approve biogen ionis launch first sma treatment spinraza december last year consolidated biogen position neurological disease market drug be first only treatment be approve unite state sma drug be promising start witness strong patient uptake unite state internationally sma be hereditary neuromuscular disease progressively destroy lower motor neuron lead severe progressive muscular atrophy weakness most severe type sma result paralysis difficulty perform basic function breathe swallow market potential sma disease be huge accord sma foundation disease be believe affect child adult unite state make most common rare disease child be born disease person approximately american carry gene mutation cause sma be divide sub category type type be most severe biogen share have rise year better industry growth same time frame zack rank stock considerbiogen carry zack rank hold better rank stock pharma biotech sector include lundbeck hluyy free report xoma corporation xoma free report xoma carry zack rank strong buy lundbeck have zack rank buy see complete list today zack rank stock here share lundbeck have rise so far year earning estimate have go past day xoma share have sky-rocket year date loss estimate have narrow almost past day medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
73,BIIB,biogen biib free report plc alk free report announce global license collaboration agreement develop commercialize phase iii multiple sclerosis ms candidate alk deal biogen be grant worldwide right alk upfront payment return biogen pay royalty teen percentage rate global sale alk deal be beneficial company reduce cost bring strong partner meanwhile potential approval give biogen drug bioequivalent key oral ms drug tecfidera remind investor tecfidera patient demand be decline slightly due increase competition medicine roche rhhby free report ocrevus slowdown overall ms market tecfidera be also expect face generic competition early potential launch alk help biogen offset tecfidera sale erosion certain extent follow announcement biogen share be nov also open more monday however close biogen share be share be so far year industry have gain period term deal biogen bear development cost alk begin next year biogen start bearing full development cost candidate also pay milestone payment various clinical regulatory achievement currently be responsible seek regulatory approval unite state alk development expense more double year year be total research development cost first month biogen bearing cost also responsible alk potential approval reduce expense next year be expect boost bottom line phase iii study be currently evaluate alk patient relapse form ms pharmacokinetic bridge study prove candidate tecfidera alk have show lower side effect compare tecfidera plan file new drug application regulatory pathway second half biogen inc price biogen inc price biogen inc quotezack rank stock considerbiogen currently carry zack rank hold ligand pharmaceutical inc lgnd free report be better rank stock pharma sector carry zack rank buy see complete list today zack rank strong buy stock here ligand earning estimate be flat increase last day company deliver positive earning surprise trail quarters average beat company share have return so far year note be reissue article correct mistake original article issue yesterday november longer be rely today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
74,BIIB,pipeline regulatory update be focus week ultragenyx pharmaceutical rare free report gain fda approval first drug company cytokinetic cytk free report acorda therapeutic acor free report be hit pipeline setback recap week most important get fda approval rare genetic disease drug ultragenyx gain fda approval first drug mepsevii vestronidase alfa treatment child adult vii mps also know sly syndrome mepsevii be also first medicine be approve rare genetic disease be estimate affect patient develop world mepsevii be launch later month fda have ask post marketing study evaluate long term safety product mps be extraordinarily rare disease sale build gradually patient be identify place therapy meanwhile mepsevii be currently review eu opinion committee medicinal product human use chmp be available first half addition gain fda approval mepsevii ultragenyx also get rare pediatric disease priority review voucher be used gain priority review subsequent drug application be not eligible priority review company also sell voucher million dollar other company want fasten review process candidate biomarin unite therapeutic knight therapeutic be company sell priority review voucher million dollar read more ultragenyx rhgus get fda nod rare genetic disease cytokinetic phase iii setback cytokinetic share plunge negative datum company late stage study tirasemtiv patient amyotrophic lateral sclerosis al company say study fail meet primary endpoint well secondary endpoint cytokinetic have decide suspend development tirasemtiv focus now shift cytokinetic next generation fast skeletal muscle activator ck company believe be better tolerate potentially more effective tirasemtiv phase ii result ck be expect ck be also be evaluate spinal muscular atrophy chronic obstructive pulmonary disease al progressive disease afflict person unite state approximately new case be diagnosed year country be high unmet need new therapy average life expectancy al patient be year diagnosis only patient survive more year cytokinetic have previously say tirasemtiv generate sale more unite state alone cytokinetic share be year date compare gain record industry belong acorda scraps tozadenant program just few day announce safety issue associate late stage study investigational treatment parkinson disease acorda say be discontinue clinical development program tozadenant read more acorda stock phase iii trial tozadenant stop company say immediately discontinue dose participant currently enrolled tozadenant study decision discontinue development be base new information obtain phase iii program related previously disclose agranulocytosis absence white blood cell fight infection associate serious adverse event company say not be confident weekly white blood cell count screening be enough ensure patient safety last week acorda have announce have identify case agranulocytosis possibly drug related case associate sepsis death time company have say be higher frequency blood cell count monitoring phase iii program tozadenant read more acorda report death parkinson trial stock tozadenant oral adenosine receptor antagonist become part acorda pipeline follow acquisition biotie approximately last year acorda have say pipeline candidate inbrija cvt tozadenant parkinson plumiaz epilepsy represent potential peak net sale more however addition tozadenant setback acorda run trouble plumiaz discontinue program have also not be sailing inbrija company have file new drug application nda inbrija june fda issue refusal file rtf letter acorda intend resubmit nda year end pipeline setback weigh acorda start face generic competition flagship drug ampyra august month additional exclusivity uthr adcirca unite therapeutic uthr free report announce have gain pediatric exclusivity unite state pulmonary arterial hypertension pah treatment adcirca mean drug now enjoy exclusivity fda grant approval generic version read more unite therapeutic pah drug exclusivity period extend alnylam start roll nda patisiran alnylam have start submit roll nda unite state patisiran investigational rnai therapeutic target transthyretin ttr treatment hereditary attr hattr amyloidosis company expect finish submission year end alnylam be seek priority review nda grant review process be cut month meanwhile regulatory application eu also be submit end year alnylam have collaboration agreement sanofi patisiran once approve drug be market alnylam unite state canada western europe sanofi sell product rest world read more alnylam start roll nda submission rnai candidate tesaro ovarian cancer drug get eu nod tesaro tsro free report ovarian cancer drug zejula gain approval european commission ec use monotherapy maintenance treatment adult patient platinum sensitive relapse high grade serous epithelial ovarian fallopian tube primary peritoneal cancer be complete response cr partial response pr platinum base chemotherapy make zejula first parp inhibitor be approve europe regardless brca mutation biomarker status treatment initially be launch germany uk december eu approval be largely expect consider chmp have issue positive opinion zejula september zejula be already available unite state gain approval earlier year march read more tesaro ovarian cancer drug zejula get approval eu tesaro be zack rank hold stock see complete list today zack rank strong buy stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock celgene celg free report be vertex decline last month biogen biib free report be regeneron lose see last biotech stock roundup here dynavax vaccine get fda nod loxo inks deal bayer next biotech world watch usual pipeline regulatory update wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
75,BIIB,biotech industry turn year drug pricing issue cripple performance last year have number thing go favor strong quarterly result new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval continue strong performance legacy product play pivotal role bring sector track year however rise first month year january september medical biotech genetic industry have decline so far fourth quarter oct date macro industry specific factor result sudden downfall uncertain macro picturea big component sell be confusion pass tax reform reform aim bring corporate tax stimulate economic well employment growth propose tax reform approve leave more cash hand biotech company cash be invest merger acquisition have be relatively fewer year compare last go say significant uncertainty regard timely pass tax reform have cast shadow future biotech sector october president trump once again criticize high drug price come time investor have start expect trump action drug price not be onerous previously fear send health care stock lower tepid resultscome industry specific factor most big biotechs beat estimate earning sale however share most company decline post earning release various reason gilead gild free report top earning revenue estimate third quarter witness continue decline sale hcv drug harvoni sovaldi result competitive pricing pressure amgen amgn free report also beat expectation earning sale raise earning guidance however sale decline year year result share price decline post earning call sale pcsk inhibitor repatha be also disappointing celgene celg free report share plunge follow release third quarter result celgene earning top estimate revenue fall short moreover company lower outlook otezla sale well total revenue earning outlook biogen biib free report third quarter result be better expect share be concern regard company multiple sclerosis franchise sale well sale recently launch spinal muscular atrophy sma treatment spinraza alexion alxn free report top earning estimate miss revenue third quarter vertex vrtx free report abbvie abbv free report be only outperformer conclusionwe believe biotech space be back track be more certainty regard timing tax reform be fundamental sector remain strong meanwhile earning season now stock start pick positive datum key clinical study drive sector share price biotechs be correlated success key study major biotech player need infusion new growth driver pipeline product portfolio internal development buy asset outside strategic deal sign biotechs also push stock higher look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
76,BIIB,pdl biopharma inc pdli free report report earning cent share third quarter surpass zack consensus estimate cent bottom line be also higher year figure cent company generate total revenue quarter compare year earlier figure upside be mainly drive rise royalty right change fair value primarily back current period increase fair value depome royalty asset also increase net product revenue contribute stronger top line quarter notably company receive cash payment royalty right acquire depome primarily related glumetza product market valeant pharmaceutical international inc vrx free report authorize generic version glumetza be also launch valeant subsidiary february pdl biopharma receive gross margin share company have outperformed industry so far year stock have surge compare industry increase quarter detailrevenue include royalty license queen et al patent consist royalty earn sale tysabri net royalty payment acquire royalty right change fair value royalty right asset interest revenue product revenue sale noden product tekturna tekturna hct unite state lease lensar laser system revenue queen et al license be lower year figure due recognition refund liability potential overpayment amount receive biogen biib free report be related royalty tysabri sale unite state spain italy south africa research development expense quarter come year quarter general administrative expense escalate nearly year figure pdl biopharma inc price consensus ep surprise pdl biopharma inc price consensus ep surprise pdl biopharma inc quotezack rank key pickpdl biopharma carry zack rank hold better rank stock health care sector be ligand pharmaceutical inc lgnd free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have surge year date look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
77,BIIB,expect biogen inc biib free report well know name multiple sclerosis ms market beat expectation report third quarter result oct market open last quarter company deliver positive earning surprise biogen share have rise year better industry growth same time frame biogen earning performance have be pretty impressive so far have deliver positive surprise last quarters average earning beat last quarters be let see thing be shape announcement factor considerglobal patient growth be drive prescription trend sale biogen ms drug expect trend continue third quarter however rise competition roche rhhby free report newly launch ms drug ocrevus hurt sale tysabri modestly second quarter zack consensus estimate key ms drug tysabri tecfidera be respectively meanwhile combine number patient used avonex plegridy continue decline patient transition other oral ms therapy well due higher discount allowance spinraza approve spinal muscular atrophy december witness faster anticipate adoption unite state first half backed robust underlie demand june july spinraza be approve eu canada japan boost sale however call management have mentioned spinraza sale slow second half more difficult treat patient be come patient transition intensive spinraza treatment induction less intensive maintenance schedule biogen biosimilar product flixabi biosimilar reference remicade benepali biosimilar reference enbrel be also generate higher revenue trend continue quarter well headcount reduction restructure initiative be expect continue lower operate expense meanwhile expense be expect increase due increase business development payment investor focus remain tecfidera scrip trend sale rampup spinraza pipeline progress acquisition plan earning whispersour proven model show biogen be likely beat estimate have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold likely positive surprise biogen have right mix zack esp earning esp represent difference most accurate estimate share zack consensus estimate share be uncover best stock buy sell re report earning esp filter zack rank biogen have zack rank combination biogen zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision biogen inc price ep surprise biogen inc price ep surprise biogen inc quoteother stock considersome other stock biotech pharmaceutical sector have positive esp favorable zack rank includebristol myer squibb company bmy free report schedule release result oct earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report earning esp zack rank company be schedule release result oct hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
78,BIIB,acadium pharmaceutical inc acad free report announce initiation phase iii study harmony evaluate antipsychotic drug nuplazid treatment hallucination delusion associate dementia related psychosis fda also grant breakthrough therapy designation drug indication breakthrough therapy designation be grant speed development review drug target serious life threaten condition nuplazid be currently approve only treatment hallucination delusion associate parkinson disease psychosis unite state acadium stock be aftermarket hour wednesday follow news fact share company be so far year outperform industry rise harmony study evaluate ability drug prevent relapse psychotic symptom inalzheimer disease dementia lewy body parkinson disease dementia vascular dementia frontotemporal dementia indication be most common subtype dementia study observe patient week dose stabilization follow week relapse psychosis phase iii study be design base clinically meaningful statistically significant outcome phase ii study drug evaluate patient alzheimer disease psychosis study administer mg drug period week moreover breakthrough therapy designation be grant base phase ii study well phase ii study investigate drug parkinson disease psychosis dementia related psychosis be serious medical condition approve therapy available currently press release be almost person suffering dementia have psychosis sale nuplazid generate first half broaden indication successful completion phase iii study potential approval boost sale drug drive company revenue acadium pharmaceutical inc price consensus acadium pharmaceutical inc price consensus acadium pharmaceutical inc quotezack rank other stock consideracadium carry zack rank buy other stock worth consider health care sector include adaptimmune therapeutic plc adap free report biogen inc biib free report aduro biotech inc adro free report stock carry zack rank see complete list today zack rank strong buy stock here adaptimmune loss share estimate have narrow cent cent cent last day company pull positive earning surprise trail quarters average beat share price company have increase year date biogen earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date aduro loss estimate share have narrow last day company come positive earning surprise trail quarters average beat stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
79,BIIB,be relatively slow week give thanksgiving break key development week include biogen biib free report deal alk free report regeneron regn free report disappointing datum eylea recap week most important storiesbiogen inks deal ms drug biogen key player multiple sclerosis ms market have sign worldwide development alk alk novel oral monomethyl fumarate mmf small drug molecule be currently late stage development treatment relapse form ms term deal receive cost incur related development alk upfront payment well royalty mid teen rate worldwide net sale also receive achievement certain milestone first payment be record collaboration biogen be basically look protect sale blockbuster oral ms drug tecfidera dimethyl fumarate new drug application nda alk be file regulatory pathway reference tecfidera alk have be associate differentiate gi tolerability profile be also head head study tecfidera evaluate gi profile read more biogen acquire worldwide license ms candidate share be agreement biogen be biogen share be year date compare gain record industry belong eylea combination fall short mid stage study regeneron provide disappointing update related plan expand label flagship eye drug eylea company say combination eylea nesvacumab antibody evaluate couple mid stage study do not show sufficient differentiation compare eylea alone justify advancement late stage development study be patient diabetic macular edema dme other be patient wet age related macular degeneration wet amd be not first time regeneron have face setback effort co formulate blockbuster drug last year company have announce mid stage study evaluate eylea combination rinucumab pdgfr beta antibody fail show improvement eylea alone patient neovascular age related macular degeneration wet amd next be datum late stage study evaluate eylea diabetic retinopathy grow patient population significant need result be first half read more regeneron stock fall mid stage eye disease study fail catalyst drug positive second phase iii study catalyst pharmaceutical cprx free report share be positive top line result second late stage study firdapse symptomatic treatment lambert eaton myasthenic syndrome lem rare autoimmune disorder company say remain track file fda approval first quarter firdapse have breakthrough designation unite state read more catalyst report positive phase iii datum firdapse catalyst be zack rank hold stock see complete list today zack rank strong buy stock here cytomx get milestone payment bristol myer cytomx therapeutic ctmx free report be receive milestone payment partner bristol myer squibb fda accept investigational new drug application ind ctla direct probody therapeutic company be collaborate discovery development novel therapy used cytomx proprietary probody platform bristol myer have option select oncology target oncology target include ctla bristol myer have select oncology target now biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index be last trading session major biotech stock biogen be regeneron decline reflect investor disappointment eylea pipeline setback last month biogen be regeneron lose see last biotech stock roundup here rare drug get fda nod acorda cytokinetic hit pipeline setback next biotech world watch usual pipeline regulatory update amgen amgn free report get response fda december regard supplemental biologic license application sbla inclusion risk reduction major cardiovascular event base datum large repatha cardiovascular outcome study repatha be amgen pcsk inhibitor investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
80,BIIB,biogen biib free report plc alk free report announce global license collaboration agreement develop commercialize phase iii multiple sclerosis ms candidate alk deal biogen be grant worldwide right alk upfront payment return biogen pay royalty teen percentage rate global sale alk deal be beneficial company reduce cost bring strong partner meanwhile potential approval give biogen drug bioequivalent key oral ms drug tecfidera remind investor tecfidera patient demand be decline slightly due increase competition medicine roche rhhby free report ocrevus slowdown overall ms market tecfidera be also expect face generic competition early potential launch alk help biogen offset tecfidera sale erosion certain extent follow announcement biogen share be nov also open more monday however close biogen share be share be so far year industry have gain period term deal biogen bear development cost alk begin next year biogen start bearing full development cost candidate also pay milestone payment various clinical regulatory achievement currently be responsible seek regulatory approval unite state alk development expense more double year year be total research development cost first month biogen bearing cost also responsible alk potential approval reduce expense next year be expect boost bottom line phase iii study be currently evaluate alk patient relapse form ms pharmacokinetic bridge study prove candidate tecfidera alk have show lower side effect compare tecfidera plan file new drug application regulatory pathway second half biogen inc price biogen inc price biogen inc quotezack rank stock considerbiogen currently carry zack rank hold ligand pharmaceutical inc lgnd free report be better rank stock pharma sector carry zack rank buy see complete list today zack rank strong buy stock here ligand earning estimate be flat increase last day company deliver positive earning surprise trail quarters average beat company share have return so far year note be reissue article correct mistake original article issue yesterday november longer be rely today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
81,BIIB,beaten blue chip stock be value tracey top stock pick ticker recap extra tip episode roundup podcast zack comwelcome episode value investor podcastevery week tracey ryniec editor zack value investor portfolio service share top value investing tip stock pick not everything be gumdrop rose stock right now index hit new time high large cap name have sell include couple have hit multus year lows tracey hear lot person call stock value stock be do sell share automatically make value value stock be more charttracey have do podcast value stock be breaking so chart isn end be value investing value investor buy stock trading discount earning therefore earning be key be rise fall investor need know avoid value trap scenario stock appear cheap earning be decline tracey take look blue chip stock have be news recently mostly weak stock be blue chip stock value stock general electric ge free report have plunge year lows surely bad news include dividend cut be value right however forward be still isn cheap do earning forecast reveal macy free report be dirt cheap trade forward just share be year however worry department store be doom be earning estimate really signale end be biogen biib free report be weak have rally share however be still well high trade attractive forward do have earning growth get thumb chipotle cmg free report be still year date year lows be share cheap enough earning grow fast enough qualify coveted value stock designation exxon mobil xom free report share be weak compare exxon be year date be lows crude hang pretty consistently be oil stock earning finally show rebound remember price earning ratio be predicate price earning value investor need check earning decide stock be cheap else know beaten blue chip stock listen week podcast find more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
82,BIIB,expect ionis pharmaceutical inc ion free report beat expectation report third quarter result nov last quarter company report wider expect loss result negative surprise company have miss estimate twice trail quarters beating same occasion deliver average positive earning surprise notably ionis share price have increase year date compare zack classify industry decline let see thing be shape announcement earning whispersour proven model show ionis be likely beat estimate quarter have right combination key ingredient positive earning esp zack rank strong buy buy hold have significantly higher chance beating earning zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate be peg cent share zack consensus estimate be peg cent share uncover best stock buy sell re report earning esp filter zack rank ionis currently carry zack rank combine positive esp make reasonably confident earning beat note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision factor considerionis earn revenue form upfront milestone other payment partnership lead health care company biogen inc biib free report glaxo agreement also validate company technology platform ionis biogen receive fda approval spinraza december treat spinal muscular atrophy sma drug be approve europe june first treatment sma ionis have enter collaboration agreement biogen develop commercialize spinraza moreover part licensing agreement biogen ionis earn royalty spinraza sale biogen last week biogen release third quarter result announce spinraza have witness strong demand unite state drive sale company be work expand access patient june spinraza receive approval japan earn ionis milestone payment august moreover ionis receive biogen associate validation undisclosed neurological disease target apart spinraza expect investor focus be pipeline update third quarter conference call quarter ionis akcea submit regulatory application european medicine agency ema fda health canada volanesorsen treatment patient familial chylomicronemia syndrome fcs note march company have announce positive result phase iii approach study volanesorsen patient fcs fact company believe volanesorsen have potential be first treatment option patient suffering daily burden well life threaten risk fcs notably august ionis announce glaxo have decline option develop inotersen ionis fb rx ionis now retain right candidate develop independently ionis announce datum complete phase iii study demonstrated significant improvement neurological disease progression quality life patient hereditary ttr amyloidosis ionis have several early mid stage pipeline candidate various indication expect company provide update different study include path forward inotersen third quarter earning call ionis pharmaceutical inc price consensus ep surprise ionis pharmaceutical inc price consensus ep surprise ionis pharmaceutical inc quoteother stock considerhere be health care stock also want consider model show have right combination element post earning beat quarter inc agen free report have earning esp zack rank company be schedule release result nov see complete list today zack rank stock here myriad genetic inc mygn free report have earning esp zack rank company be schedule release result nov more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
83,BIIB,acorda therapeutic inc acor free report report adjust earning cent share third quarter miss zack consensus estimate cent company have incur loss cent share year acorda share have rally so far year compare industry increase include impact stock base compensation expense well other recur item company incur loss cent share report quarter compare year loss figure cent total revenue come year year mainly owing increase net product revenue however top line miss zack consensus estimate quarter majority acorda net product revenue be generate company key drug ampyra rake sale report quarter revenue grow year year inched marginally sequentially ampyra be market ex market biogen inc biib free report trade name fampyra biogen pay royalty acorda outside sale fampyra royalty be year year acorda research development expense decrease year year selling general administrative sg expense also decline pipeline company third quarter earn release announce expect resubmit new drug application nda parkinson disease pd candidate inbrija fourth quarter note august company receive refusal file rtf letter fda connection nda inbrija fda deem application incomplete preliminary review result regulatory body want additional support information review application subsequently have discussion fda resolve issue company decide resubmit same aforementioned period notably acorda have defer plan submit regulatory application inbrija eu first quarter be earlier expect be submit year end company also have late stage pipeline candidate tozadenant pd portfolio company expect present top line datum ongoing phase iii study candidate first quarter company maintain ampyra net sale guidance range company continue expect expense range millionthe company lower sg expenditure band expect previously acorda await positive cash balance excess end acorda therapeutic inc price consensus ep surprise acorda therapeutic inc price consensus ep surprise acorda therapeutic inc quotezack rank key picksacorda currently carry zack rank hold better rank stock health care sector include ligand pharmaceutical inc lgnd free report exelixis inc exel free report ligand sport zack rank strong buy exelixis carry zack rank buy see complete list today zack rank stock here ligand earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have surge year date exelixis earning share estimate have moved cent cent last day company come positive earning surprise trail quarters average beat share price company have soar year date more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
84,BIIB,biogen biib free report third quarter result surpass top bottom line expectation meanwhile gilead gild free report car therapy gain earlier expect fda approval alexion alxn free report also get regulatory boost fda expand label company flagship product soliris recap week most important storiesbiogen beat front biogen third quarter result be better expect company surpass earning revenue expectation share be concern regard company multiple sclerosis franchise sale well sale recently launch spinal muscular atrophy sma treatment spinraza spinraza sale be third quarter more less flat second quarter sale company report increase number patient therapy unite state compare end second quarter however second quarter sale include inventory buildup read more biogen top earning sale spinraza sale biogen have gain year date outperform industry rally gilead car therapy yescarta approve gilead yescarta become part company portfolio follow kite pharma acquisition gain fda approval treatment adult patient relapse refractory large cell lymphoma more line systemic therapy make yescarta first chimeric antigen receptor cell car therapy gain approval use patient population yescarta be second gene therapy gain approval unite state first be novartis kymriah treatment come box warning regard risk cytokine release syndrome crs neurologic toxicity yescarta approval be major boost gilead be currently face decline sale hepatitis virus hcv franchise accord information provide company diffuse large cell lymphoma dlbcl be most common aggressive hodgkin lymphoma nhl patient refractory dlbcl be eligible car therapy year yescarta represent new treatment option patient have run treatment option face poor prognosis yescarta be launch list price unite state be currently review eu response be expect first half read more gilead car therapy yescarta clinch fda approval gilead also announce phase ii result investigational treatment nonalcoholic steatohepatitis nash company say higher dose mg gs oral acc inhibitor achieve significant reduction buildup fat liver noninvasive marker fibrosis timp compare placebo however statistical significance be not achieve other parameter liver stiffness fibroscan mre serum alt piii np serum marker fibrogenesis meanwhile difference lower dose mg gs placebo be not statistically significant celgene hit crohn disease study discontinuation celgene celg free report share be news company be discontinue study phase iii revolve study extension study sustain be conduct investigational crohn disease drug ged mongersen decision be base recommendation datum monitoring committee october follow interim futility analysis meaningful safety imbalance be observed analysis celgene also say review full dataset phase ii ulcerative colitis study ged decide path forward company not be initiate phase iii define study crohn disease read more celgene discontinue crohn disease drug study abbvie announce immuno therapy focuse deal abbvie abbv free report announce couple deal week deal be focuse immuno neurology other be focuse immuno oncology immuno neurology deal see abbvie collaborate alector use latter immuno neurology discovery platform innovative new therapy alzheimer disease other neurological disorder immuno neurology rapidly evolve scientific area be focuse harness power immune system attack disorder alzheimer disease development cost well profit be share equally company alector get upfront payment potential future equity investment meanwhile immuno oncology deal see abbvie team harpoon therapeutic use harpoon tri specific cell activate construct tritac platform abbvie research stage immuno oncology target develop cancer therapeutic read more abbvie inks immuno oncology deal harpoon therapeutic label expansion alexion soliris fda grant approval alexion use flagship product soliris eculizumab adult patient generalized myasthenia gravis gmg be achr antibody positive soliris already approve unite state serious ultra rare disorder paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus bring sale first half year gmg indication represent incremental growth opportunity soliris alexion be zack rank hold stock see complete list today zack strong buy rank stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock celgene lose reflect sell follow crohn disease update biogen be last month vertex vrtx free report be celgene be see last biotech stock roundup here exelixis soar priority review fda panel support spark drug next biotech world week company amgen amgn free report vertex alexion gilead celgene abbvie be report third quarter result zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
85,BIIB,biogen inc biib free report well know name multiple sclerosis ms market surpass expectation earning sale third quarter company revenue be drive continue strong performance newest drug spinraza spinal muscular atrophy better expect result biogen share be almost pre market trading be probably due fact sale multiple sclerosis franchise be expectation increasingly competitive market however note biogen share have gain so far year compare unfavorably industry increase third quarter earning share be comfortably beat zack consensus estimate earning also rally year year sale come year period sale also surpass zack consensus estimate top line exclude hemophilia revenue grow year year company spun hemophilia business february year quarter detail biogen ms revenue be quarter include approximately royalty sale roche ms drug ocrevus tecfidera sale increase year period however drug record sequential drop revenue include sale ex sale unite state tecfidera inventory level third quarter be relatively flat compare year level hurt sale report quarter third quarter tysabri revenue be ex decrease year year sequentially believe ocrevus launch have put pressure tysabri sale quarter combine interferon revenue avonex plegridy third quarter be ex year period avonex revenue decline year period plegridy contribute third quarter revenue year year sequentially interferon revenue be experience decline trend due patient transition other oral ms therapy well higher discount allowance zinbryta launch collaboration abbvie inc abbv free report august last year contribute revenue third quarter sequentially newly launch spinraza bring revenue revenue third quarter register growth sequentially drug witness strong demand unite state company be work expand access patient quarter biogen record biosimilar revenue compare second quarter company market benepali biosimilar reference amgen inc amgn free report enbrel europe benepali record revenue register growth rate sequentially biogen also market flixabi biosimilar reference johnson johnson jnj free report blockbuster drug remicade record revenue report quarter compare second quarter revenue cd therapeutic program include biogen share rituxan gazyva operate profit climb year period third quarter spend decrease report quarter sg spend decline year year collaboration month biogen announce restructure collaboration arrangement eisai neurimmune improve long term value alzheimer candidate aducanumab be presently phase iii study concurrent earning release biogen announce renegotiation agreement neurimmune make time payment exchange reduction neurimmune royalty rate potential sale aducanumab re negotiate deal thus increase aducanumab profit potential oct biogen partner eisai refine exist alzheimer collaboration biogen already have agreement eisai develop phase iii bace inhibitor phase ii amyloid beta antibody ban alzheimer disease however biogen have announce eisai have exercise option jointly develop commercialize aducanumab company now receive aducanumab potential profit unite state europe japan biogen inc price consensus ep surprise biogen inc price consensus ep surprise biogen inc quotezack rankbiogen currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
86,BIIB,eli lilly company lly free report report third quarter adjust earning share beat zack consensus estimate share earning rise year quarter backed volume drive pharma sale growth higher operate profit revenue beatquarterly revenue also beat zack consensus estimate sale grow year year backed strong performance new drug well lilly diabetes product lilly diabetes product record revenue growth worldwide volume rise strong performance new product trulicity taltz basaglar jardiance lartruvo offset decline sale establish product zyprexa alimta ciali strattera effient higher realize price several drug also contribute sale growth quarter revenue revenue rise quarter backed volume growth new product revenue grow ex revenue rise establish product record growth quarter include forteo humalog sale other establish product decline quarter alimta sale decline reflect lower demand unite state due competitive pressure mainly immuno oncology agent outside unite state sale alimta be hurt loss exclusivity several country increase competition lower realize price zyprexa sale decline due loss exclusivity humulin sale decrease quarter due lower realize price unfavorable buy pattern china ciali sale decline hurt lower demand unite state well increase competition generic sale decline quarter strattera sale decline cymbalta sale decline effient sale decline quarter new product trulicity generate revenue year year revenue benefit growth glp market market share gain cyramza revenue be year year backed continue strong outside revenue improve revenue cyramza ex revenue benefit strong volume japan revenue increase drive increase volume jardiance sale be drive increase market share grow sglt class basaglar record revenue compare previous quarter backed strong launch uptake basaglar lilly partner boehringer ingelheim follow insulin sanofi sny free report blockbuster drug lantus be launch unite state mid december generate revenue quarter taltz bring sale compare previous quarter reflect strong launch uptake lartruvo olaratumab generate revenue third quarter compare previous quarter lartruvo be launch unite state eu soft tissue sarcoma fourth quarter lilly partner incyte corporation incy free report rheumatoid arthritis ra drug olumiant baricitinib have be launch select european country japan drug generate sale third quarter compare previous quarter backed strong launch uptake germany however unite state lilly receive complete response letter crl fda baricitinib april want additional datum august lilly incyte announce re submit nda baricitinib much faster previously expect nda be expect be re submit end january next year lilly elanco animal health segment sale rise due inclusion revenue acquisition boehringer ingelheim vetmedica feline canine rabies acquire january however worldwide competitive pressure continue hurt sale segment concurrent earning release lilly say be explore strategic alternative elanco animal health business include sale merger create separate company initial public offer decision regard same be expect be make later middle next year lilly ultimately opt retain business gross margin operate income risesadjust gross margin quarter decrease basis point manufacturing efficiency be offset negative product mix effect foreign exchange rate international inventory sell operate income increase total operate expense percent revenue decline basis point quarter outlook uppedlilly raise previously issue adjust earning sale outlook second time year adjust earning share be now expect range compare expect previously revenue be expect range expect previously gross margin be expect be approximately same previously expect adjust tax rate be still expect be approximately previously approximately marketing selling administrative expense be still expect range research development expense be project be compare expect previously takelilly third quarter result be strong company beating estimate count pharma giant also raise sale earning outlook year increase revenue guidance be support strong uptake trend new product also extent due positive impact euro share be pre market trading so far year lilly share price have rise compare increase industry go forward new product trulicity taltz basaglar cyramza jardiance lartruvo be expect see higher revenue lilly also expect establish product trajenta forteo humalog continue do well lilly be also progress well pipeline earlier month lilly gain fda approval verzenio abemaciclib cdk inhibitor metastatic breast cancer lilly have launch medicine include verzenio plan launch more however alimta continue be impact competition other headwind include competition immuno oncology agent well loss exclusivity many drug emerge market lilly carry zack rank hold see complete list today zack rank strong buy stock here biogen inc biib free report also report third quarter result today beat estimate earning sale however share be more pre market trading sale multiple sclerosis drug tecfidera decline sequentially quarter eli lilly company price consensus ep surprise eli lilly company price consensus ep surprise eli lilly company quotetoday stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
87,BIIB,cambridge base biogen inc biib free report world lead biotechnology company focus therapeutic area include neurology immunology company be best know multiple sclerosis ms franchise comprise treatment avonex tysabri tecfidera plegridy meanwhile feb company spin hemophilia business allow focus neurology key area expertise biib have pretty good earning track record company deliver positive earning surprise last quarters average surprise biogen inc price ep surprise biogen inc price ep surprise biogen inc quotecurrently biogen have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning beat biogen third quarter earning be better expect company post earning share consensus call ep revenue beat biogen post revenue beating consensus estimate revenue increase year year exclude hemophilia revenue key statistic oral multiple sclerosis ms drug tecfidera revenue increase year year decrease sequentially other ms drug tysabri sale decrease sequentially pre market trading share be more pre market trading check back later full biib earning report later today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
88,BIIB,third quarter report cycle be positive start evident accelerate revenue growth trend meanwhile proportion positive surprise be average quarter also estimate revision trend next quarter have be mostly favorable estimate have actually go past couple week oct member accounting index total market capitalization report result accord latest earning preview total earning index member be year quarter improvement revenue beat ratio be earning revenue report total earning company be expect grow year year higher revenue please note broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning biotech pharma bigwig only johnson johnson jnj free report have report third quarter result so far report better expect third quarter result raise sale profit outlook sale growth accelerate third quarter lead company post first positive sale surprise almost year here have biotech pharma giant be set report third quarter result oct let see thing be shape quarter eli lilly company lly free report lilly be schedule release earning market open have deliver positive earning surprise last quarter lilly earning performance have be mixed earning miss expectation last quarters beating same other bring average negative surprise quarter lilly have earning esp zack rank hold zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter new product trulicity cyramza taltz jardiance have support top line past few quarters expect trend continue third quarter well however decline sale alimta cymbalta zyprexa be expect continue due loss exclusivity read more eli lilly report earning store biogen inc biib free report biogen well know name multiple sclerosis ms market be also schedule announce result open bell biogen earning performance have be pretty impressive so far have deliver positive surprise last quarters average earning beat last quarters be last quarter company deliver positive earning surprise company have earning esp zack rank indicate likely positive surprise zack consensus estimate be peg share see complete list today zack rank strong buy stock here global patient growth be likely drive prescription trend sale biogen ms drug tecfidera however rise competition roche rhhby free report newly launch ms drug ocrevus hurt sale tysabri modestly investor focus also be spinraza performance read more biogen earning deliver beat again novartis ag nvs free report swiss pharma giant be expect report market open last quarter novartis deliver positive earning surprise company post average positive earning surprise trail quarters company have earning esp zack rank zack consensus estimate be peg share new product cosentyx entresto be expect boost top line however loss exclusivity key drug novartis portfolio be expect continue hurt company top line investor focus novartis earning call be update related newly approve car therapy kymriah acute lymphoblastic leukemia read more card novartis earning season make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
89,BIIB,emerge biotech market be time invest be large cap biotech value trap gilead biogen bluebird generic drug company teva valeant abbvie manage healthcare sector effect obamacare growth stock healthcare healthcare value stock screener episode roundup podcast zack comwelcome episode zack market edge podcast week host zack stock strategist tracey ryniec be joined guest discuss hottest investing topic stock bond etfs impact life episode tracey be joined zack senior strategist kevin cook be also editor zack healthcare innovator portfolio hold healthcare medical stock long term tracey have be get question listener wonder be value healthcare stock right now be cheap biotechs biotechs be hot again biotech etf xbi have soar year ishare nasdaq biotechnology etf ibb have gain value still be find biotechs other healthcare industry zack medical sector have company include drug company hospital manage care insurer medical device company dental company other re not create equal tracey kevin run screen quickly find basic value stock sector look only medical sector choose current year forward less next year forward didn screen zack rank return stock tracey kevin discuss dozen week podcast include big name cheap healthcare stock gilead gild free report have be cheap year trade forward just earning be decline company make last year expect just make year recently buy kite be enough give earning boost be value trap biogen biib free report be big biotech be cheap trade forward just analyst just raise price target stock gilead expect see earning growth year next year teva teva free report be cheapest group trade forward investor have be concern fall earning estimate make be expect make just be value trap abbvie abbv free report have rare combination attractive just rise earning estimate earning be expect jump abbv be short list aetna aet free report be manage care group be most difficult area be right now due obamacare uncertainty aetna have be reduce exposure exchange trade forward just be other industry be also cone uncertainty due unknown surround obamacare include hospital tracey kevin discuss hospital group especially tenet healthcare thc additionally valeant vrx appear be cheap tracey fear value trap medical device company ve be hot year be just too expensive make list find answer question more week podcast look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
90,BIIB,company amgen amgn free report regeneron regn free report be news amgen provide pipeline regulatory update regeneron partner sanofi get good news appeal court ruling favor pcsk inhibitor lawsuit amgen recap week most important storiesphase ii combination datum amgen imlygic publish positive datum amgen oncolytic viral therapy imlygic used combination bristol myer squibb yervoy be publish journal clinical oncology result mid stage study show objective response rate orr more double imlygic be used combination yervoy compare yervoy alone patient unresectable stage iiib iv melanoma versus moreover complete response rate be almost double combination arm compare yervoy alone versus response be observed inject uninjected lesion include visceral lesion advanced melanoma be highly aggressive most dangerous type skin cancer be need multiple treatment approach course disease datum be encourage open new avenue revenue imlygic eventually gain approval use combination checkpoint inhibitor sale imlygic approve october be yet pick meanwhile amgen say fda have accept regulatory application seek label expansion use prolium glucocorticoid induced osteoporosis most common form secondary osteoporosis response agency be prolium bring sale second quarter be important growth driver amgen company work improve diagnosis treatment rate duration order drive access greater number patient read more amgen label expansion application prolium accept fda amgen be zack rank buy stock share amgen have gain year date significantly outperform industry rally see complete list today zack rank strong buy stock here breather amgen neulasta biosimilar approval delay amgen get bit breather fda issue complete response letter crl mylan biocon biosimilar version amgen blockbuster drug neulasta pegfilgrastim agency do not raise query regard biosimilarity pharmacokinetic pharmacodynamic datum clinical datum immunogenicity myl crl relate pending update regulatory application certain cmc datum facility requalification activity post recent plant modification note mylan biocon be not only company get crl fda biosimilar version neulasta novartis sandoz have receive crl last year coherus be issue crl year june regeneron sanofi score pcsk inhibitor litigation regeneron partner sanofi get major boost court appeal federal circuit order new trial related amgen claim regard patent pcsk inhibitor court also vacated permanent injunction lawsuit mean sanofi regeneron continue selling pcsk inhibitor praluent unite state read more regeneron sanofi get favorable ruling amgen abbvie immuno oncology deal abbvie abbv free report have enter research option license agreement clinical stage immuno oncology company turnstone biologic deal provide abbvie exclusive option license turnstone next generation oncolytic viral immunotherapy turnstone ad mg magea therapy be couple phase ii study different solid tumor indication alone well combination approve pd checkpoint inhibitor promising new datum biogen spinraza new phase iii datum present biogen biib free report spinraza show earlier initiation treatment therapy improve motor function outcome infant child spinal muscular atrophy sma biogen ionis spinraza be first approve medicine treatment sma spinraza be promising start unite state bring sale second quarter clovis seek label expansion parp inhibitor clovis oncology clvs free report have file label expansion parp inhibitor rubraca unite state company be look get drug approve maintenance treatment patient recurrent epithelial ovarian fallopian tube primary peritoneal cancer be complete partial response platinum base chemotherapy company have present impressive late stage datum earlier year june rubraca show treatment significantly improve progression free survival ovarian cancer patient population evaluate ariel study rubraca have gain accelerate fda approval december use advanced ovarian cancer patient have be treat more chemotherapy have deleterious germline somatic brca mutation broader label boost rubraca sale potential read more clovis submit snda ovarian cancer drug rubraca biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index be last trading session major biotech stock biogen gain celgene celg free report lose last month vertex vrtx free report be see last biotech stock roundup here endocyte shoot deal amgen abbvie settle humira litigation next biotech world sector gear third quarter earning watch usual regulatory pipeline update spark therapeutic voretigene neparvovec be review fda cellular tissue gene therapy advisory committee ctgtac october spark be seek fda approval treatment patient vision loss due confirm biallelic rpe mutation associate retinal dystrophy wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
91,BIIB,equity market maintain steady momentum rebuff geopolitical threat related north korean missile test deadly terrorist attack home soil la vegas investor repose faith riskier bet equity courtesy strengthen dollar sell global bond market cash cow stock offer higher return have be seek however single cash rich stock alone do not make solid investment proposition be backed attractive efficiency ratio return equity roe high roe ensure company be reinvest cash high rate return roe key metricroe net income shareholder equityroe help investor distinguish profit generate company profit burner be useful determine financial health company other word financial metric enable investor identify stock diligently deploy cash higher return moreover roe be often used compare profitability company other firm industry higher better measure well company be multiply profit investing new equity capital portray management efficiency reward shareholder attractive risk adjust return screening parametersin order shortlist stock be cash rich high roe have add cash flow greater roe greater industry primary screening parameter addition have take few other criterium consideration arrive winning strategy price cash flow less industry metric measure much investor pay dollar free cash flow lower ratio indicate investor need pay less better cash flow generate stock return asset roa greater industry metric determine much profit company earn dollar asset include cash account receivable property equipment inventory furniture higher roa better be company year ep historical growth greater industry criterion indicate continue earning momentum have translate solid cash strength zack rank less equal zack rank strong buy buy stock be know outperform irrespective market environment here be stock qualify screen texas instrument incorporate txn free report headquarter dalla tx texas instrument be original equipment manufacturer analog mixed signal digital signal process integrate circuit company have trail quarter average earning surprise long term earning growth expectation texas instrument carry zack rank apply material inc amat free report headquarter santa clara apply material offer manufacturing equipment service software semiconductor display related industry worldwide zack rank stock have trail quarter average earning surprise long term earning growth projection see complete list today zack rank stock here pepsico inc pep free report headquarter purchase ny pepsico be lead global food beverage company premier brand frito lay snack pepsi cola beverage gatorade sport drink tropicana juice quaker food company have zack rank pepsico have trail quarter average earning surprise long term earning growth expectation cbre group inc headquarter los angele cbre group be commercial real estate service investment firm offer wide range service tenant owner lender investor office retail industrial multus family other type commercial real estate major metropolitan area globe company have trail quarter average earning surprise long term earning growth expectation cbre group sport zack rank biogen inc biib free report base cambridge biogen be world lead biotechnology company zack rank stock have trail quarter average earning surprise long term earning growth projection get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performance zack restaurant recommendation inaddition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
92,BIIB,nordisk nvo free report announce fda have approve fast act mealtime insulin aspart fiasp treatment adult diabetes fda approval be base result phase iii study show fiasp improve overall blood sugar hba post meal sugar postprandial glucose ppg control week compare conventional insulin aspart novorapid company have resubmit new drug application nda fiasp class ii re submission fda march october nordisk announce have receive complete response letter fda regard nda fast act insulin aspart letter fda request additional information related assay immunogenicity assay used generate clinical pharmacokinetic datum review nda be complete nordisk share have outperformed industry year date stock have rally compare industry gain same time frame fiasp be already approve europe improve control postprandial glucose ppg excursion patient type type ii diabetes well pump treatment fact company have strong presence diabetes care market global value market share also company have strong presence total insulin market modern new generation insulin market global value market share respectively notably nordisk have broadest diabetes portfolio industry nordisk price nordisk price nordisk quotezack rank stock considernovo nordisk carry zack rank hold better rank stock health care sector include regeneron pharmaceutical inc regn free report biogen inc biib free report aduro biotech inc adro free report regeneron sport zack rank strong buy biogen aduro carry zack rank buy see complete list today zack rank stock here regeneron earning share estimate have increase last day company pull positive earning surprise trail quarters average beat share price company have increase year date biogen earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date aduro loss estimate share have narrow last day company come positive earning surprise trail quarters average beat today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
93,BIIB,alexion pharmaceutical alxn free report get boost eu approve key revenue driver soliris additional indication meanwhile biogen biib free report be news investigation be launch rise price multiple sclerosis ms drug investigation have be launch rep elijah cumming rep peter welch letter be send company include biogen request information pricing strategy ms drug recap week most important storieseu label expansion alexion soliris alexion flagship product soliris gain eu approval treatment patient refractory generalized myasthenia gravis gmg make first only complement base therapy approve eu ultra rare subset gmg alexion launch soliris indication initially germany be evaluate additional eu launch gmg indication represent incremental growth opportunity soliris enable company enter neurology therapeutic area soliris be currently review japan response expect early next year gmg indication eu grant approval look soliris gain approval well decision be expect oct accord information provide company person suffer myasthenia gravis mg alexion target population be approximately total mg patient population result late stage study regain conduct company indicate refractory gmg patient respond treatment soliris soliris be alexion key growth driver drug bring sale first half company expect soliris revenue assume identification steady number new patient paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus globe also read alexion soliris label expansion approve europe alexion be zack rank strong buy stock see complete list today zack rank stock here biogen other face ms drug price probe biogen hold strong position ms market have be ask submit information ms drug avonex tysabri tecfidera plegridy zinbryta co promote abbvie accord letter drug have see least double digit price increase approval price drug have increase almost moreover zinbryta be introduce price annum price biogen other ms drug be hike match zinbryta price biogen have respond letter aug also read biogen other multiple sclerosis drug stock focus here pipeline setback ultragenyx ultragenyx pharmaceutical rare free report company focuse develop treatment rare ultra rare disease suffer pipeline setback candidate fail late stage study aceneuramic acid extend release ace fail meet primary well key secondary endpoint phase iii study patient gne myopathy gnem ultragenyx have decide discontinue development ace ultragenyx currently have investigational treatment fda review vestronidase alpha mps decision expect nov be look file fda approval burosumab link shortly fda nod ironwood gout drug ironwood pharmaceutical irwd free report once daily gout treatment gain fda approval duzallo have be approve treatment hyperuricemia associate gout patient have not achieve target serum uric acid level medically appropriate daily dose allopurinol alone make duzallo first fda approve fix dose combination treatment available single pill address cause hyperuricemia gout production excretion serum uric acid ironwood expect launch product fourth quarter ironwood expect duzallo drive sale gout franchise be expect deliver total annual peak sale more note duzallo label include box warning acute renal failure also read ironwood pharma combination gout drug get fda approval start roll nda submission mdd drug alk free report have start roll submission new drug application nda investigational major depressive disorder mdd drug alk roll nda submission once daily oral medicine novel mechanism action adjunctive treatment mdd be slate complete year end also read initiate roll submission depression drug alk have fast track designation have lose value year date versus growth industry biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index inched slightly last trading session major biotech stock alexion be celgene lose last month vertex vrtx free report be biogen slip see last biotech stock roundup here regeneron drop rsv antibody gilead hiv drug get priority review next biotech world watch usual regulatory pipeline update amgen amgn free report be present new datum pcsk inhibitor repatha european society cardiology esc congress surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
94,BIIB,have already crossed halfway mark second quarter report cycle earn season have show broad base growth record earning quarter jul member accounting index total market capitalization report result accord earning preview company beat count compare first quarter total earning index member be year quarter improvement revenue beat ratio be earning revenue medical segment have also perform well so far earning increase revenue report total earning company second quarter be expect grow year year higher revenue plenty result still come actual earning growth quarter exceed mark follow earning growth first quarter increase revenue highest almost year johnson johnson jnj free report begin earning season pharma sector mixed second quarter result performance novartis nvs free report lilly lly free report biogen inc biib free report be encourage company beat earning revenue estimate lilly biogen also raise earning revenue estimate other pharma bigwig report last week abbvie inc abbv free report report better expect result earning sale surpass expectation lymphoma drug imbruvica record record growth merck co inc mrk free report also beat estimate earning sale second quarter mainly backed strong sale pd inhibitor keytruda let take look pharma biotech company be set report second quarter result aug let see thing be shape quarter pfizer inc pfe free report pfizer be schedule release earning open bell deliver positive earning surprise last quarter pfizer earning performance have be mixed earning miss expectation last quarters beating same twice result average negative surprise quarter pfizer have earning esp zack rank hold indicate likely beat zack consensus estimate be peg cent share uncover best stock buy sell re report earning esp filter pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quotenew product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain eliquis blood thinner be likely contribute top line meaningfully read more be beat card pfizer earning aerie pharmaceutical inc aeri free report aerie pharma be schedule announce result close bell aerie pharma have miss estimate past quarters have average negative earning surprise company have earning esp zack rank buy see complete list today zack rank strong buy stock here aerie pharmaceutical inc price ep surprise aerie pharmaceutical inc price ep surprise aerie pharmaceutical inc approve product portfolio aerie depend heavily late stage candidate rhopressa roclatan aerie have submit regulatory application rhopressa expect submit same eu second half hence expect investor focus remain pipeline update read more card aerie earning season incyte corporation incy free report company be expect report market open incyte deliver earning surprise last quarter incyte performance have be pretty impressive company report positive surprise consistently average earning beat last quarters be company have earning esp zack rank zack consensus estimate be peg loss cent share incyte corporation price ep surprise incyte corporation price ep surprise incyte corporation quotemore stock news company verge apple rundid miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
95,BIIB,acorda therapeutic inc acor free report report adjust earning cent share second quarter include impact stock base compensation expense compare loss cent share year quarter acorda share have lose more thursday follow second quarter earning release however share company have rally so far year compare industry increase include impact stock base compensation expense well other recur item second quarter loss amount cent share significantly miss zack consensus estimate earning cent company have incur loss cent share year total revenue come year year mainly due increase net product revenue however revenue be almost line zack consensus estimate quarter majority acorda net product revenue be generate ampyra rake sale report quarter revenue grow year year rally sequentially ampyra be market ex market biogen inc biib free report trade name fampyra biogen pay royalty acorda outside sale fampyra royalty be year year acorda research development expense include stock base compensation expense exclude re structuring cost decrease year year selling general administrative sg expense include stock base compensation expense exclude re structuring cost also decline pipeline updatesin jun company have submit new drug application nda fda inbrija treatment patient suffering parkinson disease pd nda be submit section fda base current guideline company expect fda notify submission be accept full review september end year nda submission be support datum phase iii safety efficacy study span pd ongoing long term safety study cvt cvt patient parkinson acorda be also plan submit regulatory application approval inbrija eu end give indication notably company have late stage pipeline candidate tozadenant pd portfolio company expect datum ongoing phase iii study first quarter company maintain ampyra net sale guidance range company continue expect expense range exclude share base compensation company also maintain sg expenditure band exclude share base compensation acorda await positive cash balance excess end acorda therapeutic inc price consensus ep surpriseacorda therapeutic inc price consensus ep surprise acorda therapeutic inc quotezack rank key picksacorda currently carry zack rank strong sell top rank stock healthcare sector be enzo inc exelixis inc exel free report sporting zack rank strong buy see complete list today zack rank stock here exelixis earning share estimate inched cent cent last day company have deliver positive earning surprise trail quarters average beat exelixis share have soar so far year enzo loss share estimate narrow cent cent cent cent last day company deliver positive earning surprise trail quarters average beat share price company have surge year date hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
96,BIIB,earning season be fly start equity market scaling record high owing slew upbeat economic datum strong corporate performance president donald trump tax reform proposal however performance have be mixed bag biotech company beating market expectation few fail do so read fiscal deficit gdp etfs focus now discuss performance few biotech giant such amgen inc amgn free report gilead science gild free report biogen inc biib free report alexion pharmaceutical alxn free report read keep portfolio healthy biotech etfs earning focusamgen report third quarter adjust earning share oct surpass zack consensus estimate increase share year quarter company also beat zack consensus estimate revenue front amgen report revenue surpass zack consensus estimate decrease year quarter company update full year gaap ep guidance range previous guide range owing hurricane recovery cost also update revenue guidance range previous guide range company share lose hour trading oct revise guidance gilead science report third quarter adjust earning share oct miss zack consensus estimate decrease more share year quarter however company beat zack consensus estimate revenue front company report revenue surpass zack consensus estimate decrease more year quarter company update full year revenue guidance range previous guide range company share fall hour trading oct owing ep miss biogen inc report third quarter adjust earning share oct surpass zack consensus estimate increase share year quarter company report revenue surpass zack consensus estimate increase roughly year quarter company share decline market close oct due weaker expect sale sclerosis franchise alexion pharmaceutical inc report third quarter adjust earning share oct surpass zack consensus estimate increase roughly share year quarter company report revenue fail beat consensus estimate increase roughly year quarter company update full year gaap ep guidance range increase revenue guidance company share decline market close oct primarily due revenue miss now discuss few etfs high exposure company discuss ishare nasdaq biotechnology etf ibb free report fund seek provide exposure biotech industry have aum charge fee basis point year fund have exposure amgen biogen gilead alexion oct fund have return year year date oct have zack etf rank hold high risk outlook vaneck vector biotech etf bbh free report fund have aum charge fee basis point year fund have exposure amgen gilead biogen alexion oct fund have return year year date oct have zack etf rank high risk outlook proshare ultra nasdaq biotechnology etf bib free report fund have aum charge fee basis point year fund have exposure amgen biogen gilead alexion sep fund have return last year year date oct want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
97,BIIB,third quarter report cycle be witness revenue acceleration positive revision trend result third company member be already revenue beat ratio company be slightly precede quarter be unusually high compare historically total earning member have report already be same period last year higher revenue beating ep estimate accord latest earning preview report company account index total market capitalization report total earning company be expect grow year year higher revenue biotech pharma bigwig eli lilly company lly free report biogen inc biib free report amgen inc amgn free report have report third quarter result week company beat expectation earning sale lilly also raise earning sale outlook amgen slightly raise lower end previously issue sale outlook raise earning guidance back effective cost management however share biogen amgen decline follow result announcement concern regard biogen multiple sclerosis franchise sale well sale recently launch spinal muscular atrophy sma treatment spinraza hurt investor sentiment amgen year year decline sale lead share price fall here have large pharma company be set report third quarter result oct let see thing be shape quarter abbvie inc abbv free report abbvie be schedule release earning market open have deliver positive earning surprise last quarter lilly earning performance have be mixed earning breaking even last quarters beating same other bring average surprise quarter abbvie have earning esp almost zack rank hold zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter company key drug humira be likely remain main growth driver backed higher demand quarter abbvie expect humira sale rise high teen range internationally same be estimate increase mid single digit range operational basis other drug duopa creon be also expect continue perform well soon be report quarter read more abbvie spring surprise earning season abbvie inc price consensus abbvie inc price consensus abbvie inc quotemerck co inc mrk free report merck be schedule release earning market open merckhad deliver positive earning surprise last quarter company earning performance have be pretty impressive so far have deliver positive surprise last quarters average earning beat last quarters be company also have earning esp almost zack rank zack consensus estimate be peg share see complete list today zack rank strong buy stock here merck new product keytruda cancer zepatier hcv bridion sugammadex injection be likely drive top line quarter keytruda sale unite state be gain particularly back strong momentum new indication first line lung cancer read more merck keep earning streak alive previous article show merck be likely beat earning quarter however estimate change thereafter be not certain beat earning season merck company inc price consensus merck company inc price consensus merck company inc quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
98,BIIB,second quarter report cycle be full swing quarter undoubtedly be strong start jul member accounting index total market capitalization report result accord earning preview total earning index member be year quarter improvement revenue beat ratio be earning revenue earning momentum be expect continue season report total earning company second quarter be expect grow year year higher revenue follow earning growth first quarter increase revenue highest almost year pharma bigwig eli lilly company lly free report biogen inc biib free report release second quarter result week company beat earning revenue estimate raise sale earning expectation full year moreover vertex pharmaceutical incorporate vrtx free report amgen inc amgn free report report encourage second quarter result jul beating estimate count however glaxosmithkline plc gsk free report report mixed second quarter result same day beating earning miss sale let take look large cap pharma company be set report second quarter result jul abbvie inc abbv free report abbvie be schedule release earning market open have deliver positive earning surprise last quarter abbvie earning performance have be mixed earning beating expectation last quarters meeting same remain result average positive surprise quarter abbvie have earning esp zack rank hold do not conclusively show abbvieis likely beat estimate quarter zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter abbvie inc price ep surprise abbvie inc price ep surprise abbvie inc quoteabbvie key drug humira be perform well be expect continue do well second quarter imbruvica have be record strong sale past few quarters expect trend continue however hcv franchise continue be pricing pressure read more abbvie earning disappointment store merck co inc mrk free report merck be also schedule announce result open bell merck have beaten estimate last quarters result average positive surprise last report quarter merck deliver positive surprise merck company inc price ep surprise merck company inc price ep surprise merck company inc company have earning esp zack rank buy thus do not look poise deliver beat time see complete list today zack rank strong buy stock here merck new product keytruda cancer zepatier hcv bridion sugammadex injection drive top line quarter however company be expect face headwind form genericization increase competition negative impact currency exchange read more merck pull surprise earning season more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
99,BIIB,second quarter earning season be strong start july approximately company index total membership have report result deep look result show earning company report so far be year year higher revenue have top earning estimate have beat revenue estimate however pace growth be first quarter line quarter average have improve quarter average go forward estimate third quarter be go estimate growth be start quarter pharma sector have more less combat overall decline financial market maintain momentum last week industry bellwether johnson johnson jnj free report report mixed second quarter result beating earning miss sale swiss major novartis ag nvs free report report encourage second quarter result meanwhile biotech giant biogen inc biib free report surpass expectation earning sale second quarter raise annual guidance let take look biotech company be set report second quarter result jul bristol myer squibb company bmy free report be schedule report open bell last quarter company beat earning estimate bristol myer have decent track record so far company earning beat estimate trail quarters average positive surprise currently company have zack rank hold earning esp current rank increase predictive power esp esp make unlikely stock beat quarter uncover best stock buy sell re report earning esp filter bristol myer high profile immuno oncology drug opdivo be expect continue drive company top line be report quarter first quarter see stability second line lung cancer recent fda approval merck co inc mrk free report keytruda first line treatment metastatic nonsquamous nsclc impact sale read more offing bristol myer earning bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quotecelgene corporation celg free report be schedule report open bell last quarter company beat expectation celgene key product revlimid be expect continue be main growth driver first quarter drive share gain important market longer treatment duration newly diagnosed multiple myeloma mm other key product pomalyst imnovid abraxane otezla continue perform well second quarter call investor be expect remain focuse company performance label expansion effort update pipeline front celgene have submit new drug application fda idhifa relapse refractory aml nda idhifa be grant priority review prescription drug user fee act pdufa action date aug celgene track record have be pretty decent company toppingearning estimate thrice trail quarters overall company have deliver average positive surprise currently company carry zack rank earning esp indicate likely earning beat quarter read more be celgene poise beat earning season celgene corporation price ep surprise celgene corporation price ep surprise celgene corporation quotealexion pharmaceutical inc alxn free report be schedule report result open bell last report quarter company earning surpass zack consensus estimate alexion blockbuster drug soliris continue perform well label expansion drug additional indication be expect boost revenue new product strensiq be do well kanuma lag expectation management be reassess strategy drug go forward alexion track record be excellent company have consistently top expectation last quarters average positive earning surprise currently company carry zack rank earning esp indicate be likely beat estimate quarter read more be beat store alexion earning season alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
100,BIIB,biogen inc biib free report announce datum long term study alzheimer disease ad candidate aducanumab datum study show continue benefit rate amyloid decline year period patient prodromal mild alzheimer disease treat aducanumab share be monday response promise show amyloid candidate company say result recently conduct analysis long term extension lte ongoing phase ib study prime aducanumab be consistent previously report datum prime prime be randomize double blind placebo controlled multiple dose phase ib study be conduct evaluate safety tolerability pharmacokinetic pharmacodynamic aducanumab patient suffering prodromal mild ad so far year biogen share have rise industry record increase biogen be conduct other phase iii study engage emerge aducanumab treatment early ad result lte study support design engage emerge study biogen be look strengthen ad other disorder pipeline biogen ad pipeline comprise candidate different mechanism action include tau candidate biib bms potential ad well progressive supranuclear palsy psp amyloid aducanumab candidate well bace inhibitor elenbecestat program however successful development therapy treatment alzheimer disease be challenge note several company have fail develop treatment same november last year eli lilly company lly free report amyloid candidate solanezumab fail meet primary endpoint late stage ad study lilly decide drop development solanezumab lilly suffer major setback aug have halt development phase iii alzheimer candidate semagacestat meanwhile pfizer pfe free report shelved late stage alzheimer candidate bapineuzumab iv fail phase iii study pfizer be develop candidate collaboration johnson johnson jnj free report elan corporation alzheimer disease market represent huge commercial potential successfully develop product generate billion dollar sale once launch biogen have zack rank hold see complete list today zack rank strong buy stock here zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
101,BIIB,share expedia inc expe free report decline company chief executive officer dara khosrowshahi announce be join uber ceo biogen inc biib free report share surge follow positive result alzhiemer drug study share gilead science inc gild free report increase enter agreement kite pharma inc acquire company whopping cash johnson johnson jnj free report share increase almost announce favorable result phase study blood thin drug xarelto
102,BIIB,biogen inc biib free report announce biosimilar version abbvie inc abbv free report top selling blockbuster drug humira have be approve european commission biosimilar be market trade name imraldi imraldi sb be used whole range indication include rheumatoid arthritis axial ankylose spondylitis plaque psoriasis psoriatic arthritis crohn disease ulcerative colitis polyarticular juvenile idiopathic arthritis active enthesitis related arthritis hidradenitis suppurativa infectious uveitis remind investor biosimilar be grant positive opinion committee medicinal product human use chmp june year biogen have joint venture samsung biologic biosimilar samsung bioepis joint venture company already marketsa couple biosimilar eu flixabi biosimilar reference merck co inc mrk free report remicade benepali biosimilar reference amgen pfizer enbrel make imraldi third tnf biosimilar biogen receive marketing authorization eu benepali be do quite well generate sale first half flixabi record sale same period note earlier year amgen inc amgn free report gain eu approval amgevita biosimilar version humira biogen share have rise year so far industry record increase biogen carry zack rank hold see complete list today zack rank strong buy stock here surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
103,BIIB,biotech sector earning season round corner be not too many update week important news week include priority review exelixis exel free report label expansion plan cabometyx positive fda panel outcome spark therapeutic once free report luxturna recap week most important storiesexelixis priority review fda exelixis share shot news fda have grant priority review company regulatory application label expansion cabometyx company be look get cabometyx approve use treatment naïve advanced renal cell cancer patient fda grant priority review response be feb cabometyx be currently approve treatment patient advanced renal cell carcinoma have receive prior angiogenic therapy accord american cancer society kidney cancer be top most commonly diagnosed form cancer man woman unite state year survival rate patient advanced late stage metastatic renal cell carcinoma be only accord information provide company press release patient unite state need first line treatment advanced kidney cancer year read more fda grant priority review exelixis rcc drug cabometyx cabometyx be be evaluate other type cancer well addition announce priority review status exelixis present positive late stage datum cabometyx advanced hepatocellular carcinoma hcc aggressive form advanced liver cancer study achieve primary endpoint overall survival company intend submit supplemental new drug application snda first quarter cabometyx have orphan drug status unite state indication spark luxturna get full fda panel support spark therapeutic get boost fda advisory panel unanimously support company investigational treatment use patient biallelic rpe mediate inherited retinal disease timely approval make luxturna first pharmacologic treatment inherited retinal disease ird well first gene therapy genetic disease unite state gene therapy company get know approval status treatment jan luxturna be priority review have orphan drug breakthrough therapy rare pediatric disease designation unite state gene therapy be review eu well regeneron dupixent top allergic inflammatory disease study regeneron pharmaceutical regn free report partner sanofi announce positive phase ii result dupixent dupilumab adult active moderate severe eosinophilic esophagitis chronic allergic inflammatory disease patient receive dupixent weekly report significant improvement ability swallow versus placebo read more sanofi regeneron dupixent succeed phase ii study market be huge dupixent gain timely approval give lack fda approve treatment dupixent have orphan drug status unite state indication dupixent have blockbuster potential be currently approve eczema be be evaluate additional indication apart eosinophilic esophagitis fact last month company have announce positive top line datum late stage study dupixent uncontrolled persistent asthma regeneron sanofi be also collaborate aimmune therapeutic clinical stage company focuse development treatment potentially life threaten food allergy clinical collaboration aimmune ar be evaluate adjunctive dupixent peanut allergic patient mid stage study be schedule commence next year study be sponsored regeneron aimmune provide clinical supply ar food challenge material regeneron have gain year date outperform industry rally ionis get milestone payment biogen study initiation ionis pharmaceutical ion free report be set receive milestone payment partner biogen biib free report related initiation phase iia study ionis maptrx patient mild alzheimer disease ad biogen have option development antisense drug company already have partner drug spinraza spinal muscular atrophy market be collaborate other drug disease amyotrophic lateral sclerosis other disease ionis be zack rank strong buy stock see complete list today zack rank stock here immune design pivotal study design get positive fda feedback fda have give nod immune design imdz free report phase iii clinical study design cmb patient synovial sarcoma pivotal study evaluate cancer vaccine monotherapy compare placebo be schedule commence mid progression free survival pfs follow overall survival os be co primary endpoint fda say support full approval pfs endpoint be meet read more immune design sarcoma candidate enter phase iii biomedical genetic industry yr returnmedical biomedical genetic industry yr nasdaq biotechnology index slip last trading session stock be hit earlier week report president trump criticize high drug price again major biotech stock biogen be couple analyst upgrade boost stock regeneron be period last month vertex be see last biotech stock roundup here amgen imlygic datum promising regeneron score pcsk lawsuit next biotech world watch third quarter earning result company amgen biogen vertex alexion alxn free report also get response fda regard label expansion flagship product soliris eculizumab refractory generalized myasthenia gravis agency be expect give response october hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
104,BIIB,eli lilly company lly free report announce number leadership change order focus bring newer drug market regard company promote josh smiley post chief financial officer cfo effective jan june company announce current cfo derica rice retire year end company also promote dan skovronsky senior vice president science technology president lilly research lab change be effective june also myle neill have be promote senior vice president president manufacturing operation aarti shah be senior vice president chief information officer have be offer post executive officer become part lilly executive committee addition appointment company also announce retirement marium crowe president manufacturing operation retire december year service jan lundberg vice president science technology president lilly research lab retire end year lilly so far year lilly share price have increase compare industry gain note company have make change order focus new medicine diabetes cancer immunology pain last month company also announce restructure initiative order streamline operation so focus develop new medicine improve cost structure announce plan reduce global workforce approximately position initiative be expect amass annualize saving approximately begin furthermore be also close several site plant iowa office new jersey center china save cost however company face share challenge several key drug portfolio zyprexa cymbalta be face generic competition due loss exclusivity meanwhile blockbuster drug alimta sale be also be affected entry immuno oncology agent market outside unite state sale be already be hurt due loss exclusivity several country other headwind include competition immuno oncology agent well recent high profile pipeline setback also lilly animal health segment do not do too well first half due worldwide competitive pressure eli lilly company price eli lilly company price eli lilly company quotezack rank stock considerlilly carry zack rank hold better rank stock health care sector include regeneron pharmaceutical inc regn free report biogen inc biib free report aduro biotech inc adro free report regeneron sport zack rank strong buy biogen aduro carry zack rank buy see complete list today zack rank stock here regeneron earning share estimate have increase last day company pull positive earning surprise trail quarters average beat share price company have increase year date biogen earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date aduro loss estimate share have narrow last day company come positive earning surprise trail quarters average beat today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
105,BIIB,emergent biosolution inc ebs free report announce complete acquisition fda license smallpox vaccine business sanofi sny free report acam company paid upfront payment milestone payment deal also include potential milestone payment tie achievement remain regulatory milestone event acam include acam only vaccine license fda active immunization smallpox disease person determine be high risk smallpox infection also include cgmp live viral manufacturing facility office well warehouse space canton cgmp viral fill finish facility rockville md emergent biosolution also assume responsibility sanofi exist year center disease control prevention cdc contract remain value approximately delivery acam strategic national cdc contract be originally value expire be renewal extension pursuant acquisition emergent biosolution anticipate complete tech transfer upstream portion acam manufacturing canton facility emergent share have outperformed industry year date stock have surge compare industry gain acquisition acam be strategic fit emergent biosolution enable latter expand exist smallpox countermeasure offer diversify portfolio enable contribute revenue meaningfully further aid achieve goal total revenue company also expect generate more total revenue international market deal emergent biosolution inc price emergent biosolution inc price emergent biosolution inc quotezack rank stock carry zack rank hold better rank stock health care sector include acadium pharmaceutical inc acad free report biogen inc biib free report carry zack rank buy see complete list today zack rank strong buy stock here acadium loss share estimate have narrow last day company deliver positive earning surprise trail quarters average beat share price company have climb year date biogen earning share estimate have moved last day company pull positive earning surprise trail quarters average beat share price company have increase year date look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
106,BIIB,emergent biosolution inc ebs free report announce have close acquisition anthrax monoclonal antibody raxibacumab glaxosmithkline plc gsk free report december raxibacumab be approve fda treatment prophylaxis inhalational anthrax go forward company plan assume responsibility supply product strategic national sns multus year contract biomedical advanced research development authority barda contract be value approximately notably emergent plan transfer manufacturing raxibacumab exist facility baltimore also company expect purchase product glaxosmithkline enable completion delivery sns exist barda procurement contract emergent share have outperformed industry year date stock have rally compare industry gain same time frame moreover acquisition raxibacumab expand portfolio approve medical countermeasure be sync company strategy meeting customer requirement fact acquisition raxibacumab company expect revenue increase full year additionally emergent expect gaap net income remain neutral reflect impact initial cost begin process transfer raxibacumab manufacturing gsk emergent be expect be complete emergent biosolution inc price emergent biosolution inc price emergent biosolution inc quotezack rank stock carry zack rank hold better rank stock health care sector include acadium pharmaceutical inc acad free report biogen inc biib free report acadium biogen carry zack rank buy see complete list today zack rank strong buy stock here acadium loss share estimate have narrow last day company deliver positive earning surprise trail quarters average beat share price company have climb year date biogen earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
107,BIIB,value investing be easily most popular way find great stock market environment wouldn want find stock be fly radar be compelling buy offer tantalize discount compare fair value way find company be look several key metric financial ratio many be crucial value stock selection process let put biogen inc biib free report stock equation find be good choice value oriented investor right now investor subscribe methodology look elsewhere top pick pe ratioa key metric value investor always look be price earning ratio pe short show much investor be willing pay dollar earning give stock be easily most popular financial ratio world best use pe ratio be compare stock current pe ratio ratio have be past compare average industry sector compare market whole front biogen have trail month pe ratio see chart level actually compare pretty favorably market large pe stand focus long term pe trend biogen current pe level put midpoint past year moreover current level stand way high stock indicate be solid entry point further stock pe also compare favorably industry trail month pe ratio stand very least indicate stock be relatively undervalue right now compare peer also point biogen have forward pe ratio price relative year earning just so be fair say slightly more value oriented path be ahead apple stock term too peg ratiowhile earning be certainly important be essential know much be pay growth earning well easily do peg ratio ratio expect future earning growth rate peg ratio give more complete picture valuation stock ratio biogen peg ratio stand just compare industry average suggest decent undervalue trading relative earning growth potential right now broad value outlookin aggregate biogen currently have zack value style score putt top stock cover look make biogen solid choice value investor other key metric make pretty clear too example cf ratio great indicator value come be far better industry average clearly biib be solid choice value front multiple angle stock overall biogen be good choice value investor be plenty other factor consider investing name particular be worth note company have growth grade momentum score give biib zack vgm score overarch fundamental grade read more zack style score here current quarter have see upward estimate revision past day compare downward full year estimate have see upward downward revision same time frame result current quarter consensus estimate have increase past month full year estimate have rise see consensus estimate trend recent price action stock chart biogen inc price consensus biogen inc price consensus biogen inc stock hold zack rank hold indicate expectation line performance company term however biogen be enjoy bullish analyst sentiment indicated positive estimate revision work company favor bottom linebiogen be inspire choice value investor be hard beat incredible lineup statistic front have zack rank stock belong industry be rank top indicate broader factor be favorable company so zack rank believe bullish analyst sentiment favorable industry factor make value stock compelling pick look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
108,BIIB,biosimilar space remain spotlight number regulatory decision be pending generic drug be follow version chemically synthesize molecule biosimilar contain version active substance already approve original biological drug development biosimilar be technically challenge development generic drug former require clinical study patient be engineer match reference drug quality safety efficacy due complex nature product development regulatory pathway biosimilar differ significantly generic biosimilar be usually less expensive brand drug thus market same remain highly lucrative acceleration approval biosimilar market have thus attract lot player be witness rapid growth here be few latest development space lead biosimilar space be novartis ag nvs free report generic arm sandoz be strong player biosimilar market market biosimilar omnitrope human growth hormone binocrit erythropoiesis stimulating agent used treat anemia filgrastim neutropenia brand name zarzio outside unite state zarxio unite state company plan launch major oncology immunology biosimilar include biosimilar version rituxan rituximab be approve european commission june market rixathon recently fda accept biologic license application bla propose biosimilar version rituxan august sandoz erelzi biosimilar version amgen inc amgn free report blockbuster drug enbrel gain approval unite state indication erelzi be also approve european commission european medicine agency also accept company marketing authorization application biosimilar version humira adalimumab remicade infliximab review novartis currently carry zack rank hold see complete list today zack rank strong buy stock here generic leader mylan nv myl free report be also explore world biosimilar market have potential grow fda recently notified mylan partner biocon target action date biosimilar version herceptin trastuzumab have be extend dec decision fda be expect sep fda extend review period due review clarificatory information submit agency part application review process note biocon partnership include biosimilar program such biosimilar version herceptin neulasta humira avastin enbrel neupogen insulin analog lantus humalog novolog mylan have collaboration agreement momenta pharmaceutical inc mnta free report develop manufacture commercialize momenta current biosimilar candidate include momenta biosimilar candidate orencia mylan currently carry zack rank strong sell meanwhile amgen allergan plc agn free report have also submit bla fda abp biosimilar candidate herceptin jul note company be collaborate oncology biosimilar include abp be second be submit fda approval company have also submit marketing authorization application european medicine agency candidate earlier note amgen have total biosimilar pipeline have be approve fda march european commission grant marketing authorization amgevita biosimilar version humira available indication company have important event line fda be expect give decision approval abp biosimilar version avastin shortly amgen currently carry zack rank hold last month biotech major biogen inc biib free report announce european commission grant marketing authorization imraldi biosimilar version humira be third tnf biosimilar biogen receive marketing authorization european union follow approval benepali biosimilar enbrel flixabi infliximab biosimilar version remicade biogen currently carry zack rank hold july merck co inc mrk free report launch reneflexis biosimilar version remicade unite state be approve fda april fda also grant tentative approval lusduna nexvue biosimilar version lantus basal insulin pre filled dose device merck currently carry zack rank hold medical sector yr return medical sector yr give fact so much be happen space expect investor focus upcoming approval date trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
109,BIIB,abbvie inc abbv free report partner neurocrine bioscience announce new drug application nda pipeline candidate elagolix have be submit fda abbvie be look get elagolix approve oral medicine management pain associate endometriosis nda filing be support positive result replicate pivotal phase iii trial evaluate elagolix gonadotropin release hormone gnrh antagonist indication detailed datum study present october last year show treatment elagolix result statistically significant reduction menstrual menstrual pelvic pain associate endometriosis compare placebo datum study also demonstrated superiority compare placebo reduce painful intercourse associate endometriosis endometriosis affect estimate woman reproductive age be associate pain symptom present be cure endometriosis pain associate endometriosis be currently manage oral contraceptive progestin danazol nsaid opioid gnrh agonist many medicine be not specifically indicated treatment endometriosis so far year abbvie share price have increase compare favorably gain record industry elagolix be also be evaluate phase iii study reduce heavy menstrual bleed premenopausal woman uterine fibroid datum pivotal study be expect end apart elagolix abbvie have several candidate different stage development wide range therapeutic area have partnership company roche rhhby free report bristol myer bmy free report biogen biib free report abbvie carry zack rank hold see complete list today zack rank strong buy stock here simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
110,BIIB,novartis ag nvs free report announce positive top line result phase iii study paradigm study evaluate safety efficacy oral once daily gilenya child adolescent age multiple sclerosis ms flexible duration year double blind randomize multus center study be be conduct evaluate safety efficacy oral gilenya compare interferon beta child adolescent confirm diagnosis ms be follow year open label extension phase patient enroled study be randomize receive once daily oral gilenya mg mg dependent patient body weight intramuscular interferon beta once weekly study meet primary endpoint show significant reduction relapse gilenya versus interferon beta result study show oral gilenya result significant clinically meaningful reduction number relapse annualize relapse rate patient period year compare interferon beta intramuscular injection note gilenya be already approve unite state first line treatment relapse form ms adult europe adult patient highly active relapse remit ms rrm drug generate sale first half year period drug be not yet approve treatment pediatric ms novartis plan complete thorough analysis important datum discuss same health authority agree next step submission note biogen inc biib free report hold strong position ms market wide range product include avonex tysabri tecfidera plegridy apart gilenya novartis ms portfolio include interferon beta subcutaneous injection be approve treatment relapse form ms other pipeline candidate baf siponimod omb ofatumumab fully human monoclonal antibody investigation relapse ms novartis generic division sandoz market glatopa glatiramer acetate injection mg ml first generic version teva pharmaceutical industry ltd teva free report copaxone mg go forward expect approval new drug label expansion exist one bode well novartis even stiff generic competition key drug gleevec continue act major deterrent novartis stock have rally year date compare industry gain last week novartis get boost fda have approve breakthrough gene transfer treatment kymriah suspension treatment patient year age cell precursor acute lymphoblastic leukemia approval open new frontier treatment cancer advance immunocellular therapy child young adult cell comprise approximately cancer diagnosis child year be most common cause childhood cancer unite state zack rank key picknovartis currently carry zack rank hold better rank stock healthcare sector be aduro biotech inc adro free report carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate narrow last day company deliver positive surprise trail quarters average beat surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
111,BIIB,catabasis pharmaceutical inc catb free report announce datum phase ii study show pipeline candidate edasalonexent substantially slow disease progression male child duchenne muscular dystrophy dmd company be plan initiate phase iii study candidate first half catabasis stock close more higher wednesday follow news however share company be so far year underperform industry be period datum phase ii movedmd study show edasalonexent improve rate decline time function test clinically meaningful number compare control period control period correspond period prior administration edasalonexent prior phase placebo group average period week dose mg kg day be administer maximum week child patient age year candidate also significantly reduce level muscle enzyme baseline suppress muscle regeneration deteriorate muscle integrity base positive datum study catabasis be plan advance candidate phase iii june study observe patient period month top line datum be expect unite state edasalonexent enjoy orphan drug fast track rare pediatric disease designation treatment dmd eu candidate enjoy orphan medicinal product designation indication remind investor sarepta therapeutic inc srpt free report exondys ptc therapeutic inc ptct free report emflaza be only approve therapy dmd unite state catabasis have research partnership sarepta explore combination edasalonexent exondys treatment dmd catabasis pharmaceutical inc price consensus catabasis pharmaceutical inc price consensus catabasis pharmaceutical inc quotezack rank key pickcatabasis carry zack rank buy biogen inc biib free report be stock worth consider health care sector also carry zack rank see complete list today zack rank strong buy stock here biogen earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
112,BIIB,celsion corporation clsn free report announce result phase ib study ovation evidently show biological activity immunotherapy candidate gen advanced ovarian cancer patient celsion be develop candidate newly diagnosed patient be administer combination neoadjuvant chemotherapy investor cheer news stock sky-rocket tuesday fact share company have surge so far year outperform industry rally period ovation program be design identify safe tolerable therapeutically active dose gen future study trial also assessed cytokine base compound namely gen directly affect ovarian cancer cell tumor newly diagnosed patient stage iii iv ovarian cancer follow interval debulk surgery patient treat date have demonstrated complete response cr partial response pr stable response reflect disease control rate dcr objective response rate orr patient treat highest dose cohort be objective response rate patient achieve complete response affirm partial response company also announce improvement median progression free survival pfs increase month month longest pfs month gen bring favorable immunological change be likely get translate clinical benefit company meet advisory board last month base recommendation be plan file phase ii design fda year end celsion be also develop candidate combination pegylate doxorubicin patient platinum resistant ovarian cancer apart gen immunotherapy cancer program celsion portfolio be thermodox currently be investigate phase iii evaluation primary liver cancer spectrum pharmaceutical inc price consensus spectrum pharmaceutical inc price consensus spectrum pharmaceutical inc quotezack rank key pickscelsion carry zack rank buy other bullish rank stock health care sector be acadium pharmaceutical inc acad free report biogen inc biib free report aduro biotech inc adro free report stock carry zack rank see complete list today zack rank strong buy stock here acadium loss share estimate have narrow last day company deliver positive earning surprise trail quarters average beat share price company have climb year date biogen earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have rally year date aduro loss estimate share have narrow last day company come positive earning surprise trail quarters average beat hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
113,BIIB,key biotech stock amgen amgn free report biogen biib free report report second quarter result yesterday company surpass earning sale estimate be several other key update well company incyte incy free report medicine co mdco free report recap week most important storiesamgen biogen earning biogen result be strong company most recent offer spinraza spinal muscular atrophy sma do better expect meanwhile company multiple sclerosis ms franchise continue grow ms be biogen key area expertise biogen expect early be inflection point company key pipeline candidate expect launch period read more biogen top earning sale spinraza sale amgen also top estimate update guidance recently launch product include prolium second fourth quarters be typically strongest product repatha kyproli record strong volume drive growth amgen be work improve repatha patient access world meanwhile mature product enbrel epogen neulasta neupogen decline neupogen be impact short act biosimilar competition continue affect sale amgen stock have gain year date ytd outperform rally industry belong biogen have lag share decline ytd incyte lilly ra drug face least month delay resubmission incyte partner lilly announce be delay least month resubmission regulatory application investigational rheumatoid arthritis ra treatment baricitinib mean resubmission not take place year incyte lilly discuss path forward fda evaluate option resubmission include possibility conduct additional study require fda fda have issue complete response letter crl baricitinib earlier year april time agency have tell company be unable approve baricitinib once daily oral medication treatment moderate severe ra current form fda have ask additional clinical datum determine most appropriate dose well further characterize safety concern treatment arm note baricitinib be approve eu trade name olumiant feb european medicine agency ema committee medicinal product human use chmp recently agree label be update include precaution patient have risk factor deep venous thrombosis dvt pulmonary embolism pe incyte share be baricitinib update nektar lilly deal nektar nktr free report enter deal big pharma company lilly see nektar receive upfront well form milestone payment deal cover co development early stage asset nktr nektar pipeline nktr have potential treat number autoimmune other chronic inflammatory condition work target il receptor complex body activate regulatory cell nktr have potential bring immune system back balance other deal term include sharing phase ii development cost lilly nektar option nektar participate late stage development indication indication basis double digit royalty nektar deal be major nektar consider early stage nature candidate hefty upfront fee lilly make strong partner company nektar share be follow deal announcement ironwood heartburn drug datum ironwood irwd free report share be even company report positive datum iw mid stage study conduct patient uncontrolled reflux disease gerd study meet primary endpoint fail impress investor efficacy result fall short expectation ironwood intend conduct end phase ii meeting fda move candidate phase iii study second half accord company iw represent immense commercial potential annual peak sale opportunity more read more ironwood report positive datum reflux candidate chmp positive regeneron sanofi eczema drug regeneron sanofi be step closer gain eu approval eczema treatment dupixent chmp adopt positive opinion drug company be seek approval use adult moderate severe atopic dermatitis ad be candidate systemic therapy final decision regard approval be come month dupixent gain fda approval earlier year march dupixent have blockbuster potential be be investigate other indication well detailed datum gilead hiv regimen gilead gild free report announce detailed week result couple late stage study fix dose combination bictegravir novel investigational insti emtricitabine tenofovir alafenamide ftc taf dual nrti backbone treatment hiv infection treatment naïve adult bictegravir contain regimen be find be inferior dolutegravir contain regimen gilead hold strong position hiv market be work strengthen franchise be significant demand simple convenient dose regimen sustain virologic suppression safety profile be appropriate most hiv patient mdco tango stop early superior benefit risk medicine co get good news independent datum safety monitoring board stopping late stage study investigational antibiotic vabomere previously refer carbavance base interim analysis interim result tango study show vabomere improve clinical cure rate infection type reduce rate renal adverse event compare best available therapy vabomere be currently priority fda review response expect third quarter marketing application be file eu well medicine co be zack rank hold stock see complete list today zack rank strong buy stock here biomedical genetic industry yr return medical biomedical genetic industry yr returnearning season biotech sector be strong start big player amgen biogen report better expect result nasdaq biotechnology index climb last trading session major biotech stock record gain vertex soar last month vertex be see last biotech stock roundup here vertex boost cf datum fda nod gilead puma drug next biotech world watch earning report company vertex gilead hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
114,BIIB,neuroscience theater brain investor train brain trade assumption perception neurology be new oncology boom brain science biotech company breakthrough research appreciate difference story misdiagnosis episode roundup podcast zack comwelcome back mind money kevin cook field guide story teller fascinating arena behavioral economic today episode be brain different angle first want share lesson used begin intermediate trader perception assumption second go talk exciting biotechnology company do breakthrough research neurological disease parkinson multiple sclerosis alzheimer last be go tell story young woman lead torturous first third life neurological condition go undiagnosed drug have help anyway story come terrific book read dr john ratey clinical professor psychiatry harvard medical school user guide brain perception attention theater brainratey theater be description really appeal base read other neuroscience book year back then conclude behavior identity be complex dance create several sometimes compete force call multus mind ty something realize early be training trader first reason short term trading be so hard be brain evolved very different challenge watch money fluctuate wildly screen full red green arrow so say brain wasn make trade be barely equip manage probability risk long term plan let alone minute minute naturally do wrong thing keep lose position take profit too quickly ingredient recipe trading failure be try short term trading stock currency commodity especially leverage fail lose most not money even odd be better vegas stack unconscious cognitive biase bad habit emotional decision make hear powerful analogy use trader biase multus mind be sure listen full podcast attach article meet tony cole yumanitydoing preliminary research podcast find great article matthew herper writing forbe february matt say cover science medicine believe be biology century couldn agree more love run new portfolio here zack call healthcare innovator get focus megatrend science medicine matt story come boom brain medicine start great introduction scientist know tony cole have have job want drug industry year helm cancer drug developer onyx pharmaceutical increase market cap eightfold purchasing experimental blood cancer drug develop big seller flip whole company amgen october personally make deal biotech watcher expect start cancer company even command drug giant merck pfizer instead cole be used own money build cambridge mass base startup call yumanity be used yeast microbe help make bread beer study misfold protein brain cause alzheimer lou gehrig disease parkinson create drug base knowledge already interest big pharma cole say choose attack brain disease not tumor need be so dire science be so fresh ve get person world have disease cost year lot family mine have be affected say cole have grandmother die complication alzheimer disease think own health well end excerpt matthew herper forbe article new next frontier biotechnologyin healthcare innovator portfolio be very focuse frontier cancer research especially exciting be field immuno oncology researcher be learn harness patient own immune system fight cancer research treatment be costly reward be enormous life save second disease fight frontier follow be gene editing science be allow person genome be alter possibly cure inherited ailment new frontier have very limit experience healthcare investor be neurological disease company have favore own parkinson psychosis treatment be acadium pharmaceutical acad free report currently own sarepta therapeutic srpt free report successful launch drug treatment duchenne muscular dystrophy alfr sandrock chief medical officer biogen biib free report have say neurology be new oncology find thrilling company month trail sale be so engage new next frontier biotech podcast describe other company involved frontier alk free report neurocrine bioscience also own sangamo therapeutic sgmo free report primarily zinc finger gene editing technology doesn hurt have early stage program huntington disease alzheimer pipeline too appreciate difference appreciate healthi close podcast minute story ratey share woman name rickie be actually subject book same name frederic flach psychiatric researcher cornell university incredible story ofpersonal tragedy eventual triumph hear goal be not just help learn brain perception also encourage recognize other seem very different be also appreciate own health degree have often take grant disclosure own share srpt sgmo zack healthcare innovator portfolio kevin cook be senior stock strategist zack investment research run healthcare innovator portfolio
115,BIIB,pdl biopharma inc pdli free report report earning cent share second quarter surpass zack consensus estimate year earning cent share company generate total revenue quarter significantly skyrocket compare year earlier figure increase revenue be mainly drive royalty pdl biopharma licensee queen et al patent also rise royalty right change fair value contribute higher revenue quarter be primarily due current period increase fair value depome royalty asset notably company receive cash payment royalty right acquire depome primarily related glumetza product market valeant pharmaceutical international inc vrx free report authorize generic version glumetza be also launch valeant subsidiary february pdl biopharma receive gross margin company share rally more hour trading monday share company have outperformed industry so far year share have climb compare industry increase quarter detailrevenue include royalty license queen et al patent consist royalty earn sale tysabri net royalty payment acquire royalty right change fair value royalty right asset interest revenue product revenue sale noden product tekturna tekturna hct lease lensar laser system license other revenue revenue queen et al license be higher year figure courtesy higher royalty tysabri biogen inc biib free report research development expense quarter come cost be record year quarter general administrative expense surge nearly year figure pdl biopharma inc price consensus ep surprisepdl biopharma inc price consensus ep surprise pdl biopharma inc quotezack rank key pickspdl biopharma currently carry zack rank hold better rank stock healthcare sector be enzo inc carry zack rank buy see complete list today zack rank stock here enzo loss share estimate narrow cent cent cent cent last day company deliver positive earning surprise trail quarters average beat company share price have surge year date trade profit big league trump policy stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
116,BIIB,earning season be fly start almost company have surpass expectation performance have be quite impressive biotech company major player beating market estimate president donald trump failure implement healthcare bill be positive biotech space read biotech etfs continue surge higher week major biotech player announce quarterly result amgen inc amgn free report gilead science gild free report biogen inc biib free report alexion pharmaceutical alxn free report beat earning revenue estimate read forget big tech biotech etfs be soar higher earning focusamgen report second quarter adjust earning share july beating zack consensus estimate increase more share year quarter moreover also beat consensus estimate revenue front company report revenue surpass consensus estimate increase year quarter company update full year gaap ep guidance range also update revenue guidance range company share lose market close july update guidance fall short analyst expectation gilead science report second quarter adjust earning share july beating zack consensus estimate decrease more share year quarter moreover also beat consensus estimate revenue front company report revenue surpass consensus estimate decrease more year quarter company update full year revenue guidance range company share gain market close july owing ep revenue beat biogen inc report second quarter adjust earning share july beating zack consensus estimate decrease more share year quarter company report revenue surpass consensus estimate increase roughly year quarter company update full year gaap ep guidance range also increase revenue guidance company share gain more pre market trading due better expect result close lower july alexion pharmaceutical inc report second quarter adjust earning share july beating zack consensus estimate increase roughly share year quarter company report revenue surpass consensus estimate increase roughly year quarter company update full year gaap ep guidance range increase revenue guidance company share be market close july primarily due better expect result now discuss few etfs high exposure company discuss ishare nasdaq biotechnology etf ibb free report fund seek provide exposure biotech industry have aum charge fee basis point year fund have exposure biogen gilead amgen alexion july fund have return last year year date july currently have zack etf rank buy high risk outlook read kite pharma be revolutionize fight cancer vaneck vector biotech etf bbh free report fund have aum charge fee basis point year fund have exposure amgen gilead biogen alexion july fund have return last year year date july currently have zack etf rank high risk outlook read reason biotech etfs be soar ultra nasdaq biotechnology etf bib free report fund have aum charge fee basis point year fund have exposure biogen gilead amgen alexion july fund have return last year year date july want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
117,BIIB,drug pricing be back news investigation be launch rep elijah cumming rep peter welch skyrocket price multiple sclerosis ms drug ms unpredictable often disable disease central nervous system cns interrupt flow information brain brain body symptom range numbness tingle blindness paralysis letter have be send company request information pricing strategy ms drug letter have also raise issue shadow pricing expensive new drug be launch price exist drug be raise other company follow suit increase price match higher price accord american academy neurology study annual sale ms drug double almost meanwhile information provide national multiple sclerosis society show average wholesale price ms disease modify therapy shot letter also mention lack strong competition generic only generic copaxone mg be market have be lot focus drug pricing last couple year company mylan valeant turing other face criticism pricing strategy follow announcement investigation nyse arca pharmaceutical index lose last trading session nasdaq biotechnology index be here be look company have be issue letter request information corporate profit expense document concern pricing strategy patient assistance program drug distribution system company have be ask provide require information aug life science company bayer ag bayry free report be company receive letter ms drug betaseron accord letter betaseron price have increase approval have almost double price last year bayer share be slightly follow news investigation however year date bayer stock have gain substantially outperform rally industry belong biogen biib free report key player ms market have be ask submit information ms drug avonex tysabri tecfidera plegridy zinbryta co promote abbvie accord letter drug have see least double digit price increase approval price drug have increase almost moreover zinbryta be introduce price annum price biogen other ms drug be hike match zinbryta price biogen be follow announcement investigation company ms franchise account major part total sale year date biogen stock have lose value versus growth industry emd serono division merck kgaa have also be question increase price ms drug rebif approval moreover drug price have almost double just year rebif have be face stiff competition oral formulation merck kgaa share be follow receipt letter year date merck kgaa stock have gain versus decline industry belong swiss pharmaceutical giant novartis ag nvs free report have be ask provide information gilenya price have shot more approval gilenya price have nearly double less year novartis have ms drug portfolio glatopa be generic version copaxone mg novartis decline last trading session year date stock have gain outperform rally industry belong french pharmaceutical giant sanofi sny free report have also receive letter regard investigation sanofi recently say limit future annual price increase national health expenditure nhe growth rate company have be ask provide information price increase aubagio lemtrada sanofi share be not affected significantly share slip last trading session year date sanofi stock have gain substantially outperform rally industry belong sanofi be zack rank buy stock see complete list today zack rank strong buy stock here israel base teva pharmaceutical industry ltd teva free report share slip company pricing pattern copaxone mg copaxone mg be question mg formulation price have shot more approval mg formulation be launch steep price have witness double digit price increase year teva have lose value year date versus decline industry swiss pharmaceutical company roche rhhby free report have receive query regard recently introduce ms drug ocrevus ocrevus be launch discount other brand ms drug market question be raise ocrevus be consider be similar roche rituxan be really new breakthrough product reformulation old drug be likely face biosimilar competition soon roche share be last trading session year date roche stock have gain versus rally industry belong more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
118,BIIB,expect ionis pharmaceutical inc ion free report beat expectation report second quarter result aug last quarter company deliver positive earning surprise fact have pull positive surprise trail quarters record average beat let see thing be shape announcement notably ionis share price have increase year date compare zack classify industry gain earning whispersour proven model show ionis be likely beat estimate quarter have right combination key ingredient positive earning esp zack rank strong buy buy hold have significantly higher chance beating earning zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate be cent share zack consensus estimate be peg loss cent share uncover best stock buy sell re report earning esp filter zack rank ionis currently carry zack rank combine positive esp make reasonably confident earning beat note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision factor considerionis earn revenue form upfront milestone other payment partnership lead health care company biogen inc biib free report glaxo agreement also validate company technology platform spinraza treatment spinal muscular atrophy sma be approve dec launch subsequently be grant marketing authorization european union jun also be first approve treatment eu sma ionis enter collaboration agreement biogen develop commercialize spinraza further inonis license spinraza biogen begin receive commercial revenue spinraza royalty drug be approve last week biogen release second quarter result announce spinraza be do better expect biogen raise guidance drug company state spinraza have witness faster expect adoption biogen be ramp launch effort outside market apart spinraza expect investor focus be ionis pipeline update second quarter conference call last month ionis akcea submit marketing authorization application maa european medicine agency ema volanesorsen treatment patient familial chylomicronemia syndrome fcs march company also announce positive result phase iii approach study volanesorsen patient fcs fact believe volanesorsen have potential be first treatment option patient suffering daily burden well life threaten risk fcs notably ionis partner bayer be advance pipeline candidate ionis fxi rx ionis fxi rx second half ionis plan initiate phase iib study evaluate ionis fxirx patient end stage renal disease optimize design phase iii program furthermore plan initiate phase study ionis fxi lrx early next year ionis pharmaceutical inc price ep surprise ionis pharmaceutical inc price ep surprise ionis pharmaceutical inc quotestock considerhere be health care stock want consider model show have right combination element post earning beat quarter tesaro inc tsro free report have earning esp zack rank company be expect release result aug see complete list today zack rank stock here esperion therapeutic inc espr free report have earning esp zack rank company be schedule release result aug make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
119,BIIB,biogen inc biib free report well know name multiple sclerosis ms market surpass expectation earning sale second quarter drugmaker also raise revenue guidance sale newest drug spinraza spinal muscular atrophy witness faster expect adoption share biogen rise almost pre market trading response strong result however note biogen share have inched so far year compare unfavorably industry increase biogen report second quarter earning share beat zack consensus estimate however earning decrease year year sale come year period sale also surpass zack consensus estimate top line exclude hemophilia revenue grow year year company spun hemophilia business february quarter detail biogen ms revenue grow year year second quarter stable global share tecfidera sale rally year period drug record sequential surge revenue include sale ex sale tecfidera revenue benefit seasonal recovery unit volume discount well allowance second quarter tysabri revenue be flat year year same decrease sequentially ex note tysabri revenue first quarter benefit approximately ex market due agreement price reimbursement committee italian national medicine agency aifa related tysabri sale benefit be miss second quarter lead sequential decline combine interferon revenue avonex plegridy second quarter be ex year period avonex revenue decline year period plegridy contribute second quarter revenue year year sequentially interferon revenue be experience decline trend due patient transition other oral ms therapy well higher discount allowance zinbryta launch collaboration abbvie inc abbv free report august last year contribute revenue second quarter compare first quarter newly launch spinraza bring revenue revenue second quarter register massive growth sequentially drug witness strong demand spinraza revenue include approximately related inventory build company be work expand access patient notably jun spinraza be grant marketing authorization eu treatment spinal muscular atrophy sma be also approve japan canada recently quarter biogen record biosimilar revenue compare first quarter company market benepali biosimilar reference amgen inc amgn free report enbrel europe benepali record revenue thus register growth rate sequentially biogen also market flixabi biosimilar reference johnson johnson jnj free report blockbuster drug remicade record revenue report quarter compare first quarter revenue cd therapeutic program include biogen share rituxan gazyva operate profit climb year period second quarter spend soar report quarter sg spend decrease year year quarter company repurchase share worth share repurchase program outlookbiogen raise earning revenue outlook biogen now expect earning range share old guidance share revenue be now expect range comapr earlier guidance increase prior guidance be primarily attribute faster anticipate adoption spinraza term percentage total revenue company sg expense be expect be respectively biogen inc price consensus ep surprisebiogen inc price consensus ep surprise biogen inc quotezack rankbiogen currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
120,BIIB,be enter peak period second quarter report cycle week quarter undoubtedly be strong start jul member accounting index total market capitalization report result accord earning preview beat revenue earning estimate compare first quarter total earning index member be year quarter improvement revenue beat ratio be earning revenue earning momentum be expect continue season report total earning company second quarter be expect grow year year higher revenue follow earning growth first quarter increase revenue highest almost year pharma bigwig johnson johnson jnj free report report mixed second quarter result beating earning miss sale other hand novartis nvs free report second quarter result be encourage company top earning sale estimate jul lilly lly free report biogen inc biib free report release second quarter result company beat earning revenue estimate lilly raise previously issue adjust earning sale outlook biogen also raise earning sale outlook let take look pharma giant be set report second quarter result jul let see thing be shape quarter gilead science inc gild free report gilead be schedule release earning close bell have deliver positive earning surprise last quarter gilead earning performance have be mixed earning miss expectation last quarters beating remain result average positive surprise quarter gilead have earning esp zack rank hold indicate likely beat quarter zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter hiv other antiviral product be expect boost sale however hcv franchise continue be pricing pressure read more be gilead poise beat earning season gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quotevertex pharmaceutical inc vrtx free report vertex be also schedule announce result close bell vertex average positive earning surprise last quarters be last report quarter vertex post positive surprise company have earning esp zack rank strong buy be thus expect beat earning estimate quarter see complete list today zack rank stock here investor focus vertex second conference call be triple combination cystic fibrosis cf regimen be crucial long term growth vertex datum vx vx phase ii vx phase triple combination study present last week have show combination lead pronounce improvement lung function read more be beat card vertex earning vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate plc gsk free report company be expect report market hour glaxosmithkline report line earning last quarter glaxo performance have be pretty impressive company report positive surprise consistently average earning beat last quarters be company have earning esp zack rank glaxo pharmaceutical vaccine segment be expect drive sale second quarter well meanwhile consumer healthcare segment have slow due impact general sale tax continue slowdown nutrition category india challenge economic condition other international market nigerian beverage business divestment factor impact second quarter result well read more lie store glaxo earning season glaxosmithkline plc price ep surprise glaxosmithkline plc price ep surprise glaxosmithkline plc quotemore stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
121,BIIB,cambridge base biogen inc biib free report world lead biotechnology company focus therapeutic area include neurology immunology company be best know multiple sclerosis ms franchise comprise treatment avonex tysabri tecfidera plegridy meanwhile feb company spin hemophilia business allow focus neurology key area expertise biib have pretty good earning track record company deliver positive earning surprise last quarters average surprise biogen inc price ep surprisebiogen inc price ep surprise biogen inc quotecurrently biib have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning beat biogen second quarter earning be better expect company post earning share consensus call ep revenue miss biogen post revenue beating consensus estimate revenue increase year year exclude hemophilia revenue key statistic oral multiple sclerosis ms drug tecfidera revenue increase year year sequentially other ms drug tysabri sale decrease sequentially pre market trading share be more pre market trading check back later full biib earning report later more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
122,BIIB,second quarter report cycle seem have get good start abundance positive surprise particularly revenue front meanwhile earning revenue growth also better expectation jul member accounting index total market capitalization report result accord earning preview total earning index member be year quarter improvement revenue beat ratio be earning revenue earning momentum be expect continue season report total earning company second quarter be expect grow year year higher revenue follow earning growth first quarter increase revenue highest almost year pharma bigwig only johnson johnson jnj free report swiss company novartis ag nvs free report have report so far report mixed second quarter result beating earning miss sale be third consecutive sale miss due slowdown pharmaceutical product sale however be optimistic sale growth accelerate second half other hand novartis second quarter result be encourage company beat earning sale estimate however sandoz performance be disappointing due pricing pressure here have pharma giant be set report second quarter result jul let see thing be shape quarter eli lilly company lly free report lilly be schedule release earning market open have deliver positive earning surprise last quarter lilly earning performance have be mixed earning miss expectation last quarters beating other result average negative surprise eli lilly company price ep surprise eli lilly company price ep surprise eli lilly company quarter lilly have earning esp zack rank buy zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter new product trulicity cyramza taltz jardiance have support top line past few quarters expect trend continue second quarter well however decline sale alimta cymbalta zyprexa be expect continue due loss exclusivity read more be beat card eli lilly earning previous article show lilly be likely beat earning quarter however estimate change thereafter be not certain beat earning season biogen inc biib free report biogen well know name multiple sclerosis ms market be also schedule announce result open bell biogen earning performance have be pretty impressive so far have deliver back back positive surprise average earning beat last quarters be last quarter company deliver positive earning surprise biogen inc price ep surprise biogen inc price ep surprise biogen inc company have earning esp zack rank hold see complete list today zack rank strong buy stock here biogen expect relatively stable demand key ms drug tecfidera tysabri patient growth ex market offset modest decline due rise competition drug roche ocrevus read more biogen keep earning streak alive amgen inc amgn free report biotech giant be expect report market hour amgen deliver positive earning surprise last quarter amgen performance have be pretty impressive company report positive surprise consistently average earning beat last quarters be amgen inc price ep surprise amgen inc price ep surprise amgen inc company have earning esp zack rank amgen growth drug prolium xgeva continue do well biosimilar competition slowdown sale mature product put pressure sale growth read more amgen report earning card more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
123,BIIB,ligand pharmaceutical incorporate lgnd free report inked deal acquire crystal bioscience inc cash company also pay additional shareholder crystal bioscience success base milestone additionally crystal bioscience share revenue exist licensee defined period crystal bioscience core technology humab be chicken base antibody platform used generate human antibody consequently ligand share have outperformed industry year date stock have surge compare industry gain same time frame pursuant acquisition humab technology become part ligand omniab brand be call omnichicken notably omniab be patent protected transgenic animal platform used discovery fully human mono bispecific therapeutic antibody technology be add ligand portfolio january company acquire omt inc open monoclonal technology omniab have distinct transgenic rodent system generate antibody omnirat omnimouse omniflic omnirat be industry first human monoclonal antibody technology base rat omniflic be engineer rat fix light chain development bispecific fully human antibody omnimouse be transgenic mouse hence addition omnichicken platform ligand omniab technology add third species fully humanize antibody discovery go forward be expect omnichicken technology be utilize ligand exist omniab partner potential new partner deal add fully funded partnership ligand business boehringer ingelheim alexo therapeutic achaogen undisclosed large pharmaceutical company ligand anticipate crystal bioscience acquisition contribute revenue fourth quarter also expect total revenue be least compare previous guidance however company reiterate guidance receive additional contract revenue approximately revenue ligand outlook adjust earning share remain unchanged current year ligand expect latest buyout contribute least incremental earning least cent ligand pharmaceutical incorporate price ligand pharmaceutical incorporate price ligand pharmaceutical incorporate quotezack rank stock considerligand carry zack rank hold better rank stock health care sector include acadium pharmaceutical inc acad free report biogen inc biib free report aduro biotech inc adro free report hold zack rank buy see complete list today zack rank strong buy stock here acadium loss share estimate have narrow last day company deliver positive earning surprise trail quarters average beat share price company have climb year date biogen earning share estimate have moved last day company pull positive earning surprise trail quarters average beat share price company have increase year date aduro loss estimate share have narrow last day company come positive earning surprise trail quarters average beat stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
124,BIIB,allergan plc agn free report announce fda have approve botox cosmetic product third indication temporary improvement moderate severe forehead line appearance associate frontali muscle activity adult so far year allergan share price have slip compare industry decline approve therapeutic aesthetic use botox be key top line driver allergan cosmetic indication include improvement appearance glabellar line frown line brow severe crow foot latest fda approval make botox cosmetic only neurotoxin treatment approve facial aesthetic treatment forehead line crow foot wrinkle outer corner eye glabellar line botox therapeutic disease include overactive bladder cervical dystonia chronic migraine strabismus other drug generate sale first half increase year year drive strong demand trend latest label expansion approval forehead line treatment enjoy pent demand drive sale further remind investor botox become part allergan portfolio follow march acquisition allergan inc have previously command strong presence generic market allergan merger have find place top list world wide pharma company base sale later allergan sell generic business well anda distribution arm teva pharmaceutical industry ltd teva free report however april pfizer inc pfe free report have terminate agreement combine allergan allergan carry zack rank hold seethe complete list today zack rank strong buy stock here stock considera better rank biotech drug stock be biogen inc biib free report zack rank buy biogen have see zack consensus estimate current year earning be revise upward past day share company have rally year hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
125,BIIB,amgen inc amgn free report announce strategic immuno oncology collaboration cytomx therapeutic inc ctmx free report jointly develop cell engage bispecific probody deal amgen make upfront payment cytomx investing california base biotech company stock markedly company develop cytomx probody cell engage bispecific program target egfr protein thereby offer significant potential treat various type cancer cytomx lead early development amgen take care late stage development however late stage development cost be share company apart upfront payment equity investment cytomx also be eligible receive milestone well opt right profit royalty outside sale product be commercialize deal amgen also receive global right develop commercialize undisclosed cytomx candidate amgen take target cytomx be eligible receive upfront payment milestone well royalty result product addition bispecific technology platform expand amgen immuno oncology capability give cytomx strong partner amgen ensure regular flow fund share cytomx be hour trading tuesday amgen share remain stable nonetheless amgen share have rally better industry growth so far year currently amgen hold zack rank buy seethe complete list today zack rank strong buy stock here key pickssome other top rank biotech stock sporting same bullish rank amgen include biogen inc biib free report celgene corporation celg free report biogen have witness zack consensus estimate current year earning climb past day company share have increase year celgene earning estimate have inched past day stock have rally year outperform industry hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
126,BIIB,share endocyte inc ecyt free report have soar more oct acquire exclusive worldwide license develop commercialize abx gmbh phase iii ready prostate cancer candidate lu psma also share price increase more pre market trading oct company make upfront payment abx consequently endocyte share have outperformed industry year date stock have rally compare industry gain same time frame deal provide endocyte most advanced target radioligand therapeutic rlt be be develop treatment prostate cancer represent greater market opportunity fact lu psma target prostate specific membrane antigen psma present patient metastatic castration resistant prostate cancer mcrpc candidate have also show high response rate late stage prostate cancer patient study present recent european society medical oncology lu psma have potential be first class rlt address bone soft tissue disease be very important patient suffering mcrpc go forward endocyte intend seek regulatory approval commence phase iii study lu psma early company expect study complete also plan utilize focus resource development lu psma june endocyte announce plan reduce workforce order better focus resource more valuable opportunity interestingly company plan shift focus most promising program include car cell smdc adaptor platform dual target dna crosslinker drug ec cohort taxane expose patient receive ec moreover company narrow ec development program focus only cohort taxane expose mcrpc patient further company stop enrollment ec trial level clinical activity necessary support continue advancement candidate be not meet deal seem be lucrative company bode well future endocyte inc price endocyte inc price endocyte inc quotezack rank stock carry zack rank sell better rank stock health care sector include regeneron pharmaceutical inc regn free report biogen inc biib free report aduro biotech inc adro free report regeneron sport zack rank strong buy biogen aduro carry zack rank buy see complete list today zack rank stock here regeneron earning share estimate have increase last day company pull positive earning surprise trail quarters average beat share price company have increase year date biogen earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date aduro loss estimate share have narrow last day company come positive earning surprise trail quarters average beat make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
127,BIIB,mallinckrodt plc mnk free report announce have enter licensing agreement neuroprotexeon agreement relate development neuroprotexeon investigational pharmaceutical grade xenon gas inhalation therapy therapy be be evaluate improve survival functional outcome patient resuscitate cardiac arrest term mallinckrodt pay upfront cash hand reimburse neuroprotexeon certain product development cost give mallinckrodt exclusive right commercialize therapy mallinckrodt make additional milestone payment tentative approval xenon inhalation expand mallinckrodt portfolio hospital drug device combination product provide therapy patient phase iii registration trial begin early be design confirm potential clinical benefit associate positive biomarker outcome demonstrated magnetic resonance imaging mri scan patient be treat hypothermia therapy xenon gas inhalation be see phase iib study trial be be conduct special protocol agreement fda trial measure clinical benefit xenon inhalation term improve day survival improve functional outcome special protocol assessment have be approve fda entitle interim analysis trial completion primary endpoint follow assume primary secondary endpoint be positive trial be halter however primary secondary endpoint be not meet trial be stop mallinckrodt expect regulatory submission be drug delivery device combination full completion trial tentative approval expect mallinckrodt expect bottom line dilution remainder be cent slightly lower dilution mallinckrodt stock price have decline year date compare industry fall note mallinckrodt be currently focuse reshape product portfolio strategic acquisition core asset divestiture transform portfolio become high perform specialty pharmaceutical company company recently acquire privately hold infacare pharmaceutical corporation specialty pharmaceutical company focus development proprietary pharmaceutical neo natal pediatric patient company generic segment continue face weakness various product category be witness stiff competition be hurt volume price company expect double digit decline revenue segment addition continue expect weakness segment adversely impact gross profit margin also company sell nuclear imaging business due persistent challenge condition company also sell intrathecal therapy business focus key area acthar sale continue be strong back increase formulary position access appropriate patient commercial public environment sale therakos be expect decline zack rank stock carry zack rank hold better rank stock health care sector be regeneron pharmaceutical inc regn free report biogen inc biib free report aduro biotech inc adro free report regeneron sport zack rank strong buy biogen aduro carry zack rank buy see complete list today zack rank stock here regeneron earning share estimate have increase last day company post positive earning surprise trail quarters average share price company have increase year date biogen earning share estimate have moved last day company deliver positive earning surprise trail quarters average share price company have increase year date aduro loss estimate share have narrow last day company report positive earning surprise trail quarters average make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
128,BIIB,eli lilly company lly free report report second quarter adjust earning share beat zack consensus estimate earning rise year quarter backed volume drive pharma sale growth higher profit revenue beatquarterly revenue beat zack consensus estimate sale grow year year backed higher volume realize price however foreign exchange pull sale volume rise higher volume new product trulicity taltz basaglar jardiance lartruvo offset lower volume establish product zyprexa alimta ciali strattera pharmaceutical volume rise quarter however worldwide competitive pressure hurt sale lilly animal health segment revenue detailu revenue grow reflect higher volume product trulicity taltz basaglar jardiance lartruvo offset lower volume establish drug ex revenue decline mainly due lower volume increase competition lower realize price higher volume newer product cyramza trulicity be offset lower volume zyprexa cymbalta alimta due loss exclusivity cymbalta have lose exclusivity europe canada zyprexa japan alimta several country lower sale food companion animal product hurt outside sale well establish product record growth quarter include forteo humulin effient alimta sale however decline reflect lower demand due competitive pressure mainly immuno oncology agent outside sale alimta be hurt loss exclusivity several country increase competition lower realize price zyprexa sale decline due loss exclusivity humalog sale decrease quarter due lower realize price volume ciali sale be flat hurt lower demand well increase competition generic sale decline quarter strattera sale decline cymbalta sale decline new product trulicity generate revenue year year revenue benefit growth glp market market share gain cyramza revenue be year year backed mainly higher outside revenue cyramza ex revenue benefit strong volume japan however revenue increase only higher realize price make lower demand due competitive pressure jardiance sale be drive increase market share grow sglt class basaglar record revenue compare previous quarter basaglar lilly partner boehringer ingelheim follow insulin sanofi sny free report blockbuster drug lantus be launch mid dec generate revenue quarter taltz bring sale compare previous quarter reflect strong launch uptake lartruvo olaratumab generate revenue second quarter compare previous quarter lartruvo be launch eu soft tissue sarcoma fourth quarter revenue be compare previous quarter meanwhile lilly partner incyte corporation incy free report rheumatoid arthritis ra drug olumiant baricitinib be approve eu feb drug generate sale second quarter compare previous quarter drug receive marketing approval japan earlier month however company receive complete response letter crl fda april regard new drug application nda baricitinib concurrent earning release lilly announce nda resubmission baricitinib not occur year be delay minimum month company say fda have indicated additional clinical study be need resubmission lilly animal health segment sale decline inclusion revenue acquisition boehringer ingelheim vetmedica feline canine rabies acquire jan animal health revenue be hurt due global competitive pressure affected sale food animal companion animal revenue quarter gross margin operate income riseadjust gross margin quarter increase basis point primarily drive higher realize price manufacturing efficiency operate income increase higher gross margin operate expense remain flat quarter however total operate expense percent revenue decline basis point quarter outlook uppedlilly raise previously issue adjust earning sale outlook adjust earning share be now expect range compare previously revenue be expect range compare expect previously zack consensus estimate earning revenue be share respectively gross margin be expect be approximately lower previously adjust tax rate be still expect be approximately marketing selling administrative expense be still expect range research development expense be project be slightly higher expect previously takelilly second quarter result be strong company beating estimate count pharma giant also raise sale earning outlook year however news delay re filing baricitinib send share almost pre market trading so far year lilly share price have rise compare increase industry company also say build oncology portfolio work develop next generation immunotherapy prioritize development pipeline candidate go forward new product trulicity taltz basaglar cyramza jardiance lartruvo be expect see higher revenue lilly also expect establish product trajenta forteo humalog continue do well however alimta continue be impact competition other headwind include competition immuno oncology agent well loss exclusivity many drug emerge market meanwhile recent high profile pipeline setback be investor concern so be weak performance animal health segment first half lilly carry zack rank buy see complete list today zack rank strong buy stock here eli lilly company price consensus ep surprise eli lilly company price consensus ep surprise eli lilly company quotebiogen inc biib free report also report second quarter result today beat estimate earning sale share be almost pre market trading more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
129,BIIB,allergan plc agn free report announce supplemental new drug application snda infective drug avycaz have be accept grant priority review fda remind investor avycaz be currently approve treatment complicate urinary tract infection cuti include pyelonephritis drug combination metronidazole be approve treat complicate intra abdominal infection ciai company be look get label drug expand include hospital acquire bacterial pneumonia ventilator associate bacterial pneumonia habp vabp decision fda be expect first quarter allergan share be so far year outperform industry decline same period snda submission be base inferiority datum pivotal reprove study evaluate safety efficacy avycaz adult patient habp vabp study show avycaz be inferior meropenem reduce death irrespective cause drug also show study controlled environment outside human body activity certain gram negative bacterium cause habp vabp remind investor fda issue refusal file letter last month snda vraylar expand label include negative symptom associate schizophrenia however boost generic portfolio company receive approval september biosimilar version roche hold ag rhhby free report cancer drug avastin treatment type cancer allergan plc price consensus allergan plc price consensus allergan plc quotezack rank stock carry zack rank hold better rank stock health care sector include regeneron pharmaceutical inc regn free report biogen inc biib free report regeneron sport zack rank strong buy biogen carry zack rank buy see complete list today zack rank stock here regeneron earning share estimate have increase last day company pull positive earning surprise trail quarters average beat share price company have increase year date biogen earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
130,BIIB,biotech industry have witness great turnaround year drug pricing issue cripple performance last year decline last year medical biotech genetic industry have rise year so far outpace gain same time frame nasdaq biotechnology index be almost year date slide zack industry rank be zack industry medical biom genetic indicate bright outlook sector go forward biotech sector have number thing go favor strong quarterly result new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval continue strong performance legacy product have play pivotal role bring sector track year factor have contribute sector surge be president trump expect action drug price not be onerous previously fear factor continue drive sector rest year probably next well challenge rise competition pipeline setback slowdown growth mature product generic competition certain key drug broader macro front propose tax reform approve leave more cash hand company cash be invest merger acquisition have be relatively fewer year compare last biotech stock tear here have picked biggest biotech company look well poise growth be add portfolioamgen inc amgn free report amgen be lead biotechnology company world several blockbuster drug portfolio amgen newer drug prolium xgeva vectibix nplate sensipar be perform well amgen be also progress pipeline include biosimilar drug last month receive fda approval mvasi biosimilar version roche cancer drug avastin mvasi be first biosimilar approve unite state treatment cancer other recent positive pipeline regulatory development amgen include eu approval pediatric formulation mimpara positive long term datum kyproli endeavor study regulatory filing label expansion prolium kyproli other support positive development amgen share have outperformed industry so far year share have rise compare favorably industry gain amgen carry zack rank buy see complete list today zack rank strong buy stock here earning estimate have rise have go past day celgene corporation celg free report celgene key growth driver multiple myeloma drug revlimid continue drive revenue company meanwhile celgene label expansion effort revlimid bode well further sale growth drug other key product pomalyst imnovid abraxane otezla be also perform well recent positive development celgene be fda approval idhifa treatment adult patient relapse refractory acute myeloid leukemia aml celgene also carry zack rank earning estimate have rise past day stock have go year outperform industry biogen inc biib free report biogen have strong position multiple sclerosis market backed wide range product biogen be try diversify be look strengthen alzheimer disease ad other disorder pipeline newly launch spinraza spinal muscular atrophy be also promising start spinraza have witness faster expect adoption unite state biogen be ramp launch effort internationally recent key positive pipeline regulatory development biogen include promising long term dataon alzheimer disease candidate aducanumab eu approval imraldi biogen biosimilar version abbvie top selling blockbuster drug humira biogen have make several new executive appointment bring management team back track several key executive depart past couple year include ceo george scango cfo paul clancy biogen also rank stock have see earning estimate rise past day share have rise year other biotech company smaller mentioned company be worth mention vertex pharmaceutical incorporate vrtx free report have see share price shoot year so far earning estimate rise stock be ride high success cystic fibrosis cf pipeline particularly triple combination cf regimen have potential treat cf patient regeneron pharmaceutical inc regn free report see launch key pipeline candidate dupixent atopic dermatitis kevzara rheumatoid arthritis unite state year drug be also approve eu meanwhile regeneron key growth driver eylea continue drive revenue market share gain company be expand drug label additional indication regeneron share have rise year earning estimate have go vertex regeneron have be sporting zack rank strong buy quite time soon join league big biotech stock make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
131,BIIB,biogen inc biib free report well know name multiple sclerosis ms market report second quarter result jul market open last quarter company deliver positive earning surprise biogen share have decline year so far zack classify biom genetic industry record increase biogen earning performance have be pretty impressive so far have deliver back back positive surprise average earning beat last quarters be let see thing be shape announcement factor considerat first quarter call company have say expect relatively stable demand tecfidera tysabri multiple sclerosis drug patient growth ex market offset modest decline due rise competition drug roche ocrevus remain be see second quarter performance reflect trend meanwhile combine number patient used avonex plegridy be decline patient transition other oral multiple sclerosis therapy other high efficacy product zinbryta launch collaboration abbvie inc abbv free report aug be expect continue contribute revenue eu drug benefit increase use high efficacy product spinraza approve spinal muscular atrophy dec be promising start backed robust underlie demand notably spinraza add top line first quarter contribute further sale conference call company have say be work expand access spinraza patient however call company have warn possible logistic coverage restriction drug well other market expect management provide update issue second quarter conference call biogen biosimilar product flixabi biosimilar reference remicade benepali biosimilar reference enbrel be also generate higher revenue trend continue quarter well headcount reduction restructure initiative be expect continue lower operate expense meanwhile expense be expect increase due increase business development payment second quarter call investor focus remain tecfidera scrip trend sale ramp spinraza pipeline progress acquisition plan earning whispersour proven model do not conclusively show biogen be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be most accurate estimate stand zack consensus estimate be peg higher uncover best stock buy sell re report earning esp filter zack rank biogen zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision biogen inc price ep surprise biogen inc price ep surprise biogen inc quotestock considerstock pharmaceutical sector have positive esp favorable zack rank includeeli lilly company lly free report schedule release result jul earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report earning esp zack rank company be schedule release result aug look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
132,BIIB,key highlight week include impressive datum vertex vrtx free report cystic fibrosis cf pipeline company gilead gild free report puma pbyi free report get fda approval hepatitis virus hcv breast cancer treatment respectively recap week most important storiesvertex cf datum impress vertex get major boost positive datum different triple combination regimen person cystic fibrosis cf have del mutation minimal function mutation del min be first datum show potential treat underlie cause cf patient have severe difficult treat type disease company be look start pivotal program first half vertex share be significantly pre market trading crl amgen ucb osteoporosis drug amgen amgn free report partner ucb get complete response letter crl fda evenity romosozumab investigational treatment postmenopausal woman osteoporosis however crl doesn come surprise consider emergence new safety signal late stage study arch evenity meet primary endpoint key secondary endpoint study company say imbalance positively adjudicate cardiovascular serious adverse event be observed fda have ask company include datum arch study resubmission well datum bridge study man osteoporosis read more amgen get crl osteoporosis drug evenity bla amgen be zack rank hold stock see complete list today zack rank strong buy stock here fda nod gilead hcv drug gilead have add drug hepatitis virus hcv portfolio fda grant approval vosevi single tablet regimen re treatment adult chronic hcv vosevi provide physician new therapeutic option hardest treat patient however vosevi come box warning regard risk hepatitis virus hbv reactivation hcv hbv co infected patient limit uptake gilead hcv franchise be major revenue generator be considerable strain due new competition pricing pressure company have underperform zack categorize medical biomedical genetic industry so far share gain industry be puma fda approval nerlynx puma gain fda approval breast cancer treatment nerlynx neratinib have blockbuster potential nerlynx first approve drug puma portfolio be indicated extend adjuvant treatment early stage breast cancer aggressive type tumor mean nerlynx be take initial treatment so risk cancer come back be reduce further nerlynx approval be line expectation consider favorable advisory panel vote earlier year puma share be news year date ytd puma share be whopping sarepta biomarin settle patent dispute sarepta srpt free report biomarin settle patent dispute regard use sarepta exondys future exon skip product treatment duchenne muscular dystrophy dmd company sign licensing agreement provide sarepta global exclusive right biomarin dmd patent estate exondys future exon skip product biomarin have option convert license co exclusive right decide proceed exon skip therapy dmd term deal include time payment sarepta well certain milestone base payment royalty sarepta share be biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index be last trading session major biotech stock biogen biib free report be almost last month vertex be alexion alxn free report be see last biotech stock roundup here arena shoot study datum celg inks immuno oncology deal next biotech world watch earning report company biogen sarepta look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
